KOL | Harry Roger BüllerDepartment of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular ... |
Kol currículo para Harry Roger Büller
| Year | |
|---|---|
| 2022 | Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands |
| 2021 | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.). Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands (H.R.B.). |
| 2020 | From the Faculty of Medical Sciences, State University of Groningen, Groningen, the Netherlands (M.O.); Department of Vascular Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands (H.R.B., N.V.Es.); Department of Radiology, Haaglanden Medical Centre, The Hague, the Netherlands (D.K.); Department of Radiology, Nederlands Kanker Instituut, Amsterdam, the Netherlands (S.F.O.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, U.S.A. (T.M.); Department of Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.); 7. National Institute of Public Health, Ministry of Health, Bilthoven, the Netherlands (J.V.D.); Department of Vascular Medicine, Maastricht University, Maastricht, the Netherlands (H.T.C.); Edinburgh Imaging, Queens Medical Research Institute, University of Edinburgh, Edinburgh, U.K.(E.J.R.V.B.) Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands |
| 2019 | Department of Vascular Medicine, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands. Dept of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands |
| 2018 | Department of Vascular Medicine, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, Netherlands |
| 2017 | Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, AZ, Amsterdam, The Netherlands. From Academic Medical Center and Slotervaartziekenhuis, Amsterdam, the Netherlands; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Université de Bretagne Occidentale, Brest, France; Hospital of Padua, Padua, Italy; Clinica Universidad de Navarra, Pamplona, Spain; Virgen del Rocio Hospital, Seville, Spain; Karolinska Institutet, Stockholm, Sweden; Warsaw Medical University, Warsaw, Poland; Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France; University of Utah, Salt Lake City, Utah; University Hospital Leuven, Leuven, Belgium; and University G. D'Annunzio, Chieti-Pescara, Italy. |
| 2016 | Center for Experimental and Molecular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands |
| 2015 | Academic Medical Center University of Amsterdam Department of Vascular Medicine Amsterdam the Netherlands |
| 2014 | From the College of Public Health, University of Oklahoma Health Sciences Center (G.E.R., M.M., A.W.); Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); División Hemostasia, Academia Nacional de Medicina, Buenos Aires, Argentina (A.N.B.); Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (H.B.); SA Pathology–Department of Hematology, Flinders Medical Center, Adelaide, South Australia, Australia (A.G.); Thrombosis and Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (B.J.H.); Boston University School of Medicine, MA (E.M.H.); Thrombosis Research Institute, London, United Kingdom (A.K.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany (S.V.K.); Department of Laboratory Medicine, University of Yamanashi, Tamaho, Yamanashi, Japan (Y.O.); and McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W.). Department of General Practice, Academic Medical Centre, University of Amsterdam, Amsterdam and |
| 2013 | Department of Vascular Medicine, F4-140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands Academic Medical Center, Amsterdam (H.R.B.) |
| 2012 | Academic Medical Center, Department of Vascular Medicine, Amsterdam (H.R.B.) Vascular Medicine, AMC, Amsterdam, the Netherlands |
| 2011 | Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, From the Academic Medical Center and Slotervaart Hospital, Amsterdam |
Harry Roger Büller: Influência estatística
Relatório de execução
| Concept | World rank |
|---|---|
| rnapc2 inhibition | #1 |
| lmwh rtap | #1 |
| prevalence coagulation | #1 |
| doacs anatomical extent | #1 |
| recurrent thrombosis pts | #1 |
| pulmonary embolism fondaparinux | #1 |
| 3 idraparinux | #1 |
| standalone ddimer testing | #1 |
| simplified wells rule | #1 |
| wellsrule | #1 |
| specificity pulmonary embolism | #1 |
| p0424 | #1 |
| duration heparin treatment | #1 |
| embolism radionuclide | #1 |
| cdr ddimer test | #1 |
| 5 avidin infusion | #1 |
| rule dimer | #1 |
| bmi fondaparinux | #1 |
| nadroparin patients | #1 |
| proportion 75 years | #1 |
| chest perfusion scan | #1 |
| carriers thrombophilic defects | #1 |
| test venography | #1 |
| cdr normal | #1 |
| bleeding risk treatment | #1 |
| acute recurrent patients | #1 |
| safety outcome | #1 |
| pvo ctscan | #1 |
| travel venous thromboembolism | #1 |
| rnapc2 united states | #1 |
| leg veins patients | #1 |
| ifngamma pselectin | #1 |
| 560 pharmacies | #1 |
| vivo coagulation factor | #1 |
| tb402 prevention | #1 |
| variable d‐dimer thresholds | #1 |
| suspected deep | #1 |
| acenocoumarol therapy acenocoumarol | #1 |
| 53 amputations | #1 |
| age multiple comorbidities | #1 |
| age∗10μg | #1 |
| hellp syndrome mutations | #1 |
| principal safety | #1 |
| pulmonary angiography ultrasonography | #1 |
| thromboembolism treated | #1 |
| equinox study | #1 |
| pulmonary angiography study | #1 |
| uesvt uedvt | #1 |
| topic thrombophlebitis | #1 |
| 7268 patients | #1 |
| orthopedic thromboprophylaxis | #1 |
| fviii normal levels | #1 |
| normal dimer | #1 |
| patients enoxaparin vkas | #1 |
| oral administration bsf | #1 |
| reocclusion antithrombotic drug | #1 |
| patients initial heparin | #1 |
| tsh antitpo | #1 |
| major bleeding cancer | #1 |
| abelacimab | #1 |
| death category | #1 |
| cdrscore combination | #1 |
| carriers relative risks | #1 |
| heparin survival | #1 |
| pulmonary embolism idraparinux | #1 |
| incidental symptomatic vte | #1 |
| elevated fviii | #1 |
| wound haematoma | #1 |
| heparins cancer spread | #1 |
| women factor leiden | #1 |
| scenarioanalysis | #1 |
| intracranial clinical presentation | #1 |
| —brachial | #1 |
| lowmolecularweight heparin 95 | #1 |
| prothrombin individuals | #1 |
| strategies ultrasonography | #1 |
| edoxaban cancer patients | #1 |
| 95 intracranial | #1 |
| older patients cdr | #1 |
| rtap lmwh | #1 |
| prescriptionbased | #1 |
| 69 conclusions | #1 |
| evaluable patients 95 | #1 |
| vkas lmwh | #1 |
| 0·2 3633 patients | #1 |
| thrombophilia late loss | #1 |
| extended anticoagulation apixaban | #1 |
| initial heparin patients | #1 |
| randomized studies efficacy | #1 |
| pregnancyrelated complications relatives | #1 |
| intrinsic coagulation vivo | #1 |
| vte occurred | #1 |
| plasma concentration fviii | #1 |
| lmwh departments | #1 |
| vte addition | #1 |
| 2630 pilots | #1 |
| intravenous injections lmwh | #1 |
| idraparinux recurrent thromboembolism | #1 |
| factor viii homocysteine | #1 |
| edoxaban dalteparin | #1 |
| activecontrol placebo | #1 |
| p0001 saline | #1 |
| dvt 3 | #1 |
| efficiency subgroups | #1 |
| diagnosis deepvein thrombosis | #1 |
| poc test patients | #1 |
| fviii venous thromboembolism | #1 |
| clinically relevant disease | #1 |
| gastrointestinal cancer edoxaban | #1 |
| patients treatment duration | #1 |
| diagnostic strategy primary | #1 |
| s1p1activation | #1 |
| rivaroxaban replacement | #1 |
| gogh dvt trial | #1 |
| ecq ankle brachial | #1 |
| avidin vte | #1 |
| adjunct thrombolysis | #1 |
| 5395 patients | #1 |
| rule cdr | #1 |
| recurrence major bleeding | #1 |
| antithrombotic prescriptions adherence | #1 |
| bleeding clinically | #1 |
| cancer 145 patients | #1 |
| iii plg | #1 |
| lowmolecularweight heparin category | #1 |
| anticoagulants double | #1 |
| enoxaparin warfarin antiplatelet | #1 |
| embolism suspected | #1 |
| monoclonal antibodies apc | #1 |
| travellers thrombosis | #1 |
| association travel | #1 |
| aged venous | #1 |
| upper extremity uedvt | #1 |
| reduceddose noacs warfarin | #1 |
| systematic search cteph | #1 |
| patients advanced prostate | #1 |
| 9 incidence | #1 |
| venous thrombus growth | #1 |
| single dose tb402 | #1 |
| total vte patients | #1 |
| treatment idraparinux | #1 |
| rfviia 3 | #1 |
| cstatistic model discrimination | #1 |
| combination cdrscore | #1 |
| positive vte | #1 |
| study ecq | #1 |
| international thrombosis experts | #1 |
| wells clinical | #1 |
| acenocoumarol initial treatment | #1 |
| vte risk day | #1 |
| combination cdr | #1 |
| realtime bmode ultrasonography | #1 |
| anticoagulant fondaparinux | #1 |
| factor viii relatives | #1 |
| hokusai‐vte trial | #1 |
| heparinoid | #1 |
| cdr ddimer levels | #1 |
| predefined outcomes vte | #1 |
| death vte studies | #1 |
| patients wells rule | #1 |
| ddimer test combination | #1 |
| studies ttr | #1 |
| wells cdr | #1 |
| ventricular dysfunction edoxaban | #1 |
| carriers recurrence | #1 |
| 123362 | #1 |
| pvoq | #1 |
| leg ultrasonography patients | #1 |
| undvt | #1 |
| aptt org | #1 |
| patients khorana | #1 |
| patients tests prevalence | #1 |
| calfvein thrombi | #1 |
| cdr physicians | #1 |
| pulmonary embolism | #1 |
| dvt 56 | #1 |
| predefined outcomes | #1 |
| ventilation scan chest | #1 |
| patients uedvt uesvt | #1 |
| probability normal | #1 |
| guideline adherence justification | #1 |
| survival fondaparinux | #1 |
| einstein dvt patients | #1 |
| cancer cdr | #1 |
| dvt 69 | #1 |
| edoxaban east asian | #1 |
| aptt org 10172 | #1 |
| lowmolecularweight heparin treatment | #1 |
| crptest | #1 |
| patients compression ultrasonography | #1 |
| venous thrombosis mutations | #1 |
| acquired atiii deficiency | #1 |
| conventional therapy enoxaparin | #1 |
| prolactin venous thrombosis | #1 |
| echocardiography normotensive patients | #1 |
| relatives normal fviii | #1 |
| models development studies | #1 |
| vitamin antagonist patients | #1 |
| recurrent thromboembolism enoxaparin | #1 |
| botticelli dvt dose‐ranging | #1 |
| tinaquant assay comparison | #1 |
| respondents 60 | #1 |
| prevention topic guidelines | #1 |
| animal female heparin | #1 |
| combination cdrs | #1 |
| 378 patients edoxaban | #1 |
| beneficial lmwh | #1 |
| pulmonary embolism studies | #1 |
| extended treatment edoxaban | #1 |
| local radiologist experts | #1 |
| fxainhibitors vka recipients | #1 |
| deep vein thrombosis | #1 |
| laalleles platelets | #1 |
| patients normal tests | #1 |
| 95 3633 patients | #1 |
| 5 years lmwh | #1 |
| d‐dimer test | #1 |
| timeperiod | #1 |
| distal clots | #1 |
| uesvt recurrent vte | #1 |
| baseline pvo | #1 |
| edoxaban warfarin groups | #1 |
| apc resistance tests | #1 |
| pulmonary embolism tests | #1 |
| safety idraparinux | #1 |
| early time recurrence | #1 |
| 208791 | #1 |
| patients inherited thrombophilia | #1 |
| fondaparinux rfviia injection | #1 |
| normal venogram | #1 |
| desogestrelcontaining coagulation factors | #1 |
| wells simplified | #1 |
| acenocoumarol efficacy | #1 |
| abnormal ipg | #1 |
| abdominal pelvic strategies | #1 |
| einsteindvt | #1 |
| rfviia idraparinux | #1 |
| venous thrombosis recurrence | #1 |
| xainhibitors | #1 |
| combination ddimer testing | #1 |
| milliliter enoxaparin | #1 |
| compression ultrasonography presentation | #1 |
| lmwh venous thrombosis | #1 |
| pulmonary angiography strategies | #1 |
| women elevated levels | #1 |
| cdrs patients | #1 |
| ctscan qscan | #1 |
| cancer patients patients | #1 |
| quantitative dimer | #1 |
| placebo rnapc2 | #1 |
| alternative diagnoses patients | #1 |
| amplify trial apixaban | #1 |
| age recurrent vte | #1 |
| hemorrhage heparin | #1 |
| presence venous thrombosis | #1 |
| fviii hyperhomocysteinemia | #1 |
| standard therapy rivaroxaban | #1 |
| previous surveys netherlands | #1 |
| vka recipients | #1 |
| 023 relatives | #1 |
| noacs prevention | #1 |
| uesvt mortality | #1 |
| efficacy heparin therapy | #1 |
| heparin org 10172 | #1 |
| protein mortality | #1 |
| rnapc2 groups | #1 |
| vkas efficacy | #1 |
| scan pulmonary embolism | #1 |
| patients artificial graft | #1 |
| netherlands lmwh | #1 |
| placebo 25mg apixaban | #1 |
| riskstroponin | #1 |
| ivte | #1 |
| early discharge strategies | #1 |
| heparins data | #1 |
| 3633 patients edoxabantreated | #1 |
| pvo qscan | #1 |
| abnormal vaginal bleeding | #1 |
| enoxaparin primary efficacy | #1 |
| diagnostic strategies patients | #1 |
| protein levels mortality | #1 |
| protein resistance control | #1 |
| dimer test | #1 |
| members symptomatic carriers | #1 |
| 500 org | #1 |
| 750 μg l1 | #1 |
| baseline characteristics duration | #1 |
| 0·620·74 | #1 |
| rnapc2 groups placebo | #1 |
| ipe expert radiologists | #1 |
| tomography angiography vte | #1 |
| fibrinolysis levels | #1 |
| ldf diagnosis | #1 |
| patients examiner | #1 |
| failure rate efficiency | #1 |
| xageneration | #1 |
| avws prevalence | #1 |
| vka share | #1 |
| popliteal veins sensitivity | #1 |
| efficacy outcome | #1 |
| residual thrombotic mass | #1 |
| chest perfusion scintigraphy | #1 |
| patients antithrombotic prescriptions | #1 |
| mutation arg506 | #1 |
| asymptomatic extension | #1 |
| hokusai‐vte cancer study | #1 |
| efficacy conventional treatment | #1 |
| uesvt | #1 |
| enoxaparin vkas treatment | #1 |
| relative risks carriers | #1 |
| cvc crt | #1 |
| uesvt patients | #1 |
| anticoagulant treatment vte | #1 |
| 5‐snp scores | #1 |
| standard therapy months | #1 |
| noncarriers annual incidence | #1 |
| apc resistance factor | #1 |
| sspe proximal | #1 |
| molecular weight fondaparinux | #1 |
| intestinal microbiota coagulation | #1 |
| bleeding einstein | #1 |
| presenting location women | #1 |
| mdct expert radiologist | #1 |
| category fxainhibitors | #1 |
| ddimer test result | #1 |
| patients advanced malignancy | #1 |
| analysis hokusai | #1 |
| doses 75 microg | #1 |
| probability lung scan | #1 |
| clinically suspected dvt | #1 |
| bleeding rates quality | #1 |
| vte trial | #1 |
| anticoagulant treatment patients | #1 |
| risk homozygous women | #1 |
| chromogenic endotoxin | #1 |
| outcome recurrent | #1 |
| extended anticoagulation doacs | #1 |
| suspected cdr | #1 |
| crp test patients | #1 |
| 97 compression ultrasonography | #1 |
| ml1 ctpa | #1 |
| normal ddimer concentration | #1 |
| tb402 enoxaparin | #1 |
| factual hemorrhage heparin | #1 |
| messages justification | #1 |
| idraparinux versus | #1 |
| coagulation clinical | #1 |
| fviii vte | #1 |
| patients laalleles | #1 |
| withheld | #1 |
| pulmonary embolism role | #1 |
| year prophylaxis | #1 |
| mutation relatives | #1 |
| ivte clinical practice | #1 |
| 393 patients warfarin | #1 |
| departments orthopedic surgery | #1 |
| tb402 12 kg1 | #1 |
| patients tb402 | #1 |
| endotoxemia tests | #1 |
| idraparinux vte | #1 |
| simple diagnostic strategy | #1 |
| cancer patients uedvt | #1 |
| compression ultrasonography patients | #1 |
| subcutaneous nadroparin placebo | #1 |
| recurrent dvt dvt | #1 |
| ufh grade | #1 |
| increasing levels ft4 | #1 |
| 36 papers | #1 |
| lmwh acute treatment | #1 |
| apixaban conventional therapy | #1 |
| probability cdr | #1 |
| relatives mutation | #1 |
| lmwhmediated | #1 |
| evaluable patients apixaban | #1 |
| doacs initial heparin | #1 |
| cancer clinical presentation | #1 |
| role exclusion | #1 |
| category perelated death | #1 |
| apixaban randomized patients | #1 |
| longhaul flight | #1 |
| edoxabantreated | #1 |
| impedance thrombophlebitis | #1 |
| outcome clinically | #1 |
| progression vte | #1 |
| individualized duration | #1 |
| ultrasonography dvt | #1 |
| rule exclusion | #1 |
| loss subsequent pregnancy | #1 |
| referral basis | #1 |
| heparin acenocoumarol | #1 |
| patients idraparinux | #1 |
| deficiency proteins | #1 |
| dose daily edoxaban | #1 |
| united states rnapc2 | #1 |
| submassive incidence | #1 |
| ili score | #1 |
| enoxaparin tb402 | #1 |
| reported incidence vte | #1 |
| patency smokers | #1 |
| individuals air travel | #1 |
| d‐dimer level | #1 |
| selective ddimer thresholds | #1 |
| incidence ctni | #1 |
| non‐invasive diagnostic work‐up | #1 |
| ddimer result | #1 |
| cancer patients cvcs | #1 |
| nondiagnostic lung scan | #1 |
| initial treatment dvt | #1 |
| inherited thrombophilia patients | #1 |
| vte airline pilots | #1 |
| acute treatment lmwh | #1 |
| heparin initial treatment | #1 |
| exclusion pulmonary | #1 |
| fxiaso enoxaparin | #1 |
| preferred oral anticoagulant | #1 |
| lmwh delivery | #1 |
| vitamin antagonists time | #1 |
| vte day | #1 |
| subsequent symptomatic cancer | #1 |
| embolism sensitivity | #1 |
| 50 rivaroxaban | #1 |
| screening carriers | #1 |
| venography feasibility | #1 |
| constans score | #1 |
| unexplained dvt | #1 |
| fetal loss miscarriage | #1 |
| idraparinux | #1 |
| method factor | #1 |
| prediction models recurrence | #1 |
| severe presentation patients | #1 |
| intensity vkas doacs | #1 |
| fviii homocysteine | #1 |
| standardintensity vkas | #1 |
| clinical probability risk | #1 |
| elevated ctni patients | #1 |
| tests venography | #1 |
| strategies diagnostic management | #1 |
| nadroparin therapeutic dose | #1 |
| falsenormal | #1 |
| selective beta‐blocker treatment | #1 |
| vte difference | #1 |
| followup overt cancer | #1 |
| severity clinical presentation | #1 |
| 95 elevated ctni | #1 |
| laalleles | #1 |
| scores riete score | #1 |
| aged nadroparin | #1 |
| inr studies | #1 |
| polyethylenglycolhirudin | #1 |
| double reports | #1 |
| quantitative ddimer test | #1 |
| matisse clinical trials | #1 |
| relatives antithrombin | #1 |
| coagulationinhibiting | #1 |
| vte study | #1 |
| hokusaivte trial patients | #1 |
| casedescription | #1 |
| venous thromboembolism idraparinux | #1 |
| departments pharmacological prophylaxis | #1 |
| annual incidence patients | #1 |
| gentamicin patients netilmicin | #1 |
| avidin idrabiotaparinux | #1 |
| elderly patients dvt | #1 |
| silent dvt | #1 |
| recurrent vte statin | #1 |
| 50 years combination | #1 |
| current comprehensions | #1 |
| normohomocysteinemic relatives hyperhomocysteinaemia | #1 |
| synthetic selective factor | #1 |
| patients malignancy | #1 |
| fondaparinux unfractionated | #1 |
| presentation major | #1 |
| progression svt | #1 |
| 12 kg1 enoxaparin | #1 |
| influenza case patients | #1 |
| venous thromboembolism episode | #1 |
| prophylaxis idraparinux | #1 |
| anticoagulation period | #1 |
| relevant bleeding | #1 |
| compression ultrasound dvt | #1 |
| safety 60 dose | #1 |
| thiazoles venous | #1 |
| suspected perfusion scan | #1 |
| cstatistic major bleeding | #1 |
| atherosclerosis hemophilia patients | #1 |
| thromboembolism relatives | #1 |
| perfusion scan | #1 |
| enoxaparin vkas | #1 |
| management study | #1 |
| ldf cus | #1 |
| successful attenuation | #1 |
| ankle brachial prevalence | #1 |
| tests pulmonary embolism | #1 |
| postthrombotic symptoms patients | #1 |
| intravenous unfractionated | #1 |
| idrabiotaparinux idraparinux | #1 |
| uesvt median | #1 |
| compression ultrasonography | #1 |
| idraparinux standard therapy | #1 |
| lmwh replacement | #1 |
| pyridines recurrence | #1 |
| axa activity 5 | #1 |
| comparison vidas assay | #1 |
| presenting vte location | #1 |
| dalteparin 6 months | #1 |
| recurrence bleeding risk | #1 |
| failure diagnostic management | #1 |
| thromboembolism 3 | #1 |
| rnapc2 patients | #1 |
| hokusaivte study | #1 |
| cip diagnostic management | #1 |
| 20210a mutation | #1 |
| warfarin cstatistic | #1 |
| double heterozygous carriers | #1 |
| ufh grade 1a | #1 |
| suspected symptomatic | #1 |
| 7268 patients suspected | #1 |
| major bleeds vka | #1 |
| netherlands vka | #1 |
| extra hospital visits | #1 |
| tb402 50 | #1 |
| patients mismatched scan | #1 |
| symptomatic legs dvt | #1 |
| treated vka | #1 |
| fetal loss stillbirth | #1 |
| tests prevalence abi | #1 |
| cdrscore | #1 |
| travel‐related venous thrombosis | #1 |
| rfviia fondaparinux | #1 |
| idraparinux vitamin antagonist | #1 |
| long haul flights | #1 |
| combination nonhigh cdr | #1 |
| vte procoagulant activity | #1 |
| avidin placebo | #1 |
| lmwhs 95 | #1 |
| pulmonary embolism cdr | #1 |
| smoking graft patency | #1 |
| diagnostic management patients | #1 |
| venous thrombosis vwf | #1 |
| 547253 | #1 |
| doacs factor | #1 |
| adjusted dose ufh | #1 |
| vte fatal | #1 |
| coagulation factors markers | #1 |
| strategies abdominal pelvic | #1 |
| death venous thromboembolism | #1 |
| normal ddimer result | #1 |
| reduceddose noacs stroke | #1 |
| studies 3 months | #1 |
| clinically suspected uedvt | #1 |
| heparins inhibition | #1 |
| doac recipients | #1 |
| anticoagulants probability | #1 |
| sensitivity 100 percent | #1 |
| idraparinux months | #1 |
| oral anticoagulants phase | #1 |
| submassive elevated ctni | #1 |
| svt lmwh | #1 |
| isolated deficiencies proteins | #1 |
| elevated biomarkers hospital | #1 |
| thrombosis vte | #1 |
| guidelines abi | #1 |
| embolism wells | #1 |
| mortality postthrombotic symptoms | #1 |
| achieved inr patients | #1 |
| embolism randomized | #1 |
| elevated cardiac troponins | #1 |
| normal lung scan | #1 |
| dose rnapc2 | #1 |
| absolute annual incidences | #1 |
| controlled trials thrombophilia | #1 |
| idraparinux patients | #1 |
| puerperium diagnostic suspicion | #1 |
| standard treatment idraparinux | #1 |
| prothrombin 20210a mutation | #1 |
| amplify trial | #1 |
| qscan 3 weeks | #1 |
| dvt symptomatic | #1 |
| rabinovpaulin | #1 |
| symptomatic venous | #1 |
| 2 diagnostic management | #1 |
| recurrent vte immobilization | #1 |
| clinically suspected cancer | #1 |
| elevated fviii patients | #1 |
| clinical probability patients | #1 |
| ft4 level patients | #1 |
| venography tests | #1 |
| levels procoagulant factors | #1 |
| clinical uedvt | #1 |
| dimer result | #1 |
| relatives tafi levels | #1 |
| questionnaires thrombosis | #1 |
| thrice daily gentamicin | #1 |
| pioped study study | #1 |
| clinical decision rule | #1 |
| apixaban extended treatment | #1 |
| vka netherlands | #1 |
| oral apixaban treatment | #1 |
| lmwh edoxaban | #1 |
| 5mg apixaban | #1 |
| wells rules | #1 |
| venous thrombosis pregnancy | #1 |
| patients protein deficiencies | #1 |
| unexplained dvt patients | #1 |
| respondents lmwh | #1 |
| daily dalteparin treatment | #1 |
| oral rivaroxaban treatment | #1 |
| initial treatment patients | #1 |
| uedvt clinical | #1 |
| wells rule primary | #1 |
| treatment venous | #1 |
| wellscdrscore | #1 |
| failure cip | #1 |
| ambulatory computers | #1 |
| ddimer levels cdr | #1 |
| category death | #1 |
| wells rule exclusion | #1 |
| infections gentamicin | #1 |
| rivaroxaban lmwh vka | #1 |
| smoking patency | #1 |
| carriers pulmonary embolism | #1 |
| anticoagulants chemotherapy | #1 |
| heparins vitamin antagonists | #1 |
| normal levels fviii | #1 |
| matisse trials | #1 |
| probability ventilation | #1 |
| orthopedic surgery netherlands | #1 |
| rhir lmwh | #1 |
| ventilation lung scanning | #1 |
| procoagulant factors levels | #1 |
| dalteparin vte treatment | #1 |
| perelated death classification | #1 |
| standardintensity vkas doacs | #1 |
| doubleheterozygotes | #1 |
| dvt anticoagulants | #1 |
| segmental subsegmental | #1 |
| threemonth incidence | #1 |
| dimer clinical | #1 |
| recommendations dvt | #1 |
| graft patency patency | #1 |
| heparin initial | #1 |
| replacement vka | #1 |
| administration lmwh | #1 |
| prospective management study | #1 |
| frequency venous thromboembolism | #1 |
| 2479 relatives | #1 |
| beta thromboglobulin org | #1 |
| proximal location ipe | #1 |
| time recombinant | #1 |
| ddimer test | #1 |
| decisions duration | #1 |
| rivaroxaban dvt treatment | #1 |
| probabilityscan | #1 |
| dvt costs | #1 |
| fetal loss carriers | #1 |
| hyperhomocysteinemia relatives | #1 |
| fviii concentration | #1 |
| obstetric complications relatives | #1 |
| timerequirement | #1 |
| cart lower levels | #1 |
| plateletactivating antibodies risk | #1 |
| advanced malignancy | #1 |
| absolute thrombotic risk | #1 |
| relevant major | #1 |
| ultrasound compression ultrasound | #1 |
| flebography | #1 |
| ultrasound strategies patients | #1 |
| doacs cirrhosis patients | #1 |
| consensus strategy strategy | #1 |
| subsequent diagnosis malignancy | #1 |
| safety clinical utility | #1 |
| pulmonary embolism metaanalysis | #1 |
| 8h flight | #1 |
| scores occult cancer | #1 |
| efficacy vte | #1 |
| strategy abdominal pelvic | #1 |
| matisse dvt | #1 |
| edoxaban risk factors | #1 |
| ctscanreading | #1 |
| relatives elevated levels | #1 |
| pulmonary embolism carriers | #1 |
| dose response apixaban | #1 |
| 3633 patients edoxaban | #1 |
| 250 patients cancer | #1 |
| ccus 4 | #1 |
| elevated levels fviii | #1 |
| idraparinux placebo | #1 |
| cancer edoxaban | #1 |
| symptomatic pts | #1 |
| easier monitoring | #1 |
| 25mg apixaban | #1 |
| subcutaneous idraparinux | #1 |
| 0·2 edoxabantreated | #1 |
| incidence venous | #1 |
| patients retropubic prostatectomy | #1 |
| coagulation fibrinolytic proteins | #1 |
| wellscdr | #1 |
| level loss patency | #1 |
| current practise | #1 |
| proximal extent ipe | #1 |
| treatment cumulative incidence | #1 |
| combined training gps | #1 |
| netherlands 5 years | #1 |
| pharmacological methods prophylaxis | #1 |
| treatment experimental thrombosis | #1 |
| quantitative ddimer tests | #1 |
| false normal | #1 |
| antidote vitamin | #1 |
| vitamin anticoagulants | #1 |
| rate recurrent | #1 |
| weight heparinoid | #1 |
| uedvt terms | #1 |
| rivaroxaban standard therapy | #1 |
| nadroparin aspirin | #1 |
| clinical presentation category | #1 |
| obese hemophilic patients | #1 |
| cdr dimer | #1 |
| vte arterial | #1 |
| vitamin antagonists treatment | #1 |
| therapeutic doses lmwh | #1 |
| neoplasms heparin | #1 |
| 3 rfviia | #1 |
| association protein levels | #1 |
| vte location | #1 |
| presenting location vte | #1 |
| phase doacs | #1 |
| heparin vitamin antagonist | #1 |
| study centre duration | #1 |
| acenocoumarol heparin | #1 |
| controlledstudy | #1 |
| women edoxaban | #1 |
| 95ci tb402 | #1 |
| simplified geneva score | #1 |
| pulmonary embolism life | #1 |
| patients ivte | #1 |
| thrombosis vitamin | #1 |
| einsteinextension | #1 |
| cus strategies | #1 |
| elderly outpatients combination | #1 |
| single‐detector row | #1 |
| patients acute recurrent | #1 |
| venous thrombosis hyperglycemia | #1 |
| quantitative ddimer testing | #1 |
| low levels ft4 | #1 |
| levonorgestrel desogestrelcontaining | #1 |
| lmwh immobilization | #1 |
| cancer patients cdr | #1 |
| subcutaneous length life | #1 |
| heparin vitamin | #1 |
| treat thrombosis | #1 |
| enoxaparin heparin treatment | #1 |
| fviii women | #1 |
| fxainhibitors | #1 |
| included patients study | #1 |
| calf dvt ultrasound | #1 |
| prophylaxis crt | #1 |
| org aptt | #1 |
| 15 lmwh | #1 |
| hokusaivte trial | #1 |
| reduceddose noacs | #1 |
| thrombophlebitis tomography | #1 |
| cancer patients cancer | #1 |
| rabinov | #1 |
| thrombophilia patients doacs | #1 |
| khorana | #1 |
| inr range ttr | #1 |
| idraparinux 6 months | #1 |
| dalteparin major bleeding | #1 |
| enoxaparin initial treatment | #1 |
| normotensive patients studies | #1 |
| ldfr symptomatic legs | #1 |
| sustained antithrombotic effects | #1 |
| revascularisation procedures patients | #1 |
| patients reduceddose noacs | #1 |
| presentation category | #1 |
| oral edoxaban dose | #1 |
| relatives normal levels | #1 |
| elevated fviii age | #1 |
| recurrent vte doacs | #1 |
| presentation 1 week | #1 |
| types major bleeding | #1 |
| perelated death category | #1 |
| ddimer test patients | #1 |
| obese controls difference | #1 |
| practiceassistants | #1 |
| extensive screening cancer | #1 |
| excluding pulmonary | #1 |
| malignancy achieved inr | #1 |
| lmprovement | #1 |
| feasibility venography | #1 |
| diagnostic strategies strategies | #1 |
| 65±9years | #1 |
| symptomatic recurrent vte | #1 |
| control anticardiolipin antibodies | #1 |
| hokusai vte cancer | #1 |
| 12 months edoxaban | #1 |
| thrombo‐embolic events | #1 |
| original wells | #1 |
| protecht shr | #1 |
| local radiologist | #1 |
| outpatients symptomatic dvt | #1 |
| heparins cancer patients | #1 |
| probability categories | #1 |
| venous thromboembolism edoxaban | #1 |
| idraparinux 25 | #1 |
| patients clinical probability | #1 |
| vte risk coc | #1 |
| qscan | #1 |
| rivaroxaban acute dvt | #1 |
| ultrasonography leg veins | #1 |
| studies doac treatment | #1 |
| bleeding risk lmwh | #1 |
| somittrial | #1 |
| ultrasonography diagnostic | #1 |
| pulmonary embolism basis | #1 |
| org heparin | #1 |
| limited screening 95 | #1 |
| patients deep | #1 |
| 6 months avidin | #1 |
| dvt impedance plethysmography | #1 |
| nonhigh cdr | #1 |
| proportion pulmonary embolism | #1 |
| patients unexplained dvt | #1 |
| risk pulmonary embolism | #1 |
| crt cvc | #1 |
| 00515 | #1 |
| simplified rule proportion | #1 |
| months standard therapy | #1 |
| excluded pulmonary | #1 |
| clinical probability exclusion | #1 |
| vka treatment treatment | #1 |
| uedvt recurrent vte | #1 |
| platelets iqr | #1 |
| sgs pretest probability | #1 |
| preference doacs | #1 |
| symptomatic recurrent | #1 |
| survival lmwh | #1 |
| warfarin cancer patients | #1 |
| lmwh plasma levels | #1 |
| risk percentage points | #1 |
| superficial thrombophlebitis incidence | #1 |
| cancer patients ufh | #1 |
| initial heparin edoxaban | #1 |
| lmwh users incidence | #1 |
| compression ultrasonography detection | #1 |
| deepvein thrombosis incidence | #1 |
| efficiency diagnostic strategies | #2 |
| comparator individuals 95 | #2 |
| clinical prediction model | #2 |
| rfviia injection rfviia | #2 |
| sspe patients patients | #2 |
| patients hemorr2hages | #2 |
| ufh survival | #2 |
| safety pravastatin therapy | #2 |
| endotoxininduced activation coagulation | #2 |
| life treatment duration | #2 |
| n1423 | #2 |
| current clinical challenges | #2 |
| enoxaparin warfarin | #2 |
| analysis venous | #2 |
| adapted ddimer thresholds | #2 |
| patients khorana score | #2 |
| treatment ttr | #2 |
| wells cdr patients | #2 |
| angioplasty clopidogrel | #2 |
| mutations cleavage sites | #2 |
| suspected pulmonary | #2 |
| hasbled score hemorr2hages | #2 |
| fibrinolysis pentoxifylline | #2 |
| inflammation neutrophils thrombosis | #2 |
| fibrinolysis influenza | #2 |
| protein rnapc2 | #2 |
| test cancer | #2 |
| dimer thresholds | #2 |
| relevant patient subgroups | #2 |
| warfarintreated | #2 |
| ddimer determination | #2 |
| gcpg | #2 |
| graft occlusion patients | #2 |
| deficiencies proteins | #2 |
| recurrent deep | #2 |
| pulmonary embolism efficacy | #2 |
| embolism primary | #2 |
| coumarin sensitivity | #2 |
| symptomatic outpatients | #2 |
| crd42017056309 | #2 |
| anticoagulated patients permanent | #2 |
| sustained antithrombotic | #2 |
| suspected pulmonary embolism | #2 |
| standardised time intervals | #2 |
| amuse strategy | #2 |
| pregnancy venous thrombosis | #2 |
| endogenous activated protein | #2 |
| major clinically | #2 |
| ventilation scanning | #2 |
| rivaroxaban thiazoles | #2 |
| clinically suspected | #2 |
| measurement ankle brachial | #2 |
| suspected upper | #2 |
| hospitalbased strategies | #2 |
| factor iia | #2 |
| mild risk factor | #2 |
| thromboinflammation cardiovascular disease | #2 |
| global public awareness | #2 |
| risk deep | #2 |
| vte 1000 personyears | #2 |
| regression pravastatin | #2 |
| vte elevated fviii | #2 |
| vidas assay | #2 |
| pentasaccharide fondaparinux | #2 |
| incidence recurrent | #2 |
| quality warfarin treatment | #2 |
| wells cdr cdr | #2 |
| patients peripheral graft | #2 |
| blood coagulation inhibition | #2 |
| model cancer patients | #2 |
| major bleeding cindexes | #2 |
| hokusai vte | #2 |
| venographically | #2 |
| apixaban enoxaparin warfarin | #2 |
| incidental vte | #2 |
| scan normal | #2 |
| referred patients secondary | #2 |
| secondary efficiency | #2 |
| risk anticoagulation therapy | #2 |
| ate cancer patients | #2 |
| major bleeding recurrent | #2 |
| cancer recurrent vte | #2 |
| duration anticoagulant | #2 |
| influenza coagulation | #2 |
| thyroid hormone coagulation | #2 |
| levothyroxine exposure | #2 |
| annual incidences | #2 |
| 6 months scores | #2 |
| cdr variables cdr | #2 |
| rnapc2 | #2 |
| khorana protecht | #2 |
| interleukin‐10 response | #2 |
| decision rule | #2 |
| statins recurrent vte | #2 |
| f5 r506q | #2 |
| months 25 | #2 |
| low‐molecular‐weight heparin | #2 |
| surgical casts | #2 |
| cancer addition | #2 |
| fviii increased risk | #2 |
| lmwh users | #2 |
| lowmolecularweight heparin women | #2 |
| hellp syndrome prevalence | #2 |
| score dimer | #2 |
| c1173t dimorphism | #2 |
| 20210a mutations | #2 |
| crnm bleeds | #2 |
| lower clinical utility | #2 |
| uedvt performance | #2 |
| impedance plethysmography patients | #2 |
| risk khorana | #2 |
| employees longhaul flight | #2 |
| vte svt | #2 |
| computerized impedance | #2 |
| performance constans rule | #2 |
| prothrombin pulmonary embolism | #2 |
| screening fvl | #2 |
| embolism safely | #2 |
| enoxaparin difference | #2 |
| thrombosis normal | #2 |
| uptake noacs | #2 |
| ufh 6 months | #2 |
| subcutaneous length | #2 |
| raskob | #2 |
| 3306 patients | #2 |
| patients abi measurement | #2 |
| subsegmental emboli | #2 |
| principal safety outcome | #2 |
| tinaquant vidas | #2 |
| plasma concentrations endotoxin | #2 |
| influenza prothrombotic state | #2 |
| coagulation factors prolactin | #2 |
| years 36 | #2 |
| thrombophilic disorders | #2 |
| uedvt efficiency | #2 |
| oral direct inhibitors | #2 |
| 8292 patients | #2 |
| arterial thrombotic disease | #2 |
| administration rviia | #2 |
| presentation dvt | #2 |
| fibrinolytic proteins | #2 |
| rnapc2 doses | #2 |
| primary healthcare secondary | #2 |
| 17 apixaban | #2 |
| heparin effective | #2 |
| exposure flights | #2 |
| impedance plethysmography diagnosis | #2 |
| brain metastases doacs | #2 |
| thromboembolism thrombophilia | #2 |
| clinical pretest probability | #2 |
| heparin treatment influenza | #2 |
| age‐adjusted d‐dimer testing | #2 |
| venous thrombophlebitis | #2 |
| plasma d‐dimer concentration | #2 |
| ageadjusted ddimer testing | #2 |
| duration anticoagulant treatment | #2 |
| n832 | #2 |
| undiagnosed malignancy | #2 |
| bleeding edoxaban | #2 |
| women therapeutic doses | #2 |
| levels coagulation factors | #2 |
| sr34006 | #2 |
| antagonists vka | #2 |
| nct00633893 | #2 |
| pulmonary embolism purpose | #2 |
| rule combined | #2 |
| gauge plethysmography | #2 |
| pregnancy coc | #2 |
| primary efficacy outcome | #2 |
| limits cancer | #2 |
| vitamin antagonist rivaroxaban | #2 |
| biomarkers casecontrol studies | #2 |
| concomitant thrombophilic | #2 |
| hokusai vtecancer study | #2 |
| mdct reference standard | #2 |
| failure rate strategy | #2 |
| apixaban lmwh vka | #2 |
| vte orthopedic surgery | #2 |
| healthcare settings findings | #2 |
| bleeding rate patients | #2 |
| normohomocysteinemic relatives | #2 |
| 8 wk risk | #2 |
| beta‐receptor blockade | #2 |
| nonpermanent heart failure | #2 |
| medscape | #2 |
| heparin nadroparin | #2 |
| euro138 | #2 |
| incidental venous | #2 |
| resource utilisation treatment | #2 |
| thrombophilic defects risk | #2 |
| rivaroxaban 30 bid | #2 |
| pulmonary embolism asthma | #2 |
| hyperglycemia diagnosis | #2 |
| simplified wells | #2 |
| plasmin activity inhibition | #2 |
| primary hospitalbased strategies | #2 |
| compression doppler | #2 |
| vte 12 | #2 |
| cdr wells cdr | #2 |
| common alternative diagnoses | #2 |
| patients prior vte | #2 |
| serum tnf activity | #2 |
| travel venous | #2 |
| intrinsic cascade | #2 |
| treated anticoagulants | #2 |
| treated edoxaban | #2 |
| coagulation fibrinolytic | #2 |
| recurrent vte risk | #2 |
| mutations propeptide | #2 |
| ultrasonography patients | #2 |
| 95 dvt | #2 |
| outcome symptomatic | #2 |
| recombinant nematode | #2 |
| hemorr2hages atria scores | #2 |
| fvl carriers carriers | #2 |
| pharmacological strategies | #2 |
| uedvt cancer patients | #2 |
| bleeding complications treatment | #2 |
| treatment deep | #2 |
| secondary strategies | #2 |
| major bleeding intermediate | #2 |
| intermediate phenotype vte | #2 |
| acquired antithrombin | #2 |
| lmwh efficacy | #2 |
| patients oral factor | #2 |
| venous thromboembolism enoxaparin | #2 |
| amadeus study | #2 |
| central localization | #2 |
| mutation 35 | #2 |
| cha2ds2vasc nri | #2 |
| single administration tb402 | #2 |
| heparin compounds | #2 |
| computed venous | #2 |
| diagnostic lung | #2 |
| composite scores area | #2 |
| relation coagulation factors | #2 |
| efficiency strategy | #2 |
| venous | #2 |
| rule proportion | #2 |
| alife study | #2 |
| received edoxaban | #2 |
| death vte | #2 |
| clinical probability estimate | #2 |
| major bleeding edoxaban | #2 |
| blood coagulation rnapc2 | #2 |
| vein compressibility | #2 |
| 95 0·2 | #2 |
| exclusion pulmonary embolism | #2 |
| negative ageadjusted ddimer | #2 |
| vitamin antagonists quality | #2 |
| nematode anticoagulant | #2 |
| bleeding occurred | #2 |
| absolute incidence | #2 |
| 95 comparator individuals | #2 |
| hmb primary outcome | #2 |
| patients low probability | #2 |
| extended constans score | #2 |
| efficiency original score | #2 |
| exclude pulmonary | #2 |
| simplired test | #2 |
| heparin administered | #2 |
| idraparinux vitamin | #2 |
| recombinant hirudin cgp | #2 |
| events severe | #2 |
| pravastatin therapy children | #2 |
| normal ddimer test | #2 |
| ddimer assay | #2 |
| recurrence thromboembolism | #2 |
| 95 cancer patients | #2 |
| embolism deep | #2 |
| prolactin relation | #2 |
| dip placebo | #3 |
| patients proximalvein thrombosis | #3 |
| strategies efficiency | #3 |
| vte venous thrombosis | #3 |
| idrabiotaparinux | #3 |
| ddimer threshold | #3 |
| thromboembolism low | #3 |
| venous thrombosis cancer | #3 |
| vein thrombosis | #3 |
| mutation venous | #3 |
| protein thrombophilia | #3 |
| cohort study employees | #3 |
| dvt major | #3 |
| subcutaneous lmwh | #3 |
| lmwh | #3 |
| pad smokers | #3 |
| activecontrol | #3 |
| outpatient treatment dvt | #3 |
| bleeding 3 | #3 |
| recombinant hirudin rhir | #3 |
| negative predictive proportion | #3 |
| 20210ga | #3 |
| recurrent thromboembolic | #3 |
| einstein studies | #3 |
| apc protective | #3 |
| 95 wells rule | #3 |
| vte performance | #3 |
| dvt systematic differences | #3 |
| discontinuation ufh | #3 |
| female humans inhibitors | #3 |
| patients gastrointestinal cancer | #3 |
| low probability models | #3 |
| safely excluded | #3 |
| coagulation air travel | #3 |
| enoxaparin follow | #3 |
| inhibition blood coagulation | #3 |
| patients ultrasonography | #3 |
| patients venography | #3 |
| cancer patients ate | #3 |
| fxiaso | #3 |
| diagnosis pulmonary embolism | #3 |
| adult patients vte | #3 |
| intravenous loading dose | #3 |
| pulmonary embolism gestalt | #3 |
| heparin edoxaban | #3 |
| 3month incidence | #3 |
| diagnosis pulmonary | #3 |
| rnapc2 fviia | #3 |
| bleeding major | #3 |
| patients 6575 years | #3 |
| safely exclude | #3 |
| approaches primary | #3 |
| cancer active cancer | #3 |
| prevalence avws | #3 |
| patients ft4 level | #3 |
| desogestrelcontaining | #3 |
| cancer patients ipe | #3 |
| svt vte | #3 |
| safety acenocoumarol | #3 |
| venous thromboembolism apixaban | #3 |
| normal result | #3 |
| revised geneva efficiency | #3 |
| pulmonary embolism models | #3 |
| knee factor | #3 |
| einstein patients | #3 |
| diagnosis deep | #3 |
| multiple comorbidities polypharmacy | #3 |
| venous thrombosis positive | #3 |
| detection dvt | #3 |
| hokusai‐vte | #3 |
| venous thromboembolism | #3 |
| idrabiotaparinux warfarin | #3 |
| vte denmark | #3 |
| thrombophilic defect | #3 |
| 3633 patients | #3 |
| healthy donor fmt | #3 |
| dvt einstein | #3 |
| time venous thrombosis | #3 |
| prolactin controls | #3 |
| incidence total vte | #3 |
| incidence enoxaparin | #3 |
| efficacy heparin | #3 |
| outpatients dvt | #3 |
| compensated dic | #3 |
| topic heparin heparin | #3 |
| ventilation scan | #3 |
| vte 3 | #3 |
| gestalt probability | #3 |
| extensive screening | #3 |
| thiophenes venous | #3 |
| warfarin subgroup | #3 |
| factors prothrombin | #3 |
| venous arterial | #3 |
| studies hemorrhage | #3 |
| cdr combination | #3 |
| death clinical studies | #3 |
| treatment vitamin antagonists | #3 |
| placebo n4 | #3 |
| presenting location | #3 |
| ipe cancer patients | #3 |
| heparins cancer | #3 |
| hf severity risk | #3 |
| lowmolecularweight heparin placebo | #3 |
| prevalence hemostatic abnormalities | #3 |
| patients incidental vte | #3 |
| studies cus strategies | #3 |
| 100 years year | #3 |
| atria hemorr2hages | #3 |
| clinical models patients | #3 |
| selectine | #3 |
| ultrasonography strategies | #3 |
| recurrence thrombophlebitis | #3 |
| vte low | #3 |
| combination wells score | #3 |
| coagulation influence | #3 |
| gestalt 95 | #3 |
| safely | #3 |
| embolism‐related | #3 |
| favour lmwh | #3 |
| endogenous apc | #3 |
| dose reduction edoxaban | #3 |
| deep vein | #3 |
| alternative diagnoses | #3 |
| influence heparins | #3 |
| travel venous thrombosis | #3 |
| einstein dvt | #3 |
| cardiac troponine | #3 |
| composite stroke | #3 |
| patients venous | #3 |
| mechanisms heparin | #3 |
| treatment lowmolecularweight heparin | #3 |
| axa activity | #3 |
| primary rule | #3 |
| wells rule gestalt | #3 |
| ctnt risk stratification | #3 |
| lmwh pph | #3 |
| monoclonal replacement | #3 |
| venous thrombosis travel | #3 |
| venous thromboembolism thrombophilia | #3 |
| failurerate | #3 |
| nct00643201 | #3 |
| definition perelated death | #3 |
| dvt hip | #3 |
| factor viiic | #3 |
| tb‐402 | #3 |
| therapy venous | #3 |
| 12month study period | #3 |
| tfindependent | #3 |
| proximalvein thrombosis | #3 |
| capillary blood sample | #3 |
| older children vte | #3 |
| primary wells rule | #3 |
| stable acute | #3 |
| lowmolecularweight humans length | #3 |
| platelet agents | #3 |
| 3month vte incidence | #3 |
| ddimer assays | #3 |
| single diagnostic | #3 |
| sensitivity compression | #3 |
| cancer randomised trials | #3 |
| crt cancer patients | #3 |
| administration rnapc2 | #3 |
| age annual incidence | #3 |
| “gestalt | #3 |
| heparin heparin | #3 |
| dimer blood | #3 |
| pulmonary embolism primary | #3 |
| wells rule dvt | #3 |
| outcome venous | #3 |
| thromboembolism background | #3 |
| oral hormonal cross | #3 |
| impedance predictive | #3 |
| female hemorrhage humans | #3 |
| treatment vka | #3 |
| 02011 | #3 |
| vte major burden | #3 |
| incidental pulmonary embolism | #3 |
| hasbled | #3 |
| thrombophlebitis treatment | #3 |
| dvt primary | #3 |
| ft4 risk | #3 |
| patients wells | #3 |
| nadroparin placebo | #3 |
| patients 6 months | #3 |
| dalteparin difference | #3 |
| thombosis | #3 |
| chemotherapy prophylaxis | #3 |
| idiopathic venous | #3 |
| 6575 years | #3 |
| plethysmography impedance | #3 |
| pulmonary embolism‐related death | #3 |
| normal ctnt presentation | #3 |
| subcutaneous fondaparinux | #3 |
| antithrombin iii concentrate | #3 |
| users incidence | #3 |
| simplified wells specificity | #3 |
| baseline values placebo | #3 |
| probability dimer | #3 |
| pph lmwh | #3 |
| products follow | #3 |
| predictable pharmacokinetics | #3 |
| iii deficiency | #3 |
| treatment low | #3 |
| introduction mdct | #3 |
| standard therapy treatment | #3 |
| treatment vte recurrence | #3 |
| tinaquant assay | #3 |
| tinaquant | #4 |
| vte global burden | #4 |
| arterial thrombotic | #4 |
| travel thrombosis | #4 |
| women apc resistance | #4 |
| questionnaires venous | #4 |
| global disease burden | #4 |
| embolism tomography | #4 |
| ageadjusted cutoff patients | #4 |
| serial impedance | #4 |
| chads2 p0001 | #4 |
| hyperhomocysteinemic relatives | #4 |
| embolism dimer | #4 |
| advanced cancer 95 | #4 |
| disease vte | #4 |
| idiopathic venous thrombosis | #4 |
| thromboembolism occurred | #4 |
| 35±4 | #4 |
| bleeding anticoagulants | #4 |
| chemotherapy shr | #4 |
| patients primary healthcare | #4 |
| lmwhs standard heparin | #4 |
| prophylaxis lmwh | #4 |
| diagnostic management | #4 |
| thromboembolism factor | #4 |
| thromboembolism study | #4 |
| netherlands pulmonary | #4 |
| thrombosis uedvt | #4 |
| doac studies | #4 |
| dutch orthopedic | #4 |
| dose noacs | #4 |
| thrombosis ischemic stroke | #4 |
| embolism background | #4 |
| ultrasonography venous | #4 |
| risk occult cancer | #4 |
| global burden vte | #4 |
| “reversal | #4 |
| coagulation endotoxin | #4 |
| patient category | #4 |
| daily netilmicin | #4 |
| patient education treatment | #4 |
| embolism roc | #4 |
| rviia thrombin generation | #4 |
| lmwh female heparin | #4 |
| 6 months prophylaxis | #4 |
| population rivaroxaban | #4 |
| levels ft4 | #4 |
| control anticoagulation | #4 |
| serial impedance plethysmography | #4 |
| 3587 | #4 |
| abdomen relationship | #4 |
| total vte | #4 |
| vitamin antagonist treatment | #4 |
| symptomatic deep | #4 |
| noacs cancer patients | #4 |
| vte treatment patients | #4 |
| apixaban efficacy | #4 |
| hemostatic profile | #4 |
| dimer assays | #4 |
| patients crcl 60 | #4 |
| gramnegative bacteria humans | #4 |
| coagulation factors risk | #4 |
| safety pravastatin | #4 |
| diagnostic management strategies | #4 |
| venous thrombosis levels | #4 |
| patients edoxaban | #4 |
| thromboembolism vitamin | #4 |
| protecht | #4 |
| ddimer assay patients | #4 |
| vte total | #4 |
| 150 microg levonorgestrel | #4 |
| criteria dose reduction | #4 |
| contraindications treatment | #4 |
| nct00571649 | #4 |
| patients clinically | #4 |
| diagnostic prediction models | #4 |
| point dimer | #4 |
| venous thromboembolism patients | #4 |
| noacs netherlands | #4 |
| chinese korean ethnicity | #4 |
| negative point | #4 |
| 150 microg desogestrel | #4 |
| enoxaparin day | #4 |
| 10172 | #4 |
| thrombosis air | #4 |
| diagnosis uedvt | #4 |
| cleavage sites apc | #4 |
| recurrent vte months | #4 |
| chemotherapy vte prophylaxis | #4 |
| vte highincome countries | #4 |
| mbe patients | #4 |
| primary pulmonary embolism | #4 |
| 0651 | #4 |
| extended treatment | #4 |
| clot resolution | #4 |
| probability prospective | #4 |
| patients alternative diagnosis | #4 |
| disease burden vte | #4 |
| episode venous | #4 |
| activation fibrinolytic | #4 |
| vitamin antagonists | #4 |
| patients dimer | #4 |
| pregnancies carriers | #4 |
| patients fondaparinux | #4 |
| clot lysis patients | #4 |
| received warfarin | #4 |
| rfviia injection | #4 |
| women normal levels | #4 |
| clinically relevant bleeding | #4 |
| sankyo | #4 |
| thrombophilia 95 | #4 |
| vte netherlands | #4 |
| rule pulmonary | #4 |
| series venograms | #4 |
| vka treatment | #4 |
| lmwh cancer patients | #4 |
| estrogen therapy patients | #4 |
| preexisting heparin | #4 |
| patients nonpermanent | #4 |
| thrombosis deep | #4 |
| rivaroxaban 20 | #4 |
| predilution postdilution | #4 |
| thrombophilic families | #4 |
| edoxaban patients | #4 |
| leiden carriers | #4 |
| vte global | #4 |
| fibrin generation test | #4 |
| enoxaparin female humans | #4 |
| patients venous thromboembolism | #4 |
| chromogenic compounds | #4 |
| lowmolecular weight heparins | #4 |
| impedance plethysmography | #4 |
| procoagulant factors | #4 |
| venography patients | #4 |
| hemorr2hages | #4 |
| postthrombotic symptoms | #4 |
| thromboembolism treatment | #4 |
| refuted | #4 |
| measurement abi | #4 |
| patients submassive | #4 |
| lowmolecularweight heparin | #4 |
| proximal patients | #4 |
| warfarin 3 months | #4 |
| oral rivaroxaban | #4 |
| primary failure rate | #4 |
| amadeus trial | #4 |
| vitamin antagonists patients | #4 |
| risk vkas | #4 |
| thromboembolism systematic | #4 |
| 335 patients | #4 |
| thrombosis symptomatic | #4 |
| cancer vwf | #4 |
| thromboembolism arterial | #4 |
| life duration | #4 |
| treatment unfractionated heparin | #4 |
| death survey | #4 |
| treatment acute dvt | #5 |
| recurrent dvt patients | #5 |
| rivaroxaban enoxaparin vka | #5 |
| southern latin america | #5 |
| exclusion venous thromboembolism | #5 |
| efficiency patients | #5 |
| patients subtherapeutic | #5 |
| vka patients | #5 |
| hokusai | #5 |
| venous thromboembolism studies | #5 |
| panwards | #5 |
| dvt prevalence | #5 |
| vte factor | #5 |
| heparin compared | #5 |
| transfusion blood loss | #5 |
| endogenous activated | #5 |
| thromboembolism idraparinux | #5 |
| pad smoking | #5 |
| burden vte | #5 |
| thrombosis leg | #5 |
| patients pulmonary embolism | #5 |
| specificity thrombophlebitis | #5 |
| fviii families | #5 |
| thrombophlebitis ultrasonography | #5 |
| asymptomatic carriers mutation | #5 |
| 2 rules | #5 |
| ventricular dysfunction echocardiography | #5 |
| predilution | #5 |
| treatment fondaparinux | #5 |
| dimer combination | #5 |
| lmwh incidence | #5 |
| patients wells score | #5 |
| embolism reproducibility | #5 |
| iii plasminogen | #5 |
| patients superficial thrombophlebitis | #5 |
| incidence prognostic significance | #5 |
| cancer strategy | #5 |
| fviia rnapc2 | #5 |
| diagnostic strategies | #5 |
| pregnancy pph | #5 |
| endotoxin testing | #5 |
| secondary dvt | #5 |
| risk prediction scores | #5 |
| isolated calfvein thrombosis | #5 |
| 8292 | #5 |
| cdr patients | #5 |
| lmwh recommended | #5 |
| fh patients cvd | #5 |
| vte patients cancer | #5 |
| molecularweight heparin | #5 |
| outpatients hospital | #5 |
| ft4 level | #5 |
| thrombosis upper | #5 |
| diagnosis questionnaire | #5 |
| medea study | #5 |
| patients recurrent dvt | #5 |
| upper extremity thrombosis | #5 |
| clinical probability assessment | #5 |
| thromboembolism studies | #5 |
| low‐molecular‐weight | #5 |
| gestalt | #5 |
| previous venous thromboembolism | #5 |
| severe pph women | #5 |
| phlebography plethysmography | #5 |
| consensus strategy | #5 |
| 8491 | #5 |
| netilmicin patients | #5 |
| secondary venous thrombosis | #5 |
| compression ultrasound | #5 |
| patients parenteral anticoagulants | #5 |
| coronary angioplasty angioplasty | #5 |
| pulmonary embolism patients | #5 |
| preschool contraceptives | #5 |
| coc pregnancy | #5 |
| women warfarin | #5 |
| endotoxin chimpanzees | #5 |
| inhibition plasminogen activation | #5 |
| repeated ultrasonography | #5 |
| bleeding cancer | #5 |
| deepvein thrombosis | #5 |
| elevated plasma level | #5 |
| factor leiden 95 | #5 |
| clinical probability | #5 |
| vte 6 | #5 |
| antithrombotic drug treatment | #5 |
| daiichi sankyo | #5 |
| thromboembolism | #5 |
| day rivaroxaban | #5 |
| clinical presentation clinical | #5 |
| thromboembolism thrombosis | #5 |
| outcome major | #5 |
| adjusted dimer | #5 |
| cgp 39393 | #5 |
| suspected uedvt | #5 |
| hirudin treatment | #5 |
| sensitivity negative predictive | #5 |
| normal ctpa | #5 |
| thrombosis primary | #5 |
| low molecularweight humans | #5 |
| risk khorana score | #6 |
| thrombophilic defects | #6 |
| d‐dimer testing | #6 |
| antagonists treatment | #6 |
| apixaban treatment dose | #6 |
| endotoxin assays | #6 |
| clinically relevant subgroups | #6 |
| patients diagnostic | #6 |
| probability pulmonary | #6 |
| symptomatic legs | #6 |
| simplired dimer | #6 |
| venograms | #6 |
| dvt trial | #6 |
| warfarin venous thromboembolism | #6 |
| subcutaneous nadroparin | #6 |
| neoplasms pulmonary embolism | #6 |
| patients tests | #6 |
| recurrent pulmonary | #6 |
| grade 1a ufh | #6 |
| conventional therapy treatment | #6 |
| 12month cumulative incidence | #6 |
| daily gentamicin | #6 |
| patients factor mutation | #6 |
| thrombosis guidelines | #6 |
| elisapositive | #6 |
| vte controls | #6 |
| risk increasing levels | #6 |
| patients anticoagulation clinic | #6 |
| selective beta | #6 |
| rate major bleeding | #6 |
| cancer primary patients | #6 |
| compression stockings patients | #6 |
| patients lowmolecularweight heparin | #6 |
| outcome occurred | #6 |
| anticoagulant treatment | #6 |
| assay fibrin | #6 |
| treatment ufh | #6 |
| diagnostic workup | #6 |
| levonorgestrel desogestrel | #6 |
| effects levonorgestrel | #6 |
| 10±4 | #6 |
| treatment pulmonary embolism | #6 |
| anticoagulants female | #6 |
| subjects vte | #6 |
| oral anticoagulants dabigatran | #6 |
| 393 patients | #6 |
| low absolute risk | #6 |
| myocardial infarction ctni | #6 |
| duration rivaroxaban | #6 |
| patients uedvt | #6 |
| lmwh cancer | #6 |
| dalteparin dose | #6 |
| factor leiden carriers | #6 |
| thromboembolism bleeding | #6 |
| svt extension | #6 |
| blood coagulation mechanism | #6 |
| fviia inhibition | #6 |
| women hyperhomocysteinemia | #6 |
| ft4 patients | #6 |
| severe dic | #6 |
| anticoagulants hemorrhage | #6 |
| ultrasonography normal | #6 |
| wells rule | #6 |
| enoxaparin incidence | #6 |
| vte cancer | #6 |
| stressinduced hyperglycaemia | #6 |
| synthetic pentasaccharides | #6 |
| severe antithrombin | #6 |
| isolated deficiencies | #6 |
| edoxaban efficacy | #6 |
| arterial cardiovascular | #6 |
| patients suspected | #6 |
| leiden | #6 |
| funding bayer | #6 |
| embolism ventricular | #6 |
| dabigatran etexilate dabigatran | #6 |
| repeatedly normal | #6 |
| effects ufh | #6 |
| initial heparin treatment | #6 |
| lmwh users users | #6 |
| endotoxininduced activation | #6 |
| oral edoxaban | #6 |
| 39393 | #6 |
| dimer cut | #6 |
| vte anticoagulant treatment | #6 |
| proportion cancer patients | #6 |
| embolism pulmonary | #6 |
| symptoms intermittent claudication | #6 |
| perioperative blood loss | #6 |
| pulmonary embolism presence | #6 |
| patients iohexol | #6 |
| pembqol questionnaire | #6 |
| vka | #6 |
| incidence recurrence | #6 |
| subcutaneous low | #6 |
| treatment intermittent claudication | #6 |
| standardized morbidity ratio | #6 |
| prevalence vte | #6 |
| efficiency proportion | #6 |
| c1173 | #6 |
| patients proximal | #6 |
| amplify | #6 |
| treatment svt | #6 |
| patients pulmonary angiography | #6 |
| combined utility | #6 |
| 049 95 | #6 |
| fixeddose regimen | #6 |
| rates edoxaban | #7 |
| stockings control | #7 |
| incidence recurrent vte | #7 |
| presence cteph | #7 |
| levels factor viii | #7 |
| tb402 | #7 |
| aspirin combined | #7 |
| spiral sensitivity | #7 |
| negative predictive npv | #7 |
| major bleeding | #7 |
| major bleeding rate | #7 |
| phenprocoumon polymorphism | #7 |
| inhibitor apixaban | #7 |
| protein protein deficiencies | #7 |
| tnf injection | #7 |
| heparin org | #7 |
| arterial cardiovascular disease | #7 |
| treatment doac | #7 |
| ufh treatment | #7 |
| placebo rivaroxaban | #7 |
| negative ddimer test | #7 |
| plasma levels ifngamma | #7 |
| 597939 | #7 |
| unselected women | #7 |
| venous thrombosis treatment | #7 |
| embolism prospective | #7 |
| perelated death | #7 |
| neoplasms pulmonary | #7 |
| thrombophilia pregnancy loss | #7 |
| nondiagnostic lung scans | #7 |
| vitamin antagonists vka | #7 |
| statin treatment risk | #7 |
| carriers defects | #7 |
| rivaroxaban 10 | #7 |
| noncompressibility | #7 |
| 220 dabigatran | #7 |
| proportion older patients | #7 |
| thromboembolism adult | #7 |
| thromboembolism vte | #7 |
| silent pulmonary embolism | #7 |
| major bleeding vkas | #7 |
| prothrombin risk | #7 |
| thromboembolism total | #7 |
| ottawa score | #7 |
| thrombophlebitis adolescent | #7 |
| relation levels | #7 |
| patients standard heparin | #7 |
| blood coagulation humans | #7 |
| pulmonary embolism sensitivity | #7 |
| primary dvt | #7 |
| recurrent dvt | #7 |
| leg ultrasonography | #7 |
| dvt ipg | #7 |
| anticoagulant parameters | #7 |
| mutations factor viii | #7 |
| vka therapy | #7 |
| mpc1609 | #7 |
| antithrombin protein | #7 |
| vte cancer diagnosis | #7 |
| deepvein thrombosis patients | #7 |
| etexilate oral | #7 |
| carriers venous thromboembolism | #7 |
| 680 | #7 |
| combination ipg | #7 |
| specific antidotes | #7 |
| doppler skin | #7 |
| coagulation humans | #7 |
| administration bsf | #7 |
| relation prolactin levels | #7 |
| factor female humans | #7 |
| general practitioners guideline | #7 |
| day initial treatment | #7 |
| lung scan | #7 |
| diagnosis venous thrombosis | #7 |
| primary efficacy | #7 |
| diagnostic suspicion | #7 |
| prevention vte | #8 |
| current approach | #8 |
| arg506 factor | #8 |
| apixaban enoxaparin | #8 |
| p0001 hasbled score | #8 |
| thrombosis adolescent | #8 |
| deficiency antithrombin | #8 |
| inr determination | #8 |
| dimer tests | #8 |
| levonorgestrelcontaining | #8 |
| recurrent vte bleeding | #8 |
| initial heparin | #8 |
| increased fibrinolytic | #8 |
| ufh initial treatment | #8 |
| contrast venography | #8 |
| consecutive outpatients | #8 |
| heparin vitamin antagonists | #8 |
| nafronyl | #8 |
| wells scores | #8 |
| cancer pulmonary embolism | #8 |
| probability lung | #8 |
| overt cancer | #8 |
| pvoct | #8 |
| 1599 patients | #8 |
| fxi aso | #8 |
| vte score | #8 |
| comorbidity polypharmacy | #8 |
| risk employees | #8 |
| leiden prothrombin | #8 |
| symptomatic deepvein thrombosis | #8 |
| administration low | #8 |
| homocysteine markers | #8 |
| v617f jak2 | #8 |
| low clinical probability | #8 |
| analysis apixaban | #8 |
| persistent risk factors | #8 |
| occult cancer patients | #8 |
| oral glucocorticoids risk | #8 |
| chemotherapy low risk | #8 |
| dimer concentration | #8 |
| agnelli | #8 |
| years cumulative incidence | #8 |
| point ultrasonography | #8 |
| normal computed | #8 |
| enoxaparin vka | #8 |
| anticoagulants antineoplastic | #8 |
| bnp ctnt | #8 |
| discontinuation anticoagulant treatment | #8 |
| 0·2 | #8 |
| warfarin hazard ratio | #8 |
| objectively confirmed | #8 |
| severe preeclampsia patients | #8 |
| testing rule | #8 |
| acute symptomatic vte | #8 |
| recurrent vte mb | #8 |
| 150 enoxaparin | #8 |
| compression surveys | #8 |
| ageadjusted ddimer cutoff | #8 |
| vka lmwh | #8 |
| inherited thrombophilic | #8 |
| euro55 | #8 |
| vitamin antagonists vkas | #8 |
| tests pulmonary | #8 |
| nondiagnostic scan | #8 |
| venous thrombosis hyperhomocysteinaemia | #8 |
| optimal intensity | #8 |
| proximal deepvein thrombosis | #8 |
| international organisations | #8 |
| products humans | #8 |
| structured algorithm | #8 |
| proximal deep | #8 |
| carriers fvl | #8 |
| physicians stockings | #8 |
| duration treatment | #8 |
| prospective management | #8 |
| inr values patients | #8 |
| xii deficient | #8 |
| vascular endothelial barrier | #8 |
| aged phlebography | #8 |
| patients extended anticoagulation | #8 |
| patients symptomatic vte | #8 |
| patients excluded | #8 |
| lmwh grade 1a | #8 |
| thrombosis prophylaxis | #8 |
| unprovoked vte patients | #8 |
| treatment venous thrombosis | #8 |
| 97 95 | #8 |
| anticoagulation unprovoked vte | #8 |
| risks dvt | #8 |
| oral apixaban | #8 |
| oac adherence | #8 |
| funding daiichi | #8 |
| fondaparinux cancer patients | #9 |
| method enoxaparin | #9 |
| compression stockings prevention | #9 |
| apixaban oral factor | #9 |
| months efficacy | #9 |
| edoxaban major bleeding | #9 |
| iii concentrate | #9 |
| major bleeding treatment | #9 |
| oral contraceptive pregnancy | #9 |
| cofact | #9 |
| vte rcts | #9 |
| thrombosis compared | #9 |
| daiichisankyo | #9 |
| longterm treatment vte | #9 |
| concomitant cancer | #9 |
| incidence postthrombotic syndrome | #9 |
| comorbidities polypharmacy | #9 |
| thromboembolism cancer | #9 |
| diagnosis mdct | #9 |
| carriers factor leiden | #9 |
| strategies dimer | #9 |
| patients active cancer | #9 |
| enoxaparin factor | #9 |
| cancer factor | #9 |
| vte relatives | #9 |
| atiii concentrates | #9 |
| cancer episode | #9 |
| thrombosis thromboinflammation | #9 |
| serotonin platelet | #9 |
| tafi levels | #9 |
| treatment prophylaxis | #9 |
| patients fxa inhibitors | #9 |
| lipoproteina women | #9 |
| characteristics severity | #9 |
| generation pill | #9 |
| postdilution | #9 |
| abnormal vaginal | #9 |
| combination stroke | #9 |
| embolism venous | #9 |
| weight heparin | #9 |
| prothrombin 20210a | #9 |
| fxa inhibitor | #9 |
| acute medical illnesses | #9 |
| factors thrombophlebitis | #9 |
| normal ddimer | #9 |
| anticoagulant pathways | #9 |
| therapeutic dose patients | #9 |
| diagnostic prediction model | #9 |
| homocysteine women | #9 |
| heparin therapy patients | #9 |
| cancer cell extravasation | #9 |
| male oligosaccharides | #9 |
| discontinuing anticoagulation | #9 |
| büller | #9 |
| hemorr2hages atria | #9 |
| ultrasonogram | #9 |
| incidental pulmonary | #9 |
| placebo plasma levels | #9 |
| treatment edoxaban | #9 |
| thrombosis venous thromboembolism | #9 |
| crcl 60 | #9 |
| bled bleeding | #9 |
| nonpermanent | #9 |
| oral antithrombins | #9 |
| lmwh mortality | #9 |
| independent committee | #9 |
| severity clinical | #10 |
| venous thrombosis | #10 |
| asymptomatic pulmonary embolism | #10 |
| factor levels patients | #10 |
| 598 patients | #10 |
| aged antithrombin | #10 |
| bled scores | #10 |
| ddimer concentration | #10 |
| heparin nomogram | #10 |
| pregnancy carriers | #10 |
| fondaparinux risk | #10 |
| embolism patients | #10 |
| lmwh studies | #10 |
| subcutaneous metaanalysis | #10 |
| crp test | #10 |
| treatment vitamin | #10 |
| probability pulmonary embolism | #10 |
| simplified geneva | #10 |
| dvt lower extremity | #10 |
| inherited thrombophilic factors | #10 |
| oral thrombin inhibitor | #10 |
| nadroparine | #10 |
| rabbits administration | #10 |
| major bleeding crnmb | #10 |
| thrombosis background | #10 |
| intimamedia thickness imt | #10 |
| patients venous thrombosis | #10 |
| thr incidence | #10 |
| year years | #10 |
| wells | #10 |
| incidence major bleeding | #10 |
| factor prevention | #10 |
| inr cases | #10 |
| incidence 1000 personyears | #10 |
| magellan trial | #10 |
| hypocoagulable state | #10 |
| deficiencies antithrombin | #10 |
| 1215 patients | #10 |
| anticoagulants | #10 |
| schedule heparin | #10 |
| rfviia blood loss | #10 |
| induced coagulation | #10 |
| vte efficacy | #10 |
| gramnegative septicemia | #10 |
| cvd fh patients | #10 |
| 100 years discontinuation | #10 |
| treatment aprotinin | #10 |
| normohomocysteinemic | #10 |
| oral administration dabigatran | #10 |
| thrombophlebitis adult | #10 |
| protein dic | #10 |
| cancer patients vte | #10 |
| patients endotoxemia | #10 |
| ageadjusted cutoff | #10 |
| injection avidin | #10 |
| cus diagnosis | #10 |
| leg veins | #10 |
| magellan study | #10 |
| fii mutation | #10 |
| cancer patients lmwh | #10 |
| venous thromboembolic event | #10 |
| extremity deep | #10 |
| treatment uedvt | #10 |
| single loss | #10 |
| vnv | #10 |
| animal heparin | #10 |
| rates recurrent vte | #10 |
| retrospective study efficacy | #10 |
| 4470 | #10 |
| snp scores | #10 |
| embolism clinical | #10 |
| gentamicin treatment patients | #11 |
| lmwh pregnancy | #11 |
| thromboembolism major | #11 |
| incidence major | #11 |
| combination dimer | #11 |
| org 10172 | #11 |
| hospital lmwh | #11 |
| air travel | #11 |
| 750 μg | #11 |
| fondaparinux hemorrhage | #11 |
| cancer patients evidence | #11 |
| haemophilia vwd | #11 |
| reference testing | #11 |
| ufh studies | #11 |
| screening cancer | #11 |
| 880 patients | #11 |
| pulmonary angiography venography | #11 |
| crnmb 95 | #11 |
| embolism recurrence | #11 |
| previous venous | #11 |
| edoxaban | #11 |
| pcc dabigatran | #11 |
| recombinant human tnf | #11 |
| medical conferences | #11 |
| oral dabigatran | #11 |
| heparinoid org | #11 |
| pyridines thiazoles | #11 |
| sulfates dermatan | #11 |
| inhibitors hemorrhage | #11 |
| pregnancyrelated complications | #11 |
| mutations prevalence | #11 |
| carriers factor | #11 |
| patients probability | #11 |
| clinical pretest | #11 |
| endotoxin pentoxifylline | #11 |
| vte vwf | #11 |
| 30 microg ethinylestradiol | #11 |
| dvt | #11 |
| patients cvcs | #11 |
| dabigatran enoxaparin | #11 |
| cancer patients dvt | #11 |
| pulmonary embolism incidence | #11 |
| levels prolactin | #11 |
| embolism prevalence | #11 |
| endotoxin assay | #11 |
| knee clinical trials | #11 |
| intensity anticoagulation | #11 |
| lmwh pregnancies | #11 |
| d‐dimer levels | #11 |
| adult anticoagulants | #11 |
| weight humans | #11 |
| variation inr | #11 |
| ldfr | #11 |
| gps training | #11 |
| factor venous | #11 |
| patients cancer vte | #11 |
| patients anticoagulant treatment | #11 |
| topic venous | #12 |
| fondaparinux unfractionated heparin | #12 |
| concomitant disorders | #12 |
| peghirudin | #12 |
| observation risk | #12 |
| outpatient management patients | #12 |
| proximal vein | #12 |
| outcomes venous thromboembolism | #12 |
| warfarin therapy inr | #12 |
| anticoagulant factor | #12 |
| deficient women | #12 |
| livebirth rate | #12 |
| hirulog1 | #12 |
| stopping anticoagulation | #12 |
| anticoagulation unprovoked | #12 |
| noacs vka | #12 |
| female heparin humans | #12 |
| vte recurrence risk | #12 |
| months primary | #12 |
| safety efficiency | #12 |
| dvt treatment | #12 |
| patients lupus anticoagulant | #12 |
| vka noacs | #12 |
| recurrent vte | #12 |
| annual incidence vte | #12 |
| 72 children | #12 |
| event recurrence | #12 |
| risk venous | #12 |
| warfarin recurrent vte | #12 |
| subsegmental pulmonary emboli | #12 |
| warfarin treated | #12 |
| paulin | #12 |
| hemodynamically stable | #12 |
| patients lmwhs | #12 |
| nephro | #12 |
| thrombophilic | #12 |
| factor leiden prothrombin | #12 |
| bayer schering pharma | #12 |
| crd42013003526 | #12 |
| proximal veins | #12 |
| thrombin generation fibrinolysis | #12 |
| 9702 | #12 |
| women factor | #12 |
| doseadjustment | #12 |
| thrombosis dvt | #12 |
| ageadjusted ddimer | #12 |
| geneva score | #12 |
| 9295 | #12 |
| recurrent vte anticoagulation | #12 |
| venous thromboembolism incidence | #12 |
| pioped study | #12 |
| treatment crt | #12 |
| perelated | #12 |
| humanized arthroplasty | #12 |
| prevention venous thrombosis | #12 |
| bnp cardiac troponin | #12 |
| control metaanalysis | #12 |
| patients incidental | #12 |
| thrombosis young | #13 |
| bayer healthcare | #13 |
| pselectin patients | #13 |
| plethysmograms | #13 |
| continuous intravenous heparin | #13 |
| daily subcutaneous | #13 |
| inhibition tnf | #13 |
| association venous thrombosis | #13 |
| dvt lower | #13 |
| arixtra | #13 |
| rivaroxaban thiophenes | #13 |
| vte 64 | #13 |
| safety oral | #13 |
| vte groups | #13 |
| 95 carriers | #13 |
| ufh dalteparin | #13 |
| inferiority efficacy | #13 |
| antithrombin iii activity | #13 |
| clinical decision rules | #13 |
| factor viii apc | #13 |
| 86 percent | #13 |
| arterial thromboembolism ate | #13 |
| marder score | #13 |
| plethysmography | #13 |
| obesity haemophilia patients | #13 |
| superficial thrombophlebitis | #13 |
| prevention venous thromboembolism | #13 |
| strain gauge plethysmography | #13 |
| dimer threshold | #13 |
| safety doacs | #13 |
| indication anticoagulation | #13 |
| randomized cross | #13 |
| selective testing | #13 |
| groups inr | #13 |
| time prothrombin | #13 |
| occult cancer | #13 |
| dabigatran 220 | #13 |
| vte major | #13 |
| patients anticoagulant | #13 |
| nct00986154 | #13 |
| hematologic pregnancy trimester | #13 |
| recombinant hirudin rhirudin | #13 |
| bleeding events edoxaban | #13 |
| treatment venous thromboembolism | #13 |
| vte recurrence 95 | #13 |
| levels factor | #13 |
| uedvt | #13 |
| conventional anticoagulants | #13 |
| dabigatran vte | #13 |
| concomitant antiplatelet therapy | #13 |
| spiral computed tomography | #13 |
| heparin low | #13 |
| vte female humans | #13 |
| dimer testing | #13 |
| category studies | #13 |
| factor leiden mutation | #13 |
| major hip | #13 |
| vte | #13 |
| thrombosis acute | #13 |
| patients thrombophilia | #13 |
| deepvein thrombosis dvt | #13 |
| ultrasound strategies | #14 |
| acute deep | #14 |
| gastrointestinal bleeding patients | #14 |
| bolus intravenous injection | #14 |
| cancer patients anticoagulation | #14 |
| edoxaban warfarin | #14 |
| thrombophilia patients | #14 |
| standard heparin | #14 |
| dvt lower extremities | #14 |
| aspirin women | #14 |
| loss women | #14 |
| plasminogen apoa | #14 |
| lmwh vka | #14 |
| effects hyperthyroidism | #14 |
| patients vka therapy | #14 |
| revised geneva | #14 |
| unprovoked vte vte | #14 |
| 17 placebo | #14 |
| aged anticoagulants | #14 |
| pregnancy venous | #14 |
| obstetric complications women | #14 |
| patients dvt | #14 |
| patients outpatients | #14 |
| treatment duration patients | #14 |
| recurrent venous | #14 |
| low molecular | #14 |
| patients acute vte | #14 |
| incidence severe pph | #14 |
| higher ddimer levels | #14 |
| experimental endotoxaemia | #14 |
| fvl carriers | #14 |
| doseranging study | #14 |
| placebo rfviia | #14 |
| crnm | #14 |
| costs dvt | #14 |
| conventionaltherapy | #14 |
| thrombosis | #14 |
| vte months | #14 |
| factor viii levels | #14 |
| symptomatic pulmonary | #14 |
| edoxaban oral factor | #14 |
| aged plethysmography | #14 |
| awareness pad | #14 |
| vte statin | #14 |
| anticoagulant rivaroxaban | #14 |
| safety edoxaban | #14 |
| recurrent venous thromboembolism | #14 |
| 12 kg1 | #14 |
| limited screening | #14 |
| riete score | #14 |
| female fibrin | #14 |
| treated lmwh | #14 |
| atiii deficiency | #14 |
| cadherins endothelium | #14 |
| thromboembolism age | #14 |
| activation contact | #15 |
| antagonist vka | #15 |
| studies pulmonary | #15 |
| enoxaparin vte | #15 |
| thrombus growth | #15 |
| thyroid hormone excess | #15 |
| lomoparan | #15 |
| cteph incidence | #15 |
| factor leiden | #15 |
| abdominal pelvic | #15 |
| patients ctpa | #15 |
| arg506 | #15 |
| inr range | #15 |
| coc vte | #15 |
| vitaminkantagonists | #15 |
| inr patient | #15 |
| prophylaxis venous thromboembolism | #15 |
| coagulation | #15 |
| doacs aspirin | #15 |
| khorana score | #15 |
| arg562 | #15 |
| fondaparinux efficacy | #15 |
| lmwh ufh | #15 |
| diagnosis venous | #15 |
| clinically relevant endpoints | #15 |
| anticoagulants patients | #15 |
| oral direct factor | #15 |
| edoxaban treatment | #15 |
| probability assessment | #15 |
| established vte | #15 |
| primary safety outcome | #15 |
| pregnancy outcome pregnancy | #15 |
| prior venous thromboembolism | #15 |
| hyperthyroidism atrial fibrillation | #15 |
| experimental thrombosis | #15 |
| treatment 12 months | #15 |
| subcutaneous regimen | #15 |
| thrombosis diagnosis | #15 |
| 500 pg | #15 |
| thrombinography | #15 |
| subcutaneous enoxaparin | #15 |
| recombinant factor viia | #15 |
| generation oral | #15 |
| patients vitamin antagonists | #15 |
| control subjects prevalence | #15 |
| cardiovascular diseases thrombosis | #15 |
| symptomatic events | #15 |
| thrombosis low | #16 |
| risk clinically | #16 |
| vterelated death | #16 |
| patients acenocoumarol | #16 |
| deep venous thrombosis | #16 |
| positivity threshold | #16 |
| recurrent symptomatic | #16 |
| analysis rivaroxaban | #16 |
| 100 95 | #16 |
| major bleeding events | #16 |
| thrombosis haemostasis | #16 |
| warfarin acenocoumarol | #16 |
| 6 months placebo | #16 |
| postthrombotic syndrome children | #16 |
| thrombosis association | #16 |
| test clinical | #16 |
| thrombosis adult | #16 |
| netilmicin gentamicin | #16 |
| factor inhibitor | #16 |
| abdomino | #16 |
| bleeding aged | #16 |
| occult cancer detection | #16 |
| women unexplained | #16 |
| viia activity | #16 |
| thromboembolism time | #16 |
| combination clinical | #16 |
| avws patients | #16 |
| major bleeding anticoagulation | #16 |
| vte khorana score | #16 |
| impaired fibrinolysis | #16 |
| ddimer levels patients | #16 |
| dvt lmwh | #16 |
| arterial vascular events | #16 |
| subsequent pregnancy loss | #16 |
| cancer cancer patients | #16 |
| cancer screening patients | #16 |
| factors major | #16 |
| venous thrombosis warfarin | #16 |
| incidence pts | #17 |
| prohemostatic | #17 |
| recurrent vte events | #17 |
| women mutation | #17 |
| anticoagulant therapy patients | #17 |
| dvt prevention | #17 |
| endotoxemia bacteremia | #17 |
| vte edoxaban | #17 |
| gentamicin netilmicin | #17 |
| lower specificity | #17 |
| thrombosis clinical | #17 |
| fragment f1 | #17 |
| patients impedance | #17 |
| anticoagulants drug | #17 |
| thromboembolism patients | #17 |
| diagnosis svt | #17 |
| mutation women | #17 |
| fibrinolysis treatment | #17 |
| patients overt hypothyroidism | #17 |
| female humans vte | #17 |
| vkorc1 gene | #17 |
| 12 months patients | #17 |
| pharmo record linkage | #17 |
| dimer assay | #17 |
| compared enoxaparin | #17 |
| topic hemorrhage humans | #17 |
| ctscans | #17 |
| 516 patients | #17 |
| 2688 | #17 |
| anticoagulants clinical | #17 |
| permanent patients | #17 |
| lmwhs patients | #17 |
| scan classification | #17 |
| factors venous | #17 |
| hematoma heparin | #17 |
| factor monoclonal | #17 |
| rivaroxaban oral factor | #17 |
| excessive blood loss | #17 |
| management crt | #17 |
| vka vte | #18 |
| intravenous heparin therapy | #18 |
| prothrombin g20210a | #18 |
| lmwh doacs | #18 |
| simplired | #18 |
| annual incidence | #18 |
| 4 clinical | #18 |
| stable anticoagulation | #18 |
| weight adjusted | #18 |
| warfarin hazard | #18 |
| commercial airline pilots | #18 |
| 023 | #18 |
| outcome events | #18 |
| women pregnancy loss | #18 |
| edoxaban vte | #18 |
| proximal vein thrombosis | #18 |
| apc thrombin generation | #18 |
| flight hours | #18 |
| cancer vte | #18 |
| thrombosis pulmonary | #18 |
| poc test | #18 |
| venous thromboembolism rivaroxaban | #18 |
| hivinfected patients cart | #18 |
| antithrombotic treatment patients | #18 |
| thromboembolism venous | #18 |
| sanofi aventis | #18 |
| combined form | #18 |
| diagnostic strategy | #18 |
| aptt heparin | #18 |
| favor lmwh | #18 |
| patients strategy | #18 |
| treatment vkas | #18 |
| vka edoxaban | #18 |
| thrombosis total | #18 |
| relevant nonmajor | #18 |
| versions version | #19 |
| lmwh patients | #19 |
| acute recurrent | #19 |
| ufh lmwh | #19 |
| patients elevated biomarkers | #19 |
| fibrinolytic response | #19 |
| low platelets | #19 |
| local angiogenesis | #19 |
| active search | #19 |
| venography sensitivity | #19 |
| subcutaneous dalteparin | #19 |
| increased risk relatives | #19 |
| retropubic prostatectomy | #19 |
| prognostic echocardiography | #19 |
| coagulation studies | #19 |
| systemic activation coagulation | #19 |
| antibodynegative | #19 |
| doubleblinding | #19 |
| recurrent venous thrombosis | #19 |
| patients prevalence | #19 |
| ipdma | #19 |
| endogenous fibrinolysis | #19 |
| adjusted dose | #19 |
| vwf vte | #19 |
| 56 95 | #19 |
| extended oral | #19 |
| recurrence vte | #19 |
| oral dabigatran enoxaparin | #19 |
| patients major bleeding | #19 |
| vitamin antagonist | #19 |
| edoxaban dose | #19 |
| abnormal ultrasound | #19 |
| patients derivation | #19 |
| increased fibrinolytic activity | #19 |
| thromboembolism administration | #19 |
| ddimer tests | #19 |
| symptomatic dvt | #19 |
| treatment heparin | #19 |
| venous thromboembolism relatives | #19 |
| fondaparinux enoxaparin | #19 |
| patients sspe | #19 |
| 35 women | #19 |
| dvt rivaroxaban | #19 |
| objective testing | #19 |
| studies factor | #19 |
| subsegmental | #20 |
| blindly | #20 |
| thrombosis ultrasonography | #20 |
| pregnancyrelated vte | #20 |
| absolute risk | #20 |
| diagnostic workup patients | #20 |
| ctnt bnp | #20 |
| statin vte | #20 |
| shr 95 | #20 |
| synthetic cross | #20 |
| prothrombin mutation | #20 |
| treatment vte | #20 |
| intravenous injections | #20 |
| risk thrombophilia | #20 |
| dabigatran 150 | #20 |
| thrombophilia vte | #20 |
| abi measurement | #20 |
| excluded patients | #20 |
| new agent | #20 |
| nadroparin | #20 |
| antitpo | #20 |
| incidences death | #20 |
| injections subcutaneous | #20 |
| life venous thrombosis | #20 |
| established atherosclerosis | #20 |
| proteins thrombin | #20 |
| control situation | #20 |
| therapy rivaroxaban | #20 |
| calf veins | #20 |
| single criterion | #20 |
| impedance plethysmography ipg | #20 |
| malignancy time | #20 |
| anticoagulation clinic | #20 |
| portola | #20 |
| carriers prothrombin | #20 |
| distance treatment | #20 |
| versions questionnaire | #20 |
| warfarin edoxaban | #20 |
| cancer severity | #20 |
| recurrence bleeding | #20 |
| guidance ssc | #20 |
| symptomatic venous thrombosis | #20 |
| compared ufh | #20 |
| residual venous | #20 |
| antagonists vkas | #20 |
| abi risk factors | #20 |
| patients ddimer testing | #20 |
| standardtherapy hazard ratio | #20 |
| major bleeding patients | #21 |
| hemodynamically stable patients | #21 |
| d‐dimer | #21 |
| risk cohort study | #21 |
| treatment apixaban | #21 |
| thromb | #21 |
| occult malignancy | #21 |
| prothrombin 20210 | #21 |
| vte patients | #21 |
| ddimer concentrations | #21 |
| fibrinolysis inflammation | #21 |
| concomitant anti | #21 |
| outcome incidence | #21 |
| doacs lmwhs | #21 |
| thrombosis anticoagulants | #21 |
| venogram | #21 |
| carriers noncarriers | #21 |
| current standard treatment | #21 |
| hemostatic abnormalities | #21 |
| patients 3 months | #21 |
| distance quality | #21 |
| treatment acenocoumarol | #21 |
| disease ischemic | #21 |
| internists cardiologists | #21 |
| discriminatory performance | #21 |
| deep venous | #21 |
| acute vte | #22 |
| cmax ctrough | #22 |
| recurrent thromboembolism | #22 |
| alternative anticoagulation | #22 |
| thrombophilia screening | #22 |
| dose subcutaneous | #22 |
| daily enoxaparin | #22 |
| treatment dvt | #22 |
| host defense response | #22 |
| hormonal cross | #22 |
| venous thromboembolic | #22 |
| safety treatment | #22 |
| dichotomously | #22 |
| patients immobilization | #22 |
| time inr | #22 |
| patients severe hf | #22 |
| anticoagulants humans | #22 |
| vascular endotoxins | #22 |
| patients recurrent symptoms | #22 |
| doppler venous thrombosis | #22 |
| ttr inr | #22 |
| bleeding treatment | #22 |
| dimer age | #22 |
| lpa plasminogen | #22 |
| patientyears | #22 |
| anticoagulants heparin | #22 |
| riskbenefit ratio | #22 |
| public awareness | #22 |
| cttr | #22 |
| kakkar | #23 |
| 5392 | #23 |
| cancer patients risk | #23 |
| 2 investigators | #23 |
| clotbound thrombin | #23 |
| hasbled score | #23 |
| patients coagulation disorders | #23 |
| rivaroxaban dosing | #23 |
| ambulatory cancer patients | #23 |
| life pulmonary embolism | #23 |
| vte studies | #23 |
| lower extremity amputation | #23 |
| elevated ctni | #23 |
| fondaparinux | #23 |
| odis | #23 |
| venous arterial thrombosis | #23 |
| normal angiogram | #23 |
| bidirectional relation | #23 |
| gentamicin patients | #23 |
| percentage increase | #23 |
| time platelet | #23 |
| development dic | #23 |
| n1157 | #23 |
| direct factor inhibitors | #23 |
| standardduration | #23 |
| enoxaparin 40 | #23 |
| 011 | #23 |
| prevalence venous thromboembolism | #23 |
| thromboembolism anticoagulants | #23 |
| recurrence venous | #23 |
| prevalence deficiencies | #24 |
| patients severe bleeding | #24 |
| fondaparinux placebo | #24 |
| specific antidote | #24 |
| therapy heparin | #24 |
| food drugs | #24 |
| recurrent thromboembolism patients | #24 |
| predefined criteria | #24 |
| month incidence | #24 |
| bleeding complication | #24 |
| ufh patients | #24 |
| patients abnormal perfusion | #24 |
| desogestrel levonorgestrel | #24 |
| followup incidence | #24 |
| thrombosis carriers | #24 |
| 049 | #24 |
| safety fondaparinux | #24 |
| patients acute treatment | #24 |
| years episode | #24 |
| presence dvt | #24 |
| independent external validation | #24 |
| lowmolecularweight humans | #24 |
| recurrent pulmonary embolism | #24 |
| parameters fibrinolysis | #24 |
| viiic | #24 |
| overt hyperthyroidism | #24 |
| subtherapeutic | #24 |
| rates venous thromboembolism | #24 |
| ddimer testing | #24 |
| a21gly | #24 |
| levels fviii | #24 |
| suggestions improvement | #25 |
| cha2ds2vasc chads2 | #25 |
| fatima | #25 |
| f1 2 levels | #25 |
| perfusion lung scan | #25 |
| treatment symptomatic | #25 |
| lmwh treatment | #25 |
| specificity efficiency | #25 |
| vte clinical | #25 |
| anatomical extent | #25 |
| xii activity | #25 |
| willebrand factor adamts13 | #25 |
| thromboembolism acute | #25 |
| expert radiologists | #25 |
| fibrinogen degradation | #25 |
| middeldorp | #25 |
| amadeus | #25 |
| studies lmwh | #25 |
| factors anticoagulants | #25 |
| patients gastrointestinal bleeding | #25 |
| influence smoking | #25 |
| sepsis intravascular coagulation | #25 |
| homozygous carriers | #26 |
| rethoracotomy | #26 |
| parameters risk | #26 |
| asymptomatic carriers | #26 |
| viia complex | #26 |
| venous thromboemboli | #26 |
| patients essential thrombocythaemia | #26 |
| patients symptomatic dvt | #26 |
| failure rate | #26 |
| miscarriage stillbirth | #26 |
| edoxaban vka | #26 |
| rate recurrent vte | #26 |
| thromboprophylaxis hospitalized patients | #26 |
| major bleeding bleeding | #26 |
| specificity negative predictive | #26 |
| doacs vitamin antagonists | #26 |
| treatment lmwh | #26 |
| hormonal manipulation | #26 |
| unprovoked vte | #26 |
| ecq | #26 |
| 9715 | #26 |
| events year | #26 |
| edoxaban versus | #26 |
| dalteparin ufh | #26 |
| patients cdr | #26 |
| vte thr | #27 |
| treating physician | #27 |
| 0·63 | #27 |
| lmwh prophylaxis | #27 |
| current guidance | #27 |
| perfusion lung | #27 |
| venous thromboembolism carriers | #27 |
| cancer spread | #27 |
| extremity venous | #27 |
| vte doacs | #27 |
| enoxaparin female | #27 |
| lowmolecularweight heparin patients | #27 |
| airline pilots | #27 |
| nonmajor | #27 |
| thrombosis venous | #27 |
| thrombocytopenia antibodies | #27 |
| unprovoked venous | #27 |
| noncarriers 95 | #27 |
| day 35 | #27 |
| patients 50 | #27 |
| patients major hemorrhage | #27 |
| anticoagulants blood | #27 |
| combined training | #27 |
| patients elevated levels | #27 |
| female heterozygote | #27 |
| months studies | #27 |
| anticoagulants factor | #27 |
| npv patients | #27 |
| training gps | #27 |
| thrombophlebitis | #27 |
| low molecularweight heparin | #27 |
| pembqol | #28 |
| vitamin aged | #28 |
| factors recurrent | #28 |
| 2½ | #28 |
| acutely medical patients | #28 |
| cancer venous thromboembolism | #28 |
| coagulation tissue factor | #28 |
| unexplained | #28 |
| therapeutic doses | #28 |
| rfviia placebo | #28 |
| pph severe pph | #28 |
| tests diagnostic | #28 |
| patients unprovoked | #28 |
| monitoring therapy | #28 |
| receiving rivaroxaban | #28 |
| anticoagulation women | #28 |
| hirudin therapy | #28 |
| objective tests | #28 |
| 4650 | #28 |
| embolism retrospective | #28 |
| specific reversal agent | #28 |
| presentation followup | #28 |
| apc plasma | #28 |
| anticoagulants compared | #28 |
| vte 6 months | #28 |
| patients avws | #29 |
| aminoglycoside therapy | #29 |
| dabigatran pcc | #29 |
| patients standard therapy | #29 |
| pulmonary embolism recurrence | #29 |
| 1000 individuals | #29 |
| prediction scores | #29 |
| cindexes | #29 |
| pulmonary angiography | #29 |
| bleeding increased | #29 |
| blind trials | #29 |
| spread cancer | #29 |
| thrombosis 95 | #29 |
| acenocoumarol patients | #29 |
| 8240 | #29 |
| plateletactivating antibodies | #29 |
| diagnosis dvt | #29 |
| years year | #29 |
| dvt pulmonary embolism | #29 |
| recurrence svt | #29 |
| pbac score | #29 |
| thrombo | #29 |
| current management strategies | #29 |
| dutch famine | #29 |
| heparin versus | #29 |
| resistance activated protein | #29 |
| g20210a mutation | #29 |
| aged morpholines | #29 |
| direct oral anticoagulants | #29 |
| pulmonary embolism death | #29 |
| authors incidence | #29 |
| sex‐specific differences | #29 |
| aspirin placebo | #29 |
| oral glucocorticoids | #29 |
| thrombosis treatment | #29 |
| septicemia | #29 |
| major bleeding rivaroxaban | #29 |
| prevention venous | #30 |
| rule patients | #30 |
| cancer venous | #30 |
| patients vte | #30 |
| doac vka | #30 |
| residual thrombosis | #30 |
| 1000 personyears incidence | #30 |
| 95 risk | #30 |
| markers coagulation activation | #30 |
| direct oral factor | #30 |
| administration pentoxifylline | #30 |
| f1 2 | #30 |
| ufh vte | #30 |
| embolism risk | #30 |
| vte coc | #30 |
| support techniques | #30 |
| costs diagnosis | #30 |
| xii factor | #30 |
| subcutaneous heparin | #30 |
| thromboembolism warfarin | #30 |
| new anticoagulants | #30 |
| patients deepvein thrombosis | #31 |
| prevalence probability | #31 |
| term risk | #31 |
| dimer cutoff | #31 |
| vte ufh | #31 |
| events 95 | #31 |
| analysis reviewers | #31 |
| placebo observation | #31 |
| antithrombotic therapies | #31 |
| imaging sensitivity specificity | #31 |
| 0206 | #31 |
| 2 antiplasmin | #31 |
| thromboembolism adolescent | #31 |
| bled | #31 |
| iii activity | #31 |
| apixaban placebo | #31 |
| rhir | #31 |
| incidence cteph | #31 |
| ufh fondaparinux | #31 |
| pharmacological prophylaxis | #31 |
| standardtherapy | #31 |
| ventilation scintigraphy | #31 |
| extended prophylaxis | #31 |
| dvt pulmonary | #31 |
| recurrent patients | #31 |
| rfviia novoseven | #31 |
| 8755 | #31 |
| incidence pph | #31 |
| thromboprophylaxis risk | #31 |
| experimental endotoxemia | #31 |
| recurrent episode | #31 |
| recurrent vte patients | #31 |
| inhibitor edoxaban | #31 |
| women recurrent miscarriage | #31 |
| activation blood coagulation | #31 |
| ufh | #32 |
| negative dimer | #32 |
| year 95 | #32 |
| factor female | #32 |
| treatment anticoagulants | #32 |
| negative septicemia | #32 |
| generation patients | #32 |
| varicosis | #32 |
| age adjusted | #32 |
| suspected patients | #32 |
| factors thrombolytic | #32 |
| khorana score patients | #32 |
| low clinical | #32 |
| international society thrombosis | #32 |
| normal genotype | #32 |
| resistance activated | #32 |
| netherlands predictive | #32 |
| warfarin vte | #32 |
| parenteral anticoagulants | #32 |
| parenteral anticoagulation | #32 |
| leiden mutation | #32 |
| unitage | #33 |
| activation factors | #33 |
| warfarin risks | #33 |
| rhirudin | #33 |
| nephrotoxicity gentamicin | #33 |
| factor viii patients | #33 |
| pulmonary angiogram | #33 |
| thromboembolism young | #33 |
| cancer patients diagnosis | #33 |
| anticoagulant protein | #33 |
| active implementation | #33 |
| chapter patients | #33 |
| mega study | #33 |
| additional tests | #33 |
| low probability | #33 |
| heparin lmwh | #33 |
| apixaban treatment | #33 |
| subcutaneous male | #33 |
| prophylaxis vte | #33 |
| data meta | #33 |
| 3 months treatment | #34 |
| vte compared | #34 |
| anticoagulant | #34 |
| apcsr | #34 |
| subsegmental pulmonary embolism | #34 |
| 10 95 | #34 |
| phytonadione | #34 |
| deficiency protein | #34 |
| lmwh unfractionated heparin | #34 |
| compare efficacy | #34 |
| pregnancy loss women | #34 |
| 590 | #34 |
| 9241 | #34 |
| reocclusion patients | #34 |
| bilateral venography | #34 |
| hemorrhage heparin humans | #34 |
| grade 1a | #34 |
| vte thrombophilia | #34 |
| control trials | #34 |
| thrombosis lower | #34 |
| warfarin adult | #34 |
| plasmin alpha | #34 |
| statin association | #35 |
| surgery hip | #35 |
| patients efficiency | #35 |
| prevention model | #35 |
| rviia | #35 |
| embolism | #35 |
| pph blood loss | #35 |
| neoplasms venous | #35 |
| activation coagulation | #35 |
| weekly subcutaneous | #35 |
| lung scanning | #35 |
| 36 95 | #35 |
| radiologists diagnosis | #35 |
| enoxaparin prevention | #35 |
| anticoagulants benzimidazoles | #35 |
| risk members | #35 |
| acute symptomatic | #36 |
| fibrinogen depletion | #36 |
| iii antithrombin | #36 |
| venous thromboembolism dabigatran | #36 |
| fibrinolytic activation | #36 |
| thrombophilia venous | #36 |
| studies echocardiography | #36 |
| levels coagulation | #36 |
| hellp patients | #36 |
| treatment acute vte | #36 |
| 4139 | #36 |
| venous thromboembolic disease | #36 |
| 287 patients | #36 |
| catheterrelated infection | #36 |
| riskbenefit | #36 |
| inherited risk factors | #36 |
| dose reduction patients | #36 |
| 1698 | #36 |
| regular monitoring | #36 |
| viii levels | #36 |
| factors travel | #36 |
| peripheral endovascular | #36 |
| novoseven | #36 |
| perelated mortality | #37 |
| magellan | #37 |
| risk factors pts | #37 |
| rivaroxaban thromboprophylaxis | #37 |
| lwmh | #37 |
| suspected venous | #37 |
| bagsvaerd | #37 |
| recombinant hirudin | #37 |
| excluding | #37 |
| ototoxicity nephrotoxicity | #37 |
| factors thrombophilia | #37 |
| warfarin 95 | #37 |
| ctpa patients | #37 |
| venography | #37 |
| risk venous thrombosis | #37 |
| prophylactic heparin | #37 |
| anticoagulant action | #37 |
| outcome composite | #37 |
| anticoagulants prevention | #37 |
| genotype 95 | #37 |
| tat complexes | #37 |
| cumulative incidence vte | #37 |
| vte increased | #37 |
| screening occult | #37 |
| pad studies | #37 |
| thrombosis humans | #37 |
| congenital deficiencies | #38 |
| anticoagulants female humans | #38 |
| catheterrelated thrombosis | #38 |
| coagulation protein | #38 |
| submassive pulmonary | #38 |
| 3306 | #38 |
| fetal loss women | #38 |
| 2835 | #38 |
| age recurrence | #38 |
| vte cancer patients | #38 |
| 10 total | #38 |
| sensitivity biomarkers | #38 |
| restenosis reocclusion | #38 |
| vte bleeding | #38 |
| recurrence day | #38 |
| nonmajor bleeding | #38 |
| doac lmwh | #38 |
| patients ddimer levels | #38 |
| rivaroxaban placebo | #38 |
| low molecular weight | #39 |
| systemic inflammatory responses | #39 |
| septic syndrome | #39 |
| children familial hypercholesterolemia | #39 |
| 277 patients | #39 |
| specificity patients | #39 |
| embolus | #39 |
| compression stocking | #39 |
| subcutaneous intention | #39 |
| fibrin fibrinogen | #39 |
| enoxaparin placebo | #39 |
| continued treatment | #39 |
| incidence patients | #39 |
| diagnostic prediction | #39 |
| incidence cancer | #39 |
| superficial vein thrombosis | #39 |
| submassive | #39 |
| heparins lmwhs | #39 |
| time compression | #39 |
| doacs | #39 |
| anticoagulant therapy | #40 |
| therapeutic dosages | #40 |
| endotoxininduced | #40 |
| arterial vascular | #40 |
| common femoral vein | #40 |
| activatable fibrinolysis | #40 |
| standardized definition | #40 |
| anticoagulation therapy patients | #40 |
| patients normal | #40 |
| pemb | #40 |
| ambulatory cancer | #40 |
| tfmp | #40 |
| episode venous thromboembolism | #40 |
| thrombinantithrombin complexes | #40 |
| clotting activation | #40 |
| dalteparin treatment | #40 |
| international clinical | #40 |
| bleeding | #40 |
| day 6 months | #40 |
| grade 1a patients | #40 |
| fviiic | #40 |
| anticoagulated patients | #41 |
| risk recurrent vte | #41 |
| endotoxin induced | #41 |
| lung scintigraphy | #41 |
| triage tests | #41 |
| placebo 6 months | #41 |
| calf vein thrombosis | #41 |
| cancer lmwh | #41 |
| 7268 | #41 |
| lowmolecularweight heparins | #41 |
| submassive pulmonary embolism | #41 |
| 95 genotype | #41 |
| dabigatran etexilate | #41 |
| pentasaccharides | #41 |
| heparin therapy | #41 |
| cell extravasation | #42 |
| patients vasopressors | #42 |
| standardization committee | #42 |
| netilmicin | #42 |
| 8101 | #42 |
| stroke thrombosis | #42 |
| thrombosis administration | #42 |
| major contributor | #42 |
| type graft | #42 |
| anticoagulation risk | #42 |
| patients prospective | #42 |
| patients silent | #42 |
| neoplasms thrombosis | #42 |
| prophylaxis venous | #42 |
| monthly incidence | #43 |
| venous thrombosis thrombophilia | #43 |
| post‐thrombotic syndrome | #43 |
| ischemic events | #43 |
| vkas patients | #43 |
| heparin risk | #43 |
| warfarin anticoagulants | #43 |
| rtap | #43 |
| draft document | #43 |
| fetal loss | #43 |
| initial treatment | #43 |
| venous thromboembolism vte | #43 |
| 543 patients | #43 |
| patients vte risk | #43 |
| cancer adjusted | #43 |
| probability patients | #43 |
| protein sepsis | #44 |
| 10–14 | #44 |
| restoration euthyroidism | #44 |
| uedvt patients | #44 |
| experimental venous thrombosis | #44 |
| 20 30 | #44 |
| enoxaparin risk | #44 |
| patients tinzaparin | #44 |
| recurrent vte 95 | #44 |
| factors thromboembolism | #44 |
| efficiency models | #44 |
| expert physicians | #44 |
| 95 pulmonary embolism | #44 |
| nonvka oral anticoagulants | #44 |
| edoxaban therapy | #44 |
| indications patients | #44 |
| mild hyperhomocysteinaemia | #44 |
| role coagulation | #44 |
| rate venous | #44 |
| coagulation activation | #45 |
| patients bnp | #45 |
| wells score | #45 |
| coumarin therapy | #45 |
| dose lmwh | #45 |
| dvt patients | #45 |
| oral direct | #45 |
| treated warfarin | #45 |
| revascularisation procedures | #45 |
| dose adjusted | #45 |
| venous thrombotic | #45 |
| fondaparinux patients | #45 |
| 95 warfarin | #45 |
| years algorithm | #45 |
| day levels | #46 |
| ssc isth | #46 |
| bleeding rivaroxaban | #46 |
| abtpo | #46 |
| ruling | #46 |
| major bleeding placebo | #46 |
| patients unprovoked vte | #46 |
| healthcare settings | #46 |
| daily rivaroxaban | #46 |
| treatment model | #46 |
| pioped | #46 |
| extended duration | #46 |
| standard therapy | #46 |
| stroke risk assessment | #46 |
| percent confidence | #46 |
| hospital outpatients | #46 |
| management venous | #46 |
| prothrombin fragment f1 | #46 |
| male methimazole | #47 |
| central venous lines | #47 |
| roccurve | #47 |
| mechanical prophylaxis | #47 |
| mutation pregnancy | #47 |
| episode vte | #47 |
| ambulatory anticoagulants | #47 |
| new oral anticoagulant | #47 |
| bristol myers squibb | #47 |
| outcome vitamin | #47 |
| boehringer ingelheim | #47 |
| plasma ddimer levels | #47 |
| iiia receptors | #47 |
| factors rivaroxaban | #48 |
| thrombotic burden | #48 |
| daiichi | #48 |
| rivaroxaban compared | #48 |
| patients acute dvt | #48 |
| elevated plasma levels | #48 |
| thromboprophylactic | #48 |
| recurrence venous thromboembolism | #48 |
| diagnosis physicians | #48 |
| travel risk | #48 |
| intermediate risk risk | #48 |
| subcommittee | #48 |
| fondaparinux heparin | #48 |
| patients pulmonary | #48 |
| risk recurrent | #48 |
| small studies | #48 |
| rivaroxaban prevention | #49 |
| vte diagnosis | #49 |
| women aspirin | #49 |
| enoxaparin | #49 |
| levels protein | #49 |
| factor viii deficiency | #49 |
| calf vein | #49 |
| lowmolecularweight heparin lmwh | #49 |
| incidence venous thromboembolism | #50 |
| prospective diagnostic | #50 |
| treatment threshold | #50 |
| thromboembolism aged | #50 |
| nonselective betablockers | #50 |
| etexilate | #50 |
| dvt diagnosis | #50 |
| buller | #50 |
| transient risk factor | #50 |
| acute respiratory insufficiency | #50 |
| intensity treatment | #50 |
| outpatient therapy | #50 |
| cardiac surgery mortality | #50 |
| atria patients | #50 |
| vitamink antagonists | #50 |
| 95 apixaban | #51 |
| factor vte | #51 |
| acenocoumarol | #51 |
| normal perfusion | #51 |
| previous survey | #51 |
| patients 11 | #51 |
| strategies treatment | #51 |
| global disease | #51 |
| protein deficiencies | #51 |
| discrimination model | #51 |
| effects coagulation | #51 |
| tomography pulmonary | #51 |
| svt patients | #52 |
| free thyroxine ft4 | #52 |
| doacs vka | #52 |
| lung scans | #52 |
| unnecessarily | #52 |
| 1·12 | #52 |
| hematologic malignancies patients | #52 |
| risk venous thromboembolism | #52 |
| vte major bleeding | #52 |
| inhibitors heparin | #52 |
| lmwh fondaparinux | #52 |
| patients comorbid conditions | #52 |
| pdvt | #52 |
| apixaban vte | #52 |
| 3 month | #52 |
| preference patients | #53 |
| reported incidence | #53 |
| 1522 | #53 |
| 40 daily | #53 |
| absolute risks | #53 |
| postthrombotic syndrome | #53 |
| patients initially | #53 |
| 479 patients | #53 |
| warfarintreated patients | #53 |
| hemostatic balance | #53 |
| thrombophilic factors | #53 |
| cross study | #53 |
| thromboembolism prevention | #53 |
| versus enoxaparin | #53 |
| suspected venous thromboembolism | #53 |
| prethrombotic | #54 |
| patients obese | #54 |
| chads2 cha2ds2vasc | #54 |
| thromboembolism death | #54 |
| male pulmonary embolism | #54 |
| antithrombotic drug | #54 |
| pai1 levels patients | #54 |
| acquired risk factors | #54 |
| major bleeds | #54 |
| familial thrombophilia | #54 |
| 034 | #54 |
| 378 patients | #54 |
| bled score | #54 |
| patients incidence | #54 |
| vte mortality | #54 |
| endocrine disorders | #54 |
| 2537 | #54 |
| rivaroxaban | #55 |
| legs patients | #55 |
| anticoagulants arthroplasty replacement | #55 |
| dosereduction | #55 |
| biological pan | #55 |
| nondeficient | #55 |
| unfractionated heparin | #55 |
| compared lmwh | #55 |
| proximal extent | #55 |
| unfractionated heparin ufh | #55 |
| long term risk | #55 |
| treatment thresholds | #55 |
| insurances | #55 |
| methods randomized | #55 |
| level mortality | #56 |
| 20210a | #56 |
| enoxaparin rivaroxaban | #56 |
| weight heparins | #56 |
| seventh accp conference | #56 |
| risk major bleeding | #56 |
| time event | #56 |
| enoxaparin patients | #56 |
| major bleeding apixaban | #56 |
| reduced capacity | #56 |
| physicians guidelines | #56 |
| tromboembólica | #56 |
| deficiency prevalence | #56 |
| vte death | #56 |
| vasopressors | #56 |
| vitamin warfarin | #56 |
| venous outflow obstruction | #56 |
| inr values | #56 |
| preeclampsia hellp syndrome | #56 |
| inhibitors female humans | #57 |
| subsegmental pulmonary | #57 |
| clinical models | #57 |
| antithrombin iii heparin | #57 |
| ctscan | #57 |
| levels survival | #57 |
| risk factors vte | #57 |
| calf dvt | #57 |
| lowmolecular weight heparin | #58 |
| unfractionated heparin patients | #58 |
| ruled | #58 |
| spiral computed | #58 |
| pharmo | #58 |
| malignancy mortality | #58 |
| doacs patients | #58 |
| inhibitors female | #58 |
| thrombin activatable | #58 |
| fibrinolysis humans | #58 |
| heterozygous factor | #59 |
| risk vte | #59 |
| incidence symptomatic | #59 |
| risk factors sensitivity | #59 |
| thrombosis aged | #59 |
| safety warfarin | #59 |
| acute venous thromboembolism | #59 |
| aventis | #59 |
| factor generation | #59 |
| risk periods | #59 |
| clot lysis time | #59 |
| mutation prothrombin | #59 |
| warfarin treatment | #59 |
| direct oral | #59 |
| bias trial | #59 |
| anticoagulants treatment | #60 |
| pulmonary embolism 95 | #60 |
| hemorrhage humans | #60 |
| target inr | #60 |
| 079 95 | #60 |
| pediatric venous thromboembolism | #60 |
| fixeddose | #60 |
| atrial fibrillation metaanalysis | #60 |
| constans | #60 |
| acute pulmonary embolism | #60 |
| awareness risk factors | #60 |
| women difference | #60 |
| prevalence pulmonary | #60 |
| perfusion ventilation | #61 |
| hypocoagulable | #61 |
| rosendaal | #61 |
| cdr score | #61 |
| amuse | #61 |
| dvt 95 | #61 |
| month surgery | #61 |
| free thyroxine | #61 |
| 3633 | #61 |
| benzimidazoles dabigatran | #61 |
| long‐term treatment | #61 |
| tests prevalence | #61 |
| association protein | #61 |
| general practitioners patients | #62 |
| 250 patients | #62 |
| protein fibrinogen | #62 |
| activated partial | #62 |
| patients administration | #62 |
| procoagulant state | #62 |
| informatizado | #62 |
| 273 patients | #62 |
| combined contraceptives oral | #62 |
| human endotoxemia | #62 |
| ttr patients | #62 |
| post thrombotic | #62 |
| cvrs | #63 |
| vte thromboprophylaxis | #63 |
| rivaroxaban lmwh | #63 |
| management anticoagulation | #63 |
| symptoms dvt | #63 |
| factor leiden risk | #63 |
| smoking smoking cessation | #63 |
| physicians predictive | #63 |
| women mutations | #63 |
| injection endotoxin | #63 |
| 33 women | #63 |
| venous thromboembolisms | #63 |
| common odds ratio | #63 |
| quantitative test | #63 |
| revised geneva score | #63 |
| treatment network | #63 |
| cancer noncancer patients | #64 |
| dvts | #64 |
| factor inhibitors | #64 |
| heparin fondaparinux | #64 |
| prior vte | #64 |
| postthrombotic | #64 |
| oral thrombin | #64 |
| acute pulmonary | #64 |
| bleeding events patients | #64 |
| thrombophilic risk | #64 |
| superficial vein | #64 |
| selfadjustment | #64 |
| vkas treatment | #64 |
| blinded trial | #64 |
| decision rules | #64 |
| patients aortic valve | #64 |
| accuracy diagnostic tests | #65 |
| prothrombin g20210a mutation | #65 |
| stroke thromboembolism | #65 |
| fvl vte | #65 |
| treatment pad | #65 |
| ultrasonograms | #65 |
| prevalence abnormalities | #65 |
| dvt sensitivity | #66 |
| rapid triage | #66 |
| elfa | #66 |
| statin therapy risk | #66 |
| 95 bleeding | #66 |
| female heparin | #66 |
| 0 points | #66 |
| newer anticoagulants | #66 |
| axa | #66 |
| risk factor thrombosis | #66 |
| death classification | #66 |
| patients tertiles | #67 |
| rate major | #67 |
| atrial fibrillation stroke | #67 |
| 1127 | #67 |
| apixaban | #67 |
| standard therapy patients | #67 |
| patients factor | #67 |
| coagulation fibrinolysis | #68 |
| academic medical centre | #68 |
| fibrinolytic | #68 |
| 1894 | #68 |
| patients bnp levels | #68 |
| perioperative blood | #68 |
| 20210g | #68 |
| 05 95 | #68 |
| 3594 | #68 |
| patients benefits | #68 |
| ranging study | #68 |
| recurrent thrombosis patients | #69 |
| postphlebitic | #69 |
| certoparin | #69 |
| enfermedad tromboembólica | #69 |
| heparin ufh | #69 |
| justify | #69 |
| thrombosis blood | #69 |
| ionis | #69 |
| plasma interleukin | #69 |
| suspected | #69 |
| 8190 | #70 |
| withhold | #70 |
| elevated cardiac | #70 |
| major bleeding complications | #70 |
| rivaroxaban treatment | #70 |
| ischemic events patients | #70 |
| fixed dose | #70 |
| thrombosis recurrence | #70 |
| patients protein | #70 |
| aged predictive | #70 |
| vwfrco | #70 |
| gramnegative sepsis | #70 |
| mantelhaenszel | #70 |
| α2ap | #70 |
| cutoff levels | #70 |
| test patients | #70 |
| clopidogrel placebo | #71 |
| plasminogen plg | #71 |
| diagnostic sensitivity specificity | #71 |
| thromboprophylaxis | #71 |
| vte vka | #71 |
| unfractionated | #71 |
| topic costs | #71 |
| asymptomatic atherosclerosis | #71 |
| levels vwf | #71 |
| tests prospective | #71 |
| overt hypothyroidism | #72 |
| ddimer values | #72 |
| versus vitamin | #72 |
| viia factor | #72 |
| patients lmwh | #72 |
| pooled rate | #72 |
| hf studies | #72 |
| trifurcation | #72 |
| activation prothrombin | #72 |
| new anticoagulant | #72 |
| antithrombin iii iii | #72 |
| complications hematologic | #72 |
| elevated factor | #72 |
| noacs | #73 |
| ddimer measurement | #73 |
| tomography spiral | #73 |
| reversal agent | #73 |
| prolongations | #73 |
| analysis diagnostic | #73 |
| ingelheim | #73 |
| soluble fibrin | #73 |
| 12 months 95 | #73 |
| 2550 | #74 |
| proteins patients | #74 |
| longterm risk | #74 |
| soluble thrombomodulin | #74 |
| dvt study | #74 |
| experimental metastasis | #74 |
| suspected dvt | #74 |
| female hemorrhage | #74 |
| carriers | #74 |
| 1732 | #74 |
| 5395 | #74 |
| 2124 | #74 |
| study selection | #74 |
| prethrombotic state | #74 |
| 1334 | #75 |
| postoperative dvt | #75 |
| carotid femoral arteries | #75 |
| 2904 | #75 |
| thrombolytic therapy patients | #75 |
| retrospective follow | #75 |
| 8492 | #75 |
| selective factor | #75 |
| incidence bleeding events | #75 |
| oral combined contraceptives | #76 |
| factor xii deficiency | #76 |
| tests primary | #76 |
| extended anticoagulation | #76 |
| risk thrombosis | #76 |
| angiography ctpa | #76 |
| duration thromboprophylaxis | #76 |
| early time | #76 |
| combined contraceptives | #76 |
| p023 | #77 |
| boehringer | #77 |
| social aspects | #77 |
| patients secondary | #77 |
| individual patient | #77 |
| thrombosis pregnancy | #77 |
| ipg | #78 |
| 20 daily | #78 |
| women thrombophilia | #78 |
| elevated dimer | #78 |
| arterial thromboembolism | #78 |
| unprovoked | #78 |
| female fibrinolysis | #78 |
| arterial wall thickness | #78 |
| topic heparin | #79 |
| humans pulmonary | #79 |
| vte fvl | #79 |
| 2486 | #79 |
| limulus test | #79 |
| vkas | #79 |
| suspected acute | #79 |
| efficacy agents | #79 |
| time therapeutic | #79 |
| factor adult | #79 |
| patient data | #80 |
| heterozygous deficiency | #80 |
| vte rate | #80 |
| subhazard ratio | #80 |
| thromboembolism incidence | #80 |
| validation models | #80 |
| bleeding mortality | #80 |
| alife | #80 |
| sspe patients | #80 |
| daily bid | #80 |
| 95 05 | #80 |
| suspected cancer | #80 |
| knee arthroplasty patients | #81 |
| test evaluation | #81 |
| lmwh vte | #81 |
| prothrombin complex concentrate | #81 |
| outpatient basis | #81 |
| vascular events | #81 |
| topic risk | #81 |
| weitz | #81 |
| walking distance | #81 |
| systemic inflammatory | #81 |
| heparin prevention | #82 |
| thrombosis thrombophilia | #82 |
| thrombolytic drugs | #82 |
| 3month followup | #82 |
| timeperiods | #82 |
| prospective validation | #82 |
| common practice | #82 |
| clinical sign | #82 |
| placebo women | #82 |
| symptomatic carriers | #82 |
| thrombosis incidence | #82 |
| 50 micrograms | #82 |
| mammography patients | #82 |
| posthoc analysis | #82 |
| crnmb | #82 |
| 287 | #83 |
| inhibitor dabigatran | #83 |
| elective coronary | #83 |
| bistro | #83 |
| dimer patients | #83 |
| bleeding women | #83 |
| 2213 | #83 |
| patients thrombi | #83 |
| normotensive patients | #84 |
| heparin treatment | #84 |
| inherited thrombophilia | #84 |
| healthcare setting | #84 |
| prophylactic dose | #84 |
| duration therapy | #84 |
| diagnostic outcome | #84 |
| screening humans | #84 |
| inhibitor rivaroxaban | #84 |
| antithrombin iii protein | #85 |
| thrombosis svt | #85 |
| asymptomatic dvt | #85 |
| normal levels | #85 |
| peripheral vascular diseases | #85 |
| venous thrombosis patients | #85 |
| endotoxins | #85 |
| anticoagulants antiphospholipid | #85 |
| major bleeding warfarin | #86 |
| dabigatran vka | #86 |
| venovenous hemofiltration | #86 |
| rhapc | #86 |
| 10⁶ | #86 |
| 4576 | #86 |
| 75 microg | #86 |
| elevated ddimer levels | #86 |
| ≤50 | #87 |
| avws | #87 |
| clinical impact | #87 |
| contact activation | #87 |
| vidas | #87 |
| 95 100 | #87 |
| obstetric patients | #87 |
| post‐hoc analysis | #87 |
| patients 28 | #87 |
| acute venous | #87 |
| aged multicenter | #88 |
| venographic | #88 |
| washout period | #88 |
| 4 points | #88 |
| treatment incidence | #88 |
| lmwhs | #88 |
| internist | #88 |
| 3319 | #88 |
| activation factor | #88 |
| cdr | #88 |
| treatment statins | #88 |
| vte venous thromboembolism | #89 |
| anticoagulants dabigatran | #89 |
| reversal strategies | #89 |
| ddimer | #89 |
| smoking incidence | #89 |
| severe hf | #89 |
| safety noacs | #89 |
| beta blockers | #89 |
| costs patient | #89 |
| stroke bleeding | #89 |
| ventilation lung | #89 |
| unexplained recurrent | #89 |
| adequate treatment | #89 |
| rates major bleeding | #89 |
| tests test | #89 |
| matisse | #89 |
| cytokine release | #89 |
| popliteal vein | #90 |
| thrombophilic risk factors | #90 |
| outweighs | #90 |
| 2293 | #90 |
| primary thromboprophylaxis | #90 |
| vka dabigatran | #90 |
| new patients | #90 |
| fibrinolytic factors | #90 |
| venous thrombosis risk | #90 |
| pediatric venous | #90 |
| agents hemorrhage | #91 |
| inconvenience | #91 |
| perfusion ratio | #91 |
| thromboembolism pregnancy | #91 |
| 60 95 | #91 |
| pyridines pyridones | #91 |
| cdrs | #91 |
| 20210 | #91 |
| anticoagulants doacs | #91 |
| thrombosis women | #91 |
| combined clinical | #92 |
| thrombotic disease | #92 |
| single intravenous | #92 |
| prophylaxis incidence | #92 |
| incidence knee | #93 |
| scenario analyses | #93 |
| direct thrombin inhibitors | #93 |
| 95 years | #93 |
| anticoagulation reversal | #93 |
| rivaroxaban edoxaban | #93 |
| compression patients | #93 |
| heparins | #94 |
| vte surgery | #94 |
| atherogenic lipid | #94 |
| 125 patients | #94 |
| hf severity | #94 |
| 1027 | #94 |
| children vte | #94 |
| test result | #94 |
| patients symptomatic | #94 |
| 2 levels | #95 |
| european consensus statement | #95 |
| direct oral anticoagulant | #95 |
| viia rfviia | #95 |
| risk symptomatic | #96 |
| randomised crossover study | #96 |
| fondaparinux treatment | #96 |
| ddimer level | #96 |
| xii deficiency | #96 |
| efficacy rivaroxaban | #96 |
| symptomatic vte | #96 |
| 6 12 months | #96 |
| abnormal perfusion | #97 |
| doacs risk | #97 |
| fibrin generation | #97 |
| studies evaluated | #97 |
| haemophilia patients | #97 |
| pyrazoles pyridones | #97 |
| tpa release | #97 |
| difference rates | #97 |
| invasive testing | #97 |
| symptomatic pulmonary embolism | #97 |
| supervised exercise therapy | #98 |
| major bleed | #98 |
| 16slice | #98 |
| hypercoagulable | #98 |
| pregnancy postpartum period | #98 |
| 2875 | #98 |
| essential thrombocythaemia | #98 |
| simplify | #98 |
| activated protein apc | #98 |
| risk arterial | #99 |
| perfusion scintigraphy | #99 |
| 2·0 | #99 |
| acute dvt | #99 |
| probast | #99 |
| lmwh warfarin | #99 |
| hirudin | #99 |
| unselected | #99 |
| prevention recurrent | #100 |
| 1116 | #100 |
| warfarin patients | #100 |
| increasing levels | #100 |
| doubleblind trial | #100 |
| fatty foods | #100 |
| previews | #100 |
| gbd 2010 | #100 |
| 3 trials | #100 |
| patient groups | #100 |
| factor viia | #101 |
| factor vii factor | #101 |
| aptts | #101 |
| morpholines | #101 |
| enoxaparin fondaparinux | #102 |
| pts patients | #102 |
| 40 microg | #102 |
| alternative diagnosis | #102 |
| venous thromboembolism women | #102 |
| 265 patients | #102 |
| low pretest probability | #102 |
| doppler method | #103 |
| cteph patients | #103 |
| 338 | #103 |
| therapeutic consequences | #103 |
| arthroscopic anterior | #103 |
| endogenous thrombin | #103 |
| adjudicated | #103 |
| pregnancy puerperium | #103 |
| partial restoration | #104 |
| separate analyses | #104 |
| term treatment | #104 |
| apparent increase | #104 |
| assay variation | #104 |
| fibrin degradation products | #104 |
| recurrence women | #104 |
| heparin pregnancy | #104 |
| diagnostic imaging humans | #104 |
| absolute increase | #104 |
| antithrombin iii | #104 |
| oral factor | #104 |
| 7 children | #105 |
| conventional therapy patients | #105 |
| embryo loss | #105 |
| 1089 | #105 |
| chest ray | #106 |
| fibrinolytic systems | #106 |
| thromboprophylaxis patients | #106 |
| essentials | #106 |
| thrombophilia | #106 |
| hospitalized patients hf | #106 |
| blind double | #106 |
| elevated levels | #106 |
| 314 | #106 |
| study total | #106 |
| 2479 | #106 |
| thrombosis age | #106 |
| survival cancer patients | #107 |
| definition classification | #107 |
| vte risk | #107 |
| ddimer levels | #107 |
| simplified version | #107 |
| thromboembolic | #107 |
| topic recurrence | #107 |
| human volunteers | #108 |
| cardiovascular death stroke | #108 |
| noncancer patients | #108 |
| patients cancer | #108 |
| post thrombotic syndrome | #108 |
| specific subgroups | #108 |
| grade 1c | #108 |
| evaluation studies | #109 |
| routine coagulation | #109 |
| viia | #109 |
| 1235 | #109 |
| thrombin antithrombin | #109 |
| synthetic pentasaccharide | #109 |
| embolism treatment | #109 |
| factor mutation | #109 |
| 500μg | #109 |
| 039 | #109 |
| anticoagulants cohort | #109 |
| antiplasmin | #110 |
| embolism quality | #110 |
| primary safety | #110 |
| cancer activity | #110 |
| inferiority trial | #110 |
| vka doac | #110 |
| thrombosis treated | #110 |
| subsequent pregnancy | #110 |
| anticoagulants biomarkers | #111 |
| negative predictive 100 | #111 |
| siset | #111 |
| predefined | #111 |
| obstetric complications | #111 |
| comparison control | #111 |
| treatment risk factors | #111 |
| humans intermittent | #111 |
| epidemiology risk factors | #112 |
| topic guidelines | #112 |
| recurrence treatment | #112 |
| emergency situations | #112 |
| patients ventricular dysfunction | #112 |
| efficacy prevention | #112 |
| rivaroxaban enoxaparin | #112 |
| patients 70 | #112 |
| chromogenic | #112 |
| thromboembolic diseases | #112 |
| publication anticoagulants | #112 |
| risk rivaroxaban | #112 |
| inappropriate treatment | #113 |
| metabolic response | #113 |
| heterozygous carriers | #113 |
| lmwh risk | #113 |
| nonionic contrast | #113 |
| patients nephrotoxicity | #113 |
| 0·0 | #114 |
| cancerassociated vte | #114 |
| patients intermediate | #114 |
| study centre | #114 |
| dialysers | #114 |
| postphlebitic syndrome | #114 |
| total knee replacement | #114 |
| fibrinogen vwf | #115 |
| hyperhomocysteinaemia | #115 |
| 393 | #115 |
| global public | #115 |
| positive predictive values | #115 |
| patients recurrent | #115 |
| major bleeding 95 | #116 |
| reference standard | #116 |
| effects tnf | #116 |
| women severe preeclampsia | #116 |
| computed tomography patients | #116 |
| agents heparin | #116 |
| anticoagulants arthroplasty | #116 |
| heparin warfarin | #116 |
| topic dabigatran | #116 |
| life treatment | #116 |
| vte data | #116 |
| protein resistance | #117 |
| protein inhibitor pci | #117 |
| women caesarean | #117 |
| 2460 | #117 |
| fibrinolytic parameters | #117 |
| vte children | #117 |
| vte complications | #117 |
| arthroscopies | #117 |
| autopsyconfirmed | #118 |
| 4118 | #118 |
| arterial thrombosis patients | #118 |
| 2744 | #118 |
| proximal dvt | #118 |
| patients extensive | #118 |
| compression stockings | #119 |
| patients doac | #119 |
| compared warfarin | #119 |
| humans leg | #119 |
| incidence pulmonary embolism | #119 |
| previous vte | #120 |
| healthy humans | #120 |
| risk thromboembolism | #120 |
| rivaroxaban patients | #120 |
| mortality diseases | #120 |
| lactoferrin leukocyte | #120 |
| months follow | #120 |
| acquired deficiency | #120 |
| dabigatran factor | #120 |
| thrombosis study | #120 |
| patients prostatic cancer | #121 |
| thrombocytopenia thrombosis | #121 |
| studies venous | #122 |
| anti factor | #122 |
| oral hormonal | #122 |
| fatal pulmonary embolism | #122 |
| patients 6 | #122 |
| heparin | #123 |
| venous thromboembolism pregnancy | #123 |
| placebo standard | #123 |
| heparin hirudin | #123 |
| acute infection | #123 |
| minor bleeding | #123 |
| 100 patients | #123 |
| early dynamics | #123 |
| factor xia | #123 |
| statin risk | #124 |
| treatment data | #124 |
| thrombophilia pregnancy | #124 |
| atherogenic lipid profile | #124 |
| association level | #124 |
| vte lmwh | #124 |
| ft4 levels | #124 |
| nonsignificantly | #125 |
| bayer | #125 |
| skin perfusion | #125 |
| peripheral arterial disease | #125 |
| incidence thrombosis | #125 |
| fibrinolysis inhibitor | #125 |
| thromboembolism recurrence | #125 |
| treatment indication | #125 |
| diseases mortality | #125 |
| intravenous heparin | #125 |
| elevated liver enzymes | #125 |
| puerperal disorders | #125 |
| distal dvt | #126 |
| doacs treatment | #126 |
| upper extremity | #126 |
| patients ventilation | #127 |
| performance scores | #127 |
| unacceptably | #127 |
| marder | #127 |
| occurrence vte | #127 |
| thromboprophylaxis lmwh | #127 |
| patients permanent | #127 |
| prevention | #128 |
| resistance apc | #128 |
| treatment months | #128 |
| venous thromboembolism risk | #128 |
| development vte | #128 |
| direct factor | #128 |
| patients conventional therapy | #128 |
| 50 age | #128 |
| 060 | #129 |
| ctrough | #129 |
| mortality cancer patients | #129 |
| riete registry | #129 |
| elevated biomarkers | #129 |
| 1041 | #129 |
| patients episode | #130 |
| day 10 | #130 |
| 220 | #130 |
| 194 patients | #130 |
| plaster cast | #130 |
| internists | #130 |
| hospital discharge records | #130 |
| anticoagulants antithrombins | #130 |
| tests specificity | #131 |
| long‐term clinical outcomes | #131 |
| linear interpolation | #131 |
| 05 patients | #131 |
| obviating | #131 |
| pooled incidence | #131 |
| postpartum period women | #132 |
| hoc analysis | #132 |
| hypocoagulability | #132 |
| rivaroxaban versus | #132 |
| cha2ds2vasc | #133 |
| fxa inhibitors | #133 |
| 80 anticoagulants | #133 |
| enoxaparin treatment | #133 |
| started | #133 |
| direct inhibitors | #133 |
| avidin | #133 |
| embolism acute | #134 |
| selectin levels | #134 |
| pulmonary angiography patients | #134 |
| instituted | #134 |
| risk pad | #134 |
| rco vwf | #134 |
| anticoagulant prophylaxis | #135 |
| bnp concentration | #135 |
| prevalence dvt | #135 |
| activator plasminogen | #135 |
| followup patients | #136 |
| severe pph | #136 |
| clinical prediction | #136 |
| apixaban edoxaban | #136 |
| months anticoagulation | #136 |
| thrombotic syndrome | #136 |
| 0056 | #136 |
| east asian patients | #136 |
| 99 patients | #137 |
| acquired thrombophilia | #137 |
| sequential application | #137 |
| point‐of‐care | #137 |
| 2283 | #137 |
| phase 3 trials | #137 |
| factor prothrombin | #137 |
| diagnostic work | #137 |
| bleeding warfarin | #138 |
| intravascular coagulation dic | #138 |
| antidote | #138 |
| studies mortality | #138 |
| complete inhibition | #138 |
| national guidelines | #138 |
| enhanced factor | #138 |
| factor viii factor | #139 |
| direct inhibitor | #139 |
| risk fatal | #139 |
| oral anticoagulant treatment | #139 |
| 95 major bleeding | #139 |
| patients comparison | #139 |
| 2465 | #139 |
| 3 weeks | #139 |
| reproducibility risk | #139 |
| 80 cohort | #140 |
| 12 95 | #140 |
| 20 iu | #140 |
| vwf rco | #140 |
| dvt incidence | #140 |
| 0114 | #140 |
| distal deep | #140 |
| ottawa | #140 |
| human activated | #140 |
| pharmacy records | #141 |
| thromboembolic disorders | #141 |
| antidotes | #141 |
| carriership | #142 |
| thrombin potential | #142 |
| ischaemic events | #143 |
| jugular veins | #143 |
| geneva | #143 |
| escherichia humans | #143 |
| points 95 | #143 |
| active malignancy | #143 |
| warfarin administration | #143 |
| treatment pulmonary | #143 |
| compared treatment | #144 |
| doac treatment | #144 |
| management vte | #144 |
| fatal pulmonary | #144 |
| topic practice patterns | #144 |
| postoperative venous | #144 |
| pregnancy female humans | #144 |
| patient populations | #145 |
| hyperthyroxinemia | #145 |
| referred patients | #145 |
| dose rivaroxaban | #145 |
| serial testing | #145 |
| thrombosis model | #145 |
| filters venous | #145 |
| protein factor | #146 |
| months treatment | #146 |
| death cancer patients | #146 |
| derived microvesicles | #146 |
| tissue factor pathway | #147 |
| personal fees | #147 |
| 2076 | #148 |
| long‐acting | #148 |
| embolism diagnosis | #148 |
| partial thromboplastin | #148 |
| intention treat | #148 |
| rebuttal | #148 |
| 10 years patients | #148 |
| antithrombotic drugs | #148 |
| acute medical illness | #148 |
| thrombocyte | #149 |
| individual patient data | #149 |
| risk subgroups | #149 |
| diagnostic score | #149 |
| relevant publications | #149 |
| procoagulant | #149 |
| vte hospitalization | #149 |
| 0·45 | #149 |
| dimer level | #150 |
| coagulation dic | #151 |
| enoxaparin unfractionated heparin | #151 |
| additional imaging | #151 |
| humans injections | #151 |
| continuous venovenous | #152 |
| bleeding patients | #152 |
| longterm treatment | #152 |
| patient eligibility | #152 |
| patients primary outcome | #152 |
| cardiopulmonary bypass surgery | #153 |
| hypercoagulable state | #153 |
| thrombosis prevention | #153 |
| extracorporeal circuit | #153 |
| point systems | #153 |
| direct thrombin | #154 |
| angioplasty patients | #154 |
| bleeding scores | #154 |
| dimer levels | #154 |
| activity mortality | #154 |
| thrombosis factor | #154 |
| active cancer | #154 |
| warfarin apixaban | #155 |
| fiia | #155 |
| states venous | #155 |
| tomography patients | #155 |
| drug factor | #155 |
| thromboembolic event | #155 |
| curve sensitivity | #155 |
| stockings | #156 |
| patients gastrointestinal | #156 |
| recurrent symptoms | #156 |
| coagulant activity | #156 |
| vte treatment | #156 |
| fvl | #156 |
| enoxaparin dose | #156 |
| 09 | #156 |
| daily oral | #156 |
| cross‐sectional survey | #157 |
| prophylaxis patients | #157 |
| hemodynamically | #157 |
| increased thrombin | #157 |
| 2126 | #158 |
| dfl | #158 |
| underlying malignancy | #158 |
| 97 | #158 |
| duration anticoagulation | #158 |
| months chemotherapy | #158 |
| increased risk thrombosis | #159 |
| adjusted relative risk | #159 |
| children fh | #160 |
| antithrombotic efficacy | #160 |
| 120 minutes | #160 |
| schering | #160 |
| guidelines prevention | #160 |
| thrombotic disorders | #160 |
| plasma dimer | #160 |
| 145 patients | #160 |
| antagonists patients | #161 |
| pvo | #161 |
| prophylactics | #161 |
| lysine analogues | #162 |
| 2206 | #162 |
| women time | #162 |
| incidence vte | #162 |
| patients imaging | #162 |
| increased plasma levels | #163 |
| rates vte | #163 |
| lmwh therapy | #163 |
| venous thrombus | #163 |
| strain gauge | #163 |
| 198 patients | #163 |
| factors bleeding | #163 |
| imaging test | #163 |
| coagulation blood | #163 |
| observer variability | #164 |
| 028 | #164 |
| age comorbidity | #164 |
| inborn humans | #164 |
| justified | #164 |
| subhazard | #165 |
| mutation factor | #165 |
| patients enoxaparin | #165 |
| relatives patients | #165 |
| strategies patients | #166 |
| stockings compression | #166 |
| management venous thromboembolism | #166 |
| microvascular thrombosis | #166 |
| phlebography | #166 |
| viii factor | #166 |
| pravastatin therapy | #166 |
| thrombin venous | #167 |
| ankle brachial abi | #167 |
| 3658 | #167 |
| recurrent thrombosis | #167 |
| cvcs | #168 |
| double heterozygosity | #168 |
| recurrent acute | #168 |
| treatment 3 months | #168 |
| current clinical practice | #168 |
| cstatistics | #168 |
| warfarin | #168 |
| syndrome pts | #168 |
| postthrombotic syndrome pts | #169 |
| risk profile | #169 |
| fold increased | #169 |
| patients infections | #169 |
| 3 12 | #169 |
| preexistent | #169 |
| therapeutic range | #169 |
| cart patients | #170 |
| thrombosis cancer | #170 |
| heavy menstrual bleeding | #170 |
| postoperative blood loss | #170 |
| interobserver agreement | #170 |
| adamts‐13 | #171 |
| aged algorithms | #171 |
| venous thrombotic events | #171 |
| 57 years | #171 |
| recombinant factor | #171 |
| pulmonology | #172 |
| patients blood transfusion | #172 |
| clinical trials patients | #172 |
| risk factors patients | #172 |
| vaginal bleeding | #172 |
| antifibrinolytic | #172 |
| lmw heparin | #172 |
| bleeds | #173 |
| pulmonary | #173 |
| hospitalized medical patients | #173 |
| inr | #173 |
| laboratory monitoring | #174 |
| bleeding tendency | #174 |
| clinically bleeding | #174 |
| patients initial | #174 |
| arterial occlusions | #174 |
| arterial venous | #175 |
| reocclusion | #175 |
| vte common | #175 |
| fragment 1 | #175 |
| data control | #175 |
| picotamide | #177 |
| mitsubishi | #177 |
| prothrombin | #177 |
| intention analysis | #178 |
| short‐ | #178 |
| aspirin ticlopidine | #178 |
| hyperthyroidism hypothyroidism | #178 |
| 122 | #178 |
| vte event | #179 |
| concomitance | #179 |
| baseline day | #179 |
| oral female humans | #179 |
| noninferior | #179 |
| ventilation perfusion | #180 |
| patients deficiency | #180 |
| isth | #180 |
| additional risk factors | #180 |
| thromboplastin time | #180 |
| referral bias | #180 |
| aged partial | #181 |
| testing patients | #182 |
| acute episode | #182 |
| antithrombin | #182 |
| painkillers | #182 |
| 2–4 | #183 |
| biological variation | #183 |
| hyperhomocysteinemic | #183 |
| patients major | #183 |
| risk bleeding | #184 |
| treat analysis | #184 |
| subsequent diagnosis | #184 |
| 4150 | #184 |
| thromboinflammation | #184 |
| incidental | #184 |
| antithrombin iii atiii | #184 |
| prognosis pulmonary | #184 |
| n110 | #184 |
| coagulation factors | #184 |
| pregnancy vte | #184 |
| vte age | #185 |
| deficient patients | #185 |
| anticoagulated | #186 |
| studies heparin | #186 |
| patients thromboprophylaxis | #186 |
| brain natriuretic | #186 |
| symptomatic | #186 |
| hemostatic effects | #186 |
| live birth rate | #186 |
| patients intensive units | #186 |
| safety apixaban | #187 |
| risk composite | #187 |
| antifibrinolytic agents | #187 |
| patients haemophilia | #187 |
| cutoff level | #187 |
| spontaneous rupture | #188 |
| absolute rate | #188 |
| prevalence cancer | #188 |
| humans international | #188 |
| doacs vkas | #188 |
| ratio inr | #188 |
| 926 | #188 |
| heparin administration | #189 |
| riete | #189 |
| viia female | #189 |
| willebrand factor antigen | #189 |
| 64slice | #189 |
| fibrinolysis | #189 |
| patients netherlands | #189 |
| clinical validity | #189 |
| blood loss patients | #189 |
| ischemic event | #190 |
| ccus | #190 |
| current views | #190 |
| anticoagulant drugs | #190 |
| thrombosis patients | #190 |
| score patients | #191 |
| gogh | #191 |
| 07 | #191 |
| attending physicians | #191 |
| acute thrombosis | #191 |
| venous outflow | #191 |
| 058 | #192 |
| 1495 | #192 |
| stroke systemic | #192 |
| coagulation assays | #193 |
| endothelial cell activation | #193 |
| 070 | #194 |
| blood coagulation | #194 |
| heparin patients | #194 |
| anticoagulation | #194 |
| prothrombin activation | #194 |
| risk major | #195 |
| recurrent ischemic events | #195 |
| antagonist treatment | #195 |
| target range | #195 |
| antixa levels | #195 |
| 65 months | #195 |
| coagulation status | #196 |
| 29 95 | #196 |
| abnormal test | #196 |
| complications cardiovascular | #196 |
| vwf adamts13 | #198 |
| difference treatment | #198 |
| ate | #198 |
| vii rfviia | #198 |
| treatment groups patients | #198 |
| sew2871 | #198 |
| cachectin | #199 |
| coagulation monitoring | #199 |
| patient diagnosis | #199 |
| obese controls | #200 |
| patients 12 months | #200 |
| incidence cardiovascular events | #200 |
| screening patients | #200 |
| patients abnormal | #201 |
| thrombin factor | #201 |
| validation sets | #201 |
| thromboembolic disease | #201 |
| vte incidence | #201 |
| arterial thrombosis | #202 |
| 17 95 | #202 |
| peritoneovenous | #202 |
| johnson | #202 |
| heparin dose | #203 |
| worldwide survey | #203 |
| symptomatic pad | #203 |
| induced activation | #203 |
| invitees | #203 |
| antithrombotic agents | #204 |
| levonorgestrel | #204 |
| stroke systemic embolism | #205 |
| thrombophilia risk | #205 |
| low incidence | #205 |
| period time | #205 |
| extended thromboprophylaxis | #205 |
| 0 95 | #205 |
| data synthesis | #206 |
| varese | #206 |
| venous ultrasonography | #206 |
| patients anticoagulant therapy | #206 |
| fgt | #206 |
| imt patients | #207 |
| algorithms anticoagulants | #207 |
| fviii | #207 |
| death female humans | #207 |
| methods consecutive | #207 |
| objectively | #207 |
| platelet activation patients | #207 |
| cardiologist | #207 |
| systematic review studies | #207 |
| 06 | #207 |
| desogestrel | #207 |
| patients hypothyroidism | #208 |
| bleeding compared | #208 |
| thrombocythaemia | #208 |
| deficiency risk | #209 |
| free protein | #209 |
| hirudins | #210 |
| antixa activity | #210 |
| tgt | #210 |
| women frequency | #210 |
| stocking | #211 |
| ioxaglate | #211 |
| toxaemia | #211 |
| systemic embolism patients | #211 |
| anticoagulation management | #212 |
| atrial fibrillation study | #212 |
| plasminogen activator activity | #213 |
| heparitin sulfate | #213 |
| topic practice | #214 |
| correct interpretation | #214 |
| dabigatran dose | #214 |
| factors vte | #215 |
| thrombin inhibition | #215 |
| current developments | #215 |
| studies rivaroxaban | #215 |
| standard duration | #215 |
| community hospital | #216 |
| warfarin stroke | #216 |
| duplex venous | #216 |
| deamino | #216 |
| betatg | #216 |
| studies difference | #217 |
| obviates | #217 |
| mildest | #217 |
| undergoing total | #217 |
| diagnostic algorithm | #217 |
| conclusive evidence | #218 |
| plasminogen activator inhibitor | #218 |
| g20210a | #218 |
| npv 100 | #218 |
| cstatistic | #218 |
| patients cart | #219 |
| cancer | #219 |
| 077 95 | #219 |
| deamino arginine | #219 |
| viii female | #220 |
| data extraction | #220 |
| techniques female | #220 |
| hip replacement surgery | #220 |
| vii factor | #220 |
| heparin humans | #221 |
| postoperative vte | #221 |
| healthy human subjects | #221 |
| hmvec | #221 |
| preventive measures | #221 |
| vte events | #222 |
| apc resistance | #222 |
| proximally | #222 |
| pulmonologists | #223 |
| substantial proportion | #223 |
| engl | #223 |
| 1 january | #223 |
| 1541 | #223 |
| topic factor | #224 |
| protein pathway | #224 |
| thromboendarterectomy | #224 |
| subsequent cancer | #224 |
| neoplasms prospective | #225 |
| org | #225 |
| balloon coronary anticoagulants | #225 |
| thrombosis warfarin | #225 |
| kruskalwallis | #225 |
| 16 95 | #226 |
| vascular events patients | #226 |
| inr monitoring | #226 |
| 0·67 | #226 |
| extremity amputation | #226 |
| tests diagnosis | #227 |
| haemostasis | #227 |
| acute medical | #227 |
| 35 ± | #227 |
| ipe | #228 |
| mild hyperhomocysteinemia | #228 |
| dalteparin | #229 |
| scant | #229 |
| residual thrombus | #229 |
| cgp | #229 |
| advocated | #230 |
| 037 | #230 |
| ft4 | #231 |
| major orthopaedic surgery | #231 |
| thiazoles | #231 |
| patients discontinuation | #231 |
| severe preeclampsia | #231 |
| equinox | #231 |
| 6 studies | #231 |
| urosepsis | #231 |
| habitual abortion | #231 |
| resource utilisation | #231 |
| patients warfarin | #232 |
| aspirin dipyridamole | #232 |
| endogenous thrombin potential | #233 |
| dimer | #233 |
| anticoagulant effects | #233 |
| recurrence risk factors | #233 |
| humans netherlands | #233 |
| surgical embolectomy | #233 |
| cancer prevalence | #233 |
| effective alternative | #234 |
| prothrombotic state | #235 |
| graduated compression | #235 |
| doac | #235 |
| brain natriuretic peptide | #236 |
| humans meta | #236 |
| venous thromboembolic events | #236 |
| oral anticoagulants | #237 |
| myocardial infarction 95 | #237 |
| treatment continuation | #237 |
| predictive tests | #238 |
| 6500 | #238 |
| patients vkas | #238 |
| 009 | #238 |
| factor viii fviii | #239 |
| rational approach | #239 |
| crossover study | #239 |
| anticoagulants aspirin | #239 |
| factor tnf | #239 |
| arterial venous thrombosis | #240 |
| patients initial treatment | #240 |
| hip knee arthroplasty | #241 |
| 045 | #241 |
| aspirin heparin | #241 |
| bleeding incidence | #242 |
| time therapeutic range | #242 |
| prothrombin fragment | #243 |
| pivotal trials | #243 |
| patients intermittent claudication | #243 |
| iohexol | #244 |
| n89 | #245 |
| vte risk factors | #245 |
| vte cases | #246 |
| casecontrol | #246 |
| children neonates | #246 |
| thrombogenesis | #246 |
| lipoproteina levels | #247 |
| antithrombotic | #247 |
| warfarin aged | #247 |
| 23 95 | #247 |
| treatment compared | #248 |
| committees | #248 |
| anti activity | #248 |
| coronary anticoagulants | #248 |
| patients solid tumours | #248 |
| score risk | #249 |
| multiple comorbidities | #249 |
| diagnostic models | #249 |
| bleeding rates | #249 |
| protein risk | #250 |
| ioxaglic | #250 |
| ischemic strokes | #250 |
| fv leiden | #250 |
| finalized | #251 |
| patients contraindications | #251 |
| microthrombosis | #251 |
| 8595 | #251 |
| vkas doacs | #252 |
| somit | #252 |
| simplification | #252 |
| thrombin thrombosis | #253 |
| incidence | #253 |
| agents anticoagulants | #254 |
| treatment duration | #254 |
| fibrinolytic activity | #255 |
| palga | #255 |
| medea | #256 |
| activation humans | #256 |
| haul | #256 |
| cost‐effectiveness | #257 |
| q24h | #257 |
| activity assay | #257 |
| clinical utility | #257 |
| bleeding risk | #257 |
| continuous intravenous | #257 |
| fibrin degradation | #258 |
| ctpa | #258 |
| patient subgroups | #258 |
| unpublished data | #259 |
| 30 50 | #259 |
| sspe | #260 |
| dvt risk | #260 |
| noncarriers | #261 |
| heparin dosing | #261 |
| toxicosis | #261 |
| thrombus size | #261 |
| patients hospitalization | #262 |
| optimal duration | #263 |
| risk pulmonary | #263 |
| blind study | #264 |
| graft type | #265 |
| 400 patients | #266 |
| pbac | #267 |
| einstein | #267 |
| endotoxaemia | #268 |
| statins risk | #268 |
| malignancy patients | #269 |
| randomised cross | #269 |
| versus aspirin | #269 |
| lysis time | #269 |
| propeptide | #269 |
| relation time | #269 |
| single test | #270 |
| discontinuing | #270 |
| exclusion | #270 |
| protein patients | #270 |
| thrombosis inflammation | #271 |
| hormonal replacement therapy | #271 |
| protein apc | #271 |
| platelet serotonin | #271 |
| 3·0 | #271 |
| orthopaedic patients | #271 |
| patients combination | #272 |
| vte recurrence | #272 |
| clopidogrel ticlopidine | #272 |
| bleeding patient | #272 |
| groups levels | #272 |
| ankle brachial | #273 |
| efficacy analysis | #273 |
| months 12 | #274 |
| prevalence pad | #274 |
| cleavage sites | #274 |
| risk levels | #274 |
| performance score | #275 |
| parenteral nutrition patients | #275 |
| international normalized | #275 |
| fourth quartile | #276 |
| antithrombotic agent | #276 |
| time aptt | #277 |
| smoking hypertension | #277 |
| dose reduction | #278 |
| imaging sensitivity | #278 |
| normalized ratio | #278 |
| blood test | #279 |
| aptt | #279 |
| rco | #279 |
| intracranial hemorrhage patients | #280 |
| propositi | #280 |
| obviate | #280 |
| exclusion criteria | #280 |
| hospitalized medical | #280 |
| partial thromboplastin time | #280 |
| patients presence | #281 |
| thromboplastin | #282 |
| diagnostic test | #282 |
| neutrophil degranulation | #283 |
| puerperal | #283 |
| presentation patients | #283 |
| thyroid diseases | #283 |
| diagnostic sensitivity | #283 |
| favor | #284 |
| noninferiority margin | #284 |
| animals anticoagulants | #284 |
| outpatient treatment | #284 |
| test characteristics | #284 |
| departments | #284 |
| major orthopaedic | #285 |
| plasma bnp | #286 |
| patients apixaban | #286 |
| gentamicin treatment | #286 |
| 2630 | #286 |
| levels measured | #287 |
| patients pancreatic cancer | #287 |
| subdistribution | #287 |
| clinically | #287 |
| disseminated intravascular | #287 |
| 227 | #288 |
| oral combined | #288 |
| md patients | #288 |
| premature atherosclerosis | #288 |
| clot lysis | #289 |
| cvt patients | #289 |
| substantiation | #289 |
| vte women | #289 |
| vte rates | #289 |
| n59 | #290 |
| thrombin time | #290 |
| 0·50 | #290 |
| 016 | #291 |
| carriers mutation | #291 |
| current clinical | #291 |
| extracted data | #291 |
| oral contraceptives | #291 |
| willebrand disease vwd | #292 |
| 1603 | #292 |
| 2 studies | #292 |
| activator inhibitor | #292 |
| pentasaccharide | #293 |
| plasmin activity | #293 |
| adverse outcome patients | #293 |
| 1000 personyears | #293 |
| patients dabigatran | #293 |
| lower extremities | #294 |
| patients rivaroxaban | #294 |
| tissuetype plasminogen activator | #294 |
| cardiac troponin ctnt | #294 |
| extremity dvt | #295 |
| 1025 | #295 |
| scenario analysis | #295 |
| peripheral vascular | #296 |
| coagulation factor viii | #296 |
| classified | #296 |
| routine monitoring | #297 |
| observer agreement | #297 |
| episode patients | #298 |
| recurrent miscarriage | #298 |
| specificity npv | #298 |
| thrombocytes | #298 |
| patients inr | #299 |
| inferiority | #300 |
| heparitin | #301 |
| 041 | #301 |
| toxemia | #302 |
| aged neoplasms | #302 |
| thromboglobulin | #302 |
| subclinical thyroid dysfunction | #302 |
| 155 patients | #302 |
| 1214 | #304 |
| absolute difference | #304 |
| rivaroxaban dabigatran | #305 |
| prophylactic administration | #306 |
| medline embase | #306 |
| chimpanzees | #307 |
| noninvasive testing | #308 |
| complex concentrate | #309 |
| vte pregnancy | #310 |
| surgery day | #310 |
| thrombotic | #310 |
| hematologic pregnancy | #310 |
| 105 patients | #311 |
| percentage points | #311 |
| antithrombins blood | #311 |
| patients 100 | #311 |
| clinical presentation | #311 |
| 598 | #312 |
| leg male | #312 |
| vte 95 | #313 |
| hereditary thrombophilia | #313 |
| negative reactions | #313 |
| obesity risk factor | #313 |
| diagnosis | #314 |
| puerperium | #315 |
| heparin aspirin | #315 |
| postpartum haemorrhage | #315 |
| cardiologists | #315 |
| funding | #315 |
| apixaban versus | #316 |
| therapeutic dose | #316 |
| adjudicators | #317 |
| patients followup | #317 |
| 0·92 | #318 |
| deciding | #318 |
| safety outcomes | #319 |
| decision model | #319 |
| failure rates | #319 |
| influenza infections | #320 |
| combined administration | #320 |
| catheter thrombosis | #320 |
| 1731 | #320 |
| patients pregnancy | #320 |
| bnp levels | #320 |
| ventricular dysfunction patients | #321 |
| additional data | #322 |
| intermediate phenotype | #322 |
| difference risk | #322 |
| patients noacs | #322 |
| glaxosmithkline | #324 |
| inrs | #324 |
| peripheral arterial | #324 |
| mortality odds ratio | #325 |
| convincing evidence | #325 |
| blood coagulation factor | #326 |
| pulmonary embolus | #326 |
| 122 patients | #326 |
| mechanical heart valves | #326 |
| surgery trauma | #327 |
| clinical | #327 |
| association vte | #329 |
| thrombotic event | #331 |
| incidence bleeding | #331 |
| vitamin administration | #331 |
| pregnancy outcome women | #331 |
| new oral | #332 |
| n69 | #333 |
| embase databases | #333 |
| 95 percent | #333 |
| analysis trials | #333 |
| incidences | #334 |
| 95 confidence limits | #334 |
| complicate | #334 |
| minor effects | #334 |
| patients healthy volunteers | #335 |
| rationale design | #335 |
| fibrillation benzimidazoles | #335 |
| pulmonary perfusion | #336 |
| central venous catheter | #336 |
| septicaemia | #336 |
| total hip replacement | #337 |
| plethysmographic | #337 |
| recurrent | #337 |
| 035 | #337 |
| 065 | #337 |
| 2 points | #337 |
| fatal bleeding | #338 |
| aged netherlands | #338 |
| coagulation abnormalities | #338 |
| outpatient management | #338 |
| prospective clinical study | #339 |
| noacs warfarin | #339 |
| placebo trials | #339 |
| 024 | #340 |
| antithrombotic effects | #340 |
| patients 12 | #340 |
| activatable | #341 |
| 217 | #341 |
| coagulation markers | #341 |
| knee arthroscopy | #342 |
| noac patients | #342 |
| pretest | #344 |
| patients covid19 infection | #344 |
| rfviia | #345 |
| splanchnic vein thrombosis | #345 |
| antithrombotic strategies | #345 |
| vte prevention | #345 |
| embolisms | #346 |
| diagnosis vte | #346 |
| activated protein resistance | #347 |
| 073 | #347 |
| patients thrombosis | #347 |
| 044 | #348 |
| cochrane central | #348 |
| bsf | #349 |
| chads2 | #349 |
| 2575 | #349 |
| randomized studies | #350 |
| brain predictive | #350 |
| tafia | #350 |
| trousseau | #350 |
| factor viii | #351 |
| 013 | #351 |
| versus warfarin | #351 |
| anticoagulants noacs | #352 |
| dermatan sulphate | #352 |
| factor activation | #352 |
| selection bias | #352 |
| 1590 | #353 |
| relative efficacy | #353 |
| oral anticoagulant therapy | #353 |
| 5075 | #353 |
| vein | #353 |
| aged pulmonary | #354 |
| international normalized ratio | #354 |
| studies diagnostic accuracy | #355 |
| patients gp | #355 |
| protein deficiency | #356 |
| categorised | #357 |
| tests prospective studies | #357 |
| intestinal microbiome | #357 |
| post hoc | #357 |
| 127 patients | #358 |
| pilots | #360 |
| sucra | #360 |
| intermittent claudication | #361 |
| consensus agreement | #362 |
| treatment risk | #362 |
| anticoagulation patients | #364 |
| conventional therapy | #365 |
| humans risk | #365 |
| topic female | #366 |
| bleeding rate | #366 |
| prediction models | #367 |
| patients 3 | #368 |
| time recurrence | #368 |
| infrainguinal | #368 |
| thrombin inhibitor | #369 |
| patients acl reconstruction | #370 |
| 6week | #370 |
| influenza infection | #370 |
| endotoxin infusion | #371 |
| venous stasis | #371 |
| 055 | #372 |
| 803 | #372 |
| aprotinin blood | #373 |
| recombinant activated | #373 |
| knee surgery | #373 |
| patients svt | #373 |
| clinical suspicion | #373 |
| human cytomegalovirus infection | #374 |
| helical computed tomography | #374 |
| patients scores | #374 |
| hmb | #375 |
| subcutaneous | #375 |
| lyg | #377 |
| subclinical hyperthyroidism | #378 |
| stroke venous | #380 |
| contraceptives oral | #380 |
| ethinyloestradiol | #381 |
| tafi | #381 |
| antitnf | #382 |
| prefilter | #383 |
| 0·8 | #384 |
| thromboembolic complications | #384 |
| reassessed | #384 |
| standardized questionnaire | #384 |
| multivariate regression analysis | #384 |
| alpha2m | #385 |
| systemic activation | #385 |
| conference proceedings | #386 |
| bleeding events | #386 |
| surrogate outcome | #386 |
| sensitivity npv | #387 |
| antithrombins | #387 |
| cumulative incidences | #387 |
| delegates | #388 |
| major orthopedic | #388 |
| 880 | #389 |
| systemic embolism | #389 |
| referred | #389 |
| safety rivaroxaban | #389 |
| vitt | #390 |
| tinzaparin | #390 |
| apixaban warfarin | #390 |
| drug prescription | #391 |
| comparison patients | #391 |
| biosis | #391 |
| abi | #391 |
| postop | #391 |
| increased bleeding | #391 |
| topic female humans | #392 |
| patients chest | #392 |
| time presentation | #392 |
| factors thrombosis | #393 |
| kappa values | #393 |
| clinical score | #394 |
| injections intravenous | #394 |
| background patients | #394 |
| pulmonary emboli | #394 |
| 007 | #395 |
| popliteal | #396 |
| bleeding event | #396 |
| 95 12 | #396 |
| hirudins humans | #397 |
| 665 | #397 |
| replacement surgery | #397 |
| embolic events | #397 |
| factors factor | #397 |
| risk score patients | #399 |
| echography | #400 |
| patients risk | #400 |
| heparin induced | #400 |
| risk factors asthma | #400 |
| hemostatic parameters | #401 |
| fibrinolytic agents | #402 |
| dabigatran | #403 |
| increased risk vte | #403 |
| controversy | #403 |
| massive pulmonary embolism | #405 |
| treatment patient | #406 |
| 075 | #406 |
| thrombolytic agents | #406 |
| 2215 | #406 |
| factor levels | #408 |
| oral anticoagulant | #408 |
| biologic effects | #410 |
| fviii levels | #411 |
| noacs patients | #411 |
| patients assigned | #411 |
| safety combination | #411 |
| major risk factor | #412 |
| 20 microg | #412 |
| transfusion patients | #412 |
| maastricht | #414 |
| coagulation patients | #414 |
| euthyroidism | #414 |
| xii | #415 |
| aged odds | #415 |
| hypocortisolism | #415 |
| pai1 levels | #416 |
| intravascular coagulation | #416 |
| dose heparin | #416 |
| deserve | #416 |
| comparable | #417 |
| data risk | #417 |
| 95 10 | #417 |
| carotid femoral | #418 |
| pretest probability | #418 |
| 95 | #418 |
| risk factors thrombosis | #419 |
| 269 | #419 |
| dermatan | #419 |
| ototoxicity | #420 |
| xia | #420 |
| fibrillation risk | #421 |
| 2850 | #422 |
| 1989 | #422 |
| tests radiography | #422 |
| fibrillation clinical | #422 |
| fibrinolysin | #423 |
| subanalysis | #424 |
| fviia | #424 |
| prevalence patients | #425 |
| fii | #426 |
| randomised double | #426 |
| cancer cohort | #426 |
| adjunct | #426 |
| consecutive | #427 |
| activated factor | #427 |
| daily practice | #428 |
| conferences | #428 |
| plg | #428 |
| excessive bleeding | #428 |
| idiopathic myelofibrosis | #429 |
| daily clinical practice | #429 |
| prolactin levels | #429 |
| undergoing elective | #429 |
| patients testing | #429 |
| 1904 | #430 |
| bleeding complications | #431 |
| heparinoids | #431 |
| rule | #431 |
| 04 | #432 |
| incidence length | #433 |
| outpatients | #433 |
| patients systematic review | #434 |
| ncb | #434 |
| blood cultures | #436 |
| firstdegree relatives patients | #436 |
| 059 | #437 |
| bolus injection | #437 |
| prostatic cancer | #439 |
| proven | #439 |
| dose adjustment | #439 |
| composite point | #439 |
| women compared | #439 |
| highrisk populations | #441 |
| concomitant medications | #441 |
| rate vte | #442 |
| 074 | #442 |
| –control study | #444 |
| standard therapies | #444 |
| prespecified | #445 |
| patients atrial fibrillation | #446 |
| febrile patients | #446 |
| female fibrinolytic | #447 |
| hellp | #449 |
| patients parenteral nutrition | #449 |
| 58 | #449 |
| utrecht | #449 |
| prevalence distribution | #450 |
| 3 12 months | #450 |
| category | #451 |
| stigmatisation | #451 |
| pipecolic | #452 |
| thrombin generation | #453 |
| noninvasive tests | #453 |
| fatal disease | #453 |
| aspirin risk | #453 |
| portal blood | #454 |
| 30 40 | #454 |
| placebo day | #454 |
| factor xii | #454 |
| microthrombi | #455 |
| 12week | #455 |
| 026 | #455 |
| fviii vwf | #456 |
| dichotomized | #456 |
| onwards | #457 |
| dicumarol | #457 |
| squibb | #457 |
| hazard ratio 95 | #458 |
| anti levels | #458 |
| iii complexes | #458 |
| plasma lipoprotein | #460 |
| recommend | #460 |
| svt | #460 |
| factor fxa | #461 |
| gastrointestinal cancer | #461 |
| expert consensus document | #462 |
| curve biomarkers | #462 |
| hip arthroplasty replacement | #462 |
| haemolysis | #463 |
| guidelines patients | #463 |
| studies ultrasonography | #464 |
| gp iib | #464 |
| patients values | #464 |
| month follow | #465 |
| cancerassociated thrombosis | #466 |
| diabetes stroke | #466 |
| thrombin formation | #467 |
| accuracy detection | #467 |
| intimamedia thickness | #468 |
| patients nsaids | #468 |
| prophylaxis | #468 |
| bmi≥30 | #469 |
| teaching hospitals | #469 |
| eligible studies | #469 |
| roc analysis | #470 |
| 077 | #470 |
| inr patients | #470 |
| test probability | #470 |
| hemihepatectomy | #470 |
| placebo recipients | #471 |
| case control study | #472 |
| hypercoagulability | #472 |
| prophylactic anticoagulation | #472 |
| cardiovascular risk assessment | #473 |
| thrombophilia testing | #474 |
| 15 95 | #475 |
| plethysmograph | #475 |
| patients heparin | #475 |
| intermittent pneumatic | #475 |
| endotoxemia | #475 |
| heterozygote humans | #475 |
| atria | #477 |
| haemophiliacs | #479 |
| patients score | #479 |
| 08 | #479 |
| versus standard | #480 |
| hit patients | #481 |
| acutely | #481 |
| thrombosis cvt | #481 |
| transportability | #482 |
| postoperative blood | #482 |
| advisory | #482 |
| 1162 | #482 |
| thrombin inhibitors | #483 |
| events mortality | #484 |
| patients hematologic malignancies | #485 |
| diagnostic efficacy | #485 |
| awaited | #486 |
| composite scores | #487 |
| secondary prophylaxis | #487 |
| silent | #488 |
| travel | #488 |
| activity patients | #489 |
| 98 | #490 |
| blinded | #491 |
| treatment period | #493 |
| pan troglodytes | #493 |
| p00007 | #493 |
| hemophilic | #493 |
| new therapy | #493 |
| residual risk | #493 |
| vcf | #494 |
| activated protein | #495 |
| replacement hip arthroplasty | #496 |
| dose oral | #496 |
| favour | #496 |
| heterozygote | #496 |
| topic risk factors | #497 |
| 271 | #497 |
| discriminative ability | #498 |
| risk factors stroke | #498 |
| blockages | #498 |
| willebrand disease | #498 |
| hip knee | #501 |
| ptp | #502 |
| nri | #502 |
| subcategories | #503 |
| deficiencies | #503 |
| ft4 tsh | #503 |
| rapid decrease | #504 |
| complications pulmonary | #505 |
| nondiagnostic | #505 |
| 1107 | #505 |
| patients referred | #505 |
| 310 | #506 |
| net clinical | #506 |
| oftentimes | #507 |
| day surgery | #507 |
| nonionic | #507 |
| inhibitors rivaroxaban | #508 |
| contraceptives | #509 |
| aminocaproates | #509 |
| coagulation tests | #509 |
| guidelines diagnosis | #509 |
| 13 95 | #509 |
| degradation products | #510 |
| angiography patients | #510 |
| thrombosis animals | #510 |
| new oral anticoagulants | #510 |
| viii fviii | #511 |
| 019 | #512 |
| epiphenomenon | #512 |
| serial | #513 |
| highintensity | #514 |
| 056 | #514 |
| interim analysis | #514 |
| daycare | #515 |
| safety | #516 |
| crcl | #517 |
| thrombotic diseases | #518 |
| sensitivity diagnosis | #518 |
| protein antithrombin | #518 |
| thrombophilia thrombosis | #518 |
| bleeding outcomes | #518 |
| treatment cancer patients | #519 |
| groups treatment | #519 |
| study sensitivity | #520 |
| 1599 | #521 |
| 8090 | #521 |
| duration intensity | #521 |
| warfarin therapy | #524 |
| general practitioner | #525 |
| fixed doses | #525 |
| 062 | #527 |
| cindices | #528 |
| cancer age | #528 |
| convincing | #529 |
| 378 | #529 |
| 923 | #529 |
| 051 | #529 |
| health female | #530 |
| fatal | #530 |
| medically patients | #531 |
| thrombosis hemostasis | #531 |
| humans postoperative | #531 |
| betaalanine | #531 |
| thrombosis risk | #532 |
| 068 | #532 |
| intensive units icu | #532 |
| ≥50 years | #532 |
| therapy cancer | #534 |
| factor thrombin | #534 |
| 730 | #536 |
| factor pathway | #537 |
| patients idiopathic | #538 |
| 449 | #538 |
| humans neoplasms | #538 |
| concise | #539 |
| comprehensive search | #539 |
| cbo | #539 |
| ddavp | #539 |
| diagnosis acute | #540 |
| clinical review | #540 |
| diagnostic accuracy studies | #540 |
| bleeding episodes | #543 |
| 234 | #543 |
| vascular obstruction | #543 |
| thrombotic risk | #543 |
| conventional treatment | #543 |
| patients eligible | #543 |
| 00 | #544 |
| pad abi | #544 |
| coagulative | #544 |
| jak2 mutation | #544 |
| hellp syndrome | #545 |
| perc | #545 |
| prospective cohort study | #545 |
| v617f | #545 |
| screening strategies | #546 |
| association statin | #546 |
| bureau | #547 |
| prothrombin complex | #547 |
| primary | #548 |
| adequate | #549 |
| overt | #549 |
| 95 difference | #549 |
| 1103 | #550 |
| reviewers | #550 |
| conduction anesthesia | #550 |
| percent patients | #550 |
| platelet inhibitors | #550 |
| cancer type | #550 |
| amsterdam | #552 |
| studies sensitivity | #552 |
| management bleeding | #552 |
| 500 patients | #552 |
| day patients | #552 |
| careful | #552 |
| femoral arteries | #553 |
| general population patients | #554 |
| ttr | #556 |
| humans infusions | #557 |
| vivo treatment | #558 |
| factor vii | #558 |
| 66 patients | #558 |
| orthopedic surgery | #559 |
| bleeding time | #559 |
| limulus | #561 |
| female humans tests | #563 |
| risk development | #563 |
| board directors | #563 |
| patients transfusion | #563 |
| anamnesis | #564 |
| hip replacement | #564 |
| appears | #564 |
| hyperfibrinolysis | #565 |
| increasing risk | #565 |
| withholding | #566 |
| solid tumours | #566 |
| cardiac troponins | #566 |
| patients 2 years | #568 |
| roc curves | #568 |
| n46 | #568 |
| alpha1antitrypsin | #571 |
| levothyroxine | #571 |
| aggravation | #572 |
| ctnt | #573 |
| menstrual bleeding | #574 |
| cutoff point | #574 |
| revascularization procedures | #574 |
| major bleedings | #575 |
| women proportion | #575 |
| subcutaneously | #575 |
| progression cancer | #577 |
| patients vka | #578 |
| endothelial barrier | #578 |
| endotoxin | #579 |
| pharma | #579 |
| thiophenes | #579 |
| 99 | #580 |
| notice | #580 |
| diagnostic tools | #580 |
| cancer thrombosis | #581 |
| subgroups patients | #583 |
| dummy | #584 |
| unselected patients | #584 |
| 094 | #585 |
| coagulation disorders | #585 |
| chondroitin sulfates | #586 |
| feasibility safety | #588 |
| major orthopedic surgery | #588 |
| helminth proteins | #589 |
| malignancy | #590 |
| thrombophilias | #590 |
| beta alanine | #590 |
| reversal agents | #590 |
| healthy human | #590 |
| massive pulmonary | #592 |
| conventional management | #592 |
| doppler ultrasound | #592 |
| bmi30 | #594 |
| factor fv | #595 |
| ldf | #597 |
| severe bleeding | #597 |
| replacement knee | #597 |
| major hemorrhage | #597 |
| patency rates | #597 |
| infusions intravenous | #598 |
| analysis topic | #599 |
| loss surgical | #600 |
| tests sensitivity | #600 |
| 046 | #601 |
| association patients | #602 |
| vwd | #603 |
| clinical characteristics patients | #604 |
| events occurred | #604 |
| comorbid conditions | #604 |
| diagnostic studies | #606 |
| activated coagulation | #607 |
| initial increase | #607 |
| 0·3 | #607 |
| patients antibodies | #607 |
| treatment acute | #608 |
| pfizer | #609 |
| arbitrage | #609 |
| tissue factor | #609 |
| airline | #610 |
| patients death | #610 |
| benefit risk | #610 |
| 100 years | #610 |
| clinical evaluation | #611 |
| ultrasonography | #613 |
| coagulation inflammation | #614 |
| leg | #615 |
| patients bariatric surgery | #615 |
| reluctant | #615 |
| complications risk | #616 |
| arterial disease | #617 |
| treatment rivaroxaban | #617 |
| 467 | #618 |
| stroke atrial fibrillation | #618 |
| occurred | #618 |
| compared placebo | #620 |
| fh patients | #620 |
| patients elevated | #621 |
| advisory committees | #621 |
| 1002 | #622 |
| thrombocytopenia hit | #623 |
| thyrotoxic | #623 |
| sgs | #623 |
| peptide bnp | #625 |
| cochrane central register | #625 |
| topic practice guidelines | #626 |
| stopped | #626 |
| stroke warfarin | #627 |
| 5000 | #628 |
| warfarin risk | #628 |
| 66 | #628 |
| women risk factors | #628 |
| human subjects | #629 |
| physical training | #629 |
| referral patients | #629 |
| diagnostic algorithms | #629 |
| sanofi | #630 |
| absolute | #630 |
| atiii | #632 |
| risk treatment | #633 |
| screening strategy | #634 |
| uneventful | #635 |
| outweigh | #635 |
| pentoxifylline | #637 |
| travelling | #638 |
| 14 95 | #640 |
| 95 allcause mortality | #640 |
| proceedings | #641 |
| study quality | #641 |
| 3050 | #642 |
| predictive performance | #642 |
| neutrophilia | #643 |
| threatening bleeding | #643 |
| association mortality | #647 |
| primary outcome measure | #647 |
| necessitating | #648 |
| statin treatment | #648 |
| studies efficacy | #648 |
| thrombolysis patients | #651 |
| 036 | #651 |
| fixed | #651 |
| organisations | #652 |
| troglodytes | #652 |
| fxa | #653 |
| hemorrhagic stroke | #653 |
| 127 | #655 |
| patients review | #657 |
| coronary stent implantation | #659 |
| 69 | #659 |
| bleeding death | #659 |
| haematoma | #660 |
| physical examination | #661 |
| tertiles | #661 |
| coagulation proteins | #661 |
| clinical presentations | #662 |
| haemophilia | #662 |
| 1028 | #663 |
| 95 studies | #663 |
| long term treatment | #664 |
| provoked | #664 |
| sepsis shock | #665 |
| phase iii studies | #666 |
| deep | #666 |
| patients completed | #667 |
| presence patients | #667 |
| onethird | #667 |
| guideline adherence | #667 |
| male medical | #668 |
| 8 wk | #669 |
| 1110 | #671 |
| phenprocoumon | #672 |
| patients cteph | #673 |
| elevated plasma | #673 |
| hospitalization hf | #674 |
| managing | #674 |
| clotting factors | #675 |
| il6 levels | #675 |
| inhibitor 1 | #675 |
| prothrombotic | #676 |
| highincome countries | #676 |
| asymptomatic subjects | #677 |
| favourably | #678 |
| jugular | #679 |
| medicine humans | #681 |
| pulmonary endarterectomy | #681 |
| suspicion | #682 |
| conclude | #687 |
| apolipoproteina | #688 |
| efficacy safety | #690 |
| ambulatory patients | #692 |
| patients bleeding | #692 |
| activator pa | #693 |
| myocardial infarctions | #693 |
| graduated | #693 |
| precise mechanisms | #694 |
| intracranial bleeding | #694 |
| composite outcome | #694 |
| administer | #694 |
| 1718 | #695 |
| moyamoya | #696 |
| combined oral contraceptives | #696 |
| stroke prevention patients | #696 |
| participant data | #698 |
| ratio male | #698 |
| difference 95 | #698 |
| compression devices | #700 |
| episode | #700 |
| diagnostic errors | #702 |
| prothrombin gene | #702 |
| therapeutic management | #702 |
| veins venous | #703 |
| patients confirmed | #703 |
| surgery risk | #703 |
| willebrand | #704 |
| data incidence | #706 |
| subclinical hypothyroidism | #708 |
| directors | #709 |
| clinical expression | #709 |
| starters | #711 |
| medical patients | #712 |
| gastrointestinal bleeding | #712 |
| 048 | #712 |
| gynaecology | #712 |
| radionuclide imaging | #713 |
| 1098 | #714 |
| rate death | #714 |
| neurosurgical patients | #714 |
| intravenous bolus | #715 |
| rivaroxaban stroke | #716 |
| menstrual period | #716 |
| adequately | #717 |
| cancer groups | #717 |
| solid cancer | #718 |
| falsely | #718 |
| 10 30 | #718 |
| reagent kits | #719 |
| plasminogen | #719 |
| pulmonary medicine | #720 |
| pyrazoles pyridines | #721 |
| nordisk | #721 |
| accp | #721 |
| clinical judgment | #721 |
| s1p1 | #722 |
| 95 hazard ratio | #724 |
| follow period | #726 |
| abnormal | #726 |
| gentamicins | #727 |
| 59 patients | #727 |
| orthopaedic surgery | #728 |
| diagnostic therapeutic | #728 |
| diagnostic tests | #730 |
| leeches | #732 |
| gentamicin | #732 |
| tumor necrosis factor | #733 |
| oral contraception | #733 |
| relative risk 95 | #734 |
| hull | #735 |
| disease pad | #735 |
| patients levels | #735 |
| atrial fibrillation risk | #736 |
| clinical prediction rule | #736 |
| tests retrospective studies | #736 |
| 6 12 | #739 |
| post hoc analysis | #739 |
| anti tnf | #740 |
| evaluable patients | #741 |
| unclear | #742 |
| early pregnancy loss | #742 |
| 040 | #742 |
| topic predictive | #743 |
| illness time factors | #744 |
| betathromboglobulin | #744 |
| molecular weight | #744 |
| antithrombin activity | #746 |
| etp | #746 |
| 285 | #746 |
| patients 50 years | #746 |
| leukocyte activation | #748 |
| thrombolytic therapy | #749 |
| hospitalization heart failure | #750 |
| indication | #752 |
| advisable | #754 |
| fibrin formation | #754 |
| primary patients | #755 |
| hf risk | #756 |
| 95 risk factors | #756 |
| pneumatic compression | #756 |
| answer | #756 |
| 95 combination | #756 |
| venovenous | #757 |
| 1·7 | #758 |
| 85 | #759 |
| loe | #759 |
| inflammation coagulation | #760 |
| patients peripheral | #761 |
| proportion women | #763 |
| 435 | #763 |
| cprs | #764 |
| start treatment | #764 |
| hip surgery | #765 |
| aspirin clopidogrel | #767 |
| 689 | #767 |
| risk pregnancy | #767 |
| 732 | #768 |
| method drug | #769 |
| 566 | #770 |
| groups patients | #770 |
| relevant | #770 |
| graft patency | #772 |
| baseline values | #772 |
| patients criteria | #773 |
| subcutaneous injections | #774 |
| bmi patients | #774 |
| 1·5 | #776 |
| 992 | #777 |
| study groups | #778 |
| dose warfarin | #778 |
| dose intravenous | #778 |
| patients 65 years | #778 |
| miscarriage | #779 |
| plasmin generation | #780 |
| 066 | #780 |
| patients hyperthyroidism | #780 |
| thromboembolism prophylaxis | #780 |
| age ≥ | #782 |
| onefifth | #785 |
| factor ixa | #785 |
| abnormalities patients | #786 |
| cteph | #787 |
| polypharmacy | #787 |
| 100 personyears | #787 |
| topic disease models | #787 |
| general practitioners | #787 |
| preferable | #788 |
| secondary outcome | #791 |
| recombinant tissue | #793 |
| mechanical heart | #793 |
| risk factors risk | #795 |
| inactivators | #795 |
| 047 | #795 |
| patency | #796 |
| patient years | #796 |
| eligible | #797 |
| netherlands | #797 |
| studies prevalence | #797 |
| lupus anticoagulant | #798 |
| femoropopliteal | #798 |
| patients lower | #799 |
| estrogen therapy | #799 |
| theme | #799 |
| hemophilia patients | #800 |
| willebrand factor | #802 |
| randomized patients | #804 |
| subclinical | #804 |
| anticoagulant agents | #805 |
| microvesicles | #805 |
| fibrillation blood | #806 |
| adverse outcomes patients | #806 |
| stroke risk factors | #807 |
| ventricular dysfunction | #808 |
| efficacy patients | #809 |
| hypertension cteph | #809 |
| activator inhibitor1 | #810 |
| 069 | #811 |
| model patients | #813 |
| primary aim | #814 |
| flights | #816 |
| factor vwf | #816 |
| 0·4 | #818 |
| vehicle control | #820 |
| irrespective | #820 |
| health predictive | #820 |
| abruptio | #821 |
| neuroradiologist | #822 |
| reduction mortality | #823 |
| prevention patients | #823 |
| single administration | #824 |
| coc | #824 |
| risk benefit | #825 |
| study incidence | #827 |
| gp | #828 |
| cardioembolic stroke | #828 |
| patients anticoagulants | #830 |
| cava filters | #832 |
| antithrombotic treatment | #833 |
| 93 | #833 |
| myers | #833 |
| abortion habitual | #835 |
| plough | #836 |
| oral adult | #836 |
| versus placebo | #837 |
| noac | #837 |
| 87 | #838 |
| 057 | #839 |
| genetic defect | #841 |
| risk scores | #844 |
| 49 | #846 |
| antithrombotic therapy | #846 |
| 072 | #847 |
| multidetector row | #847 |
| advise | #848 |
| recurrence risk | #849 |
| patients diagnosis | #850 |
| caesarean | #850 |
| area roc curve | #852 |
| reference method | #853 |
| pre‐eclampsia | #853 |
| 30 patients | #853 |
| advanced prostate | #854 |
| fibrin | #855 |
| clopidogrel aspirin | #855 |
| patients mutation | #859 |
| ultrafiltrate | #860 |
| dutch population | #861 |
| microg | #862 |
| cardiometabolic disease | #863 |
| 090 | #865 |
| placebo study | #866 |
| diagnostic methods | #868 |
| 1046 | #869 |
| pyridones | #870 |
| 6 month | #870 |
| individual participant | #872 |
| longterm clinical outcomes | #872 |
| tasman | #873 |
| favoring | #873 |
| thromboembolic pulmonary | #874 |
| targeted inhibition | #874 |
| imaging reproducibility | #874 |
| plasminogen activation | #875 |
| titles | #875 |
| n15 | #876 |
| cha2ds2 | #877 |
| risk thromboembolic | #878 |
| dabigatran rivaroxaban | #878 |
| 57 | #879 |
| anticoagulants atrial | #879 |
| oral | #881 |
| angiograms | #882 |
| control trial | #883 |
| 92 | #884 |
| imaging tests | #885 |
| prostate turp | #888 |
| handbook | #890 |
| 084 | #894 |
| domiciliary | #894 |
| male mexico | #894 |
| p011 | #896 |
| loading dose | #896 |
| repeatedly | #897 |
| uln | #901 |
| indefinite | #902 |
| bleedings | #904 |
| vkorc1 | #905 |
| wml | #906 |
| factor activity | #908 |
| 064 | #908 |
| subcutaneous administration | #909 |
| documented | #911 |
| patients clinical trials | #911 |
| haemostatic | #912 |
| initially | #912 |
| impedance | #913 |
| specificity sensitivity | #914 |
| combined approach | #916 |
| haemodialysis patients | #916 |
| 317 | #917 |
| thromboembolic events | #918 |
| 022 | #918 |
| chronic thromboembolic | #919 |
| randomeffects model | #920 |
| antagonist oral | #920 |
| standard patients | #920 |
| loss patients | #921 |
| optimal dose | #921 |
| ultrasound examination | #921 |
| practise | #923 |
| estimate male | #923 |
| study medication | #925 |
| multifactorial disease | #925 |
| total hip | #926 |
| safer | #928 |
| 902 | #928 |
| 004 | #929 |
| recurrent events | #930 |
| fxi | #931 |
| wording | #934 |
| treatment placebo | #934 |
| 84 | #936 |
| publication clinical trials | #937 |
| 60 patients | #938 |
| subgroup patients | #938 |
| rrr | #940 |
| families patients | #941 |
| teaching hospital | #943 |
| women preeclampsia | #944 |
| echocardiographically | #944 |
| stroke atrial | #944 |
| emboli | #945 |
| ssc | #946 |
| predictive values | #946 |
| anticoagulation treatment | #947 |
| extensive disease | #948 |
| diagnostic | #948 |
| knee replacement | #948 |
| previous diagnosis | #951 |
| adjudication | #954 |
| network metaanalysis | #956 |
| cancer humans | #956 |
| dic | #956 |
| registro | #956 |
| reassuring | #957 |
| venous insufficiency | #957 |
| day1 | #958 |
| efficacy | #958 |
| retropubic | #961 |
| combined oral | #961 |
| guidelines recommend | #962 |
| 3 months | #963 |
| blood product | #964 |
| travellers | #965 |
| inhibitor1 | #966 |
| reference lists | #966 |
| peaking | #969 |
| greater risk | #970 |
| allogeneic blood | #971 |
| risk allcause mortality | #973 |
| hoc | #973 |
| prevalence characteristics | #973 |
| antiplatelet | #973 |
| segmental | #974 |
| patients anticoagulation | #975 |
| vascular humans | #976 |
| female fibrinogen | #976 |
| fvii | #978 |
| false negative | #979 |
| onset aged aged | #980 |
| 50 100 | #980 |
| 071 | #980 |
| early gestation | #984 |
| 426 | #986 |
| prophylactic treatment | #987 |
| randomised trials | #987 |
| patients safety | #988 |
| vascular patency | #989 |
| study treatment | #990 |
| rises | #991 |
| missed | #991 |
| academic medical center | #992 |
| seminar | #992 |
| normal lung | #993 |
| counteracted | #993 |
| treatment bleeding | #994 |
| aged | #999 |
| 226 | #999 |
| thromboembolic risk | #1000 |
| lower extremity | #1000 |
| justification | #1000 |
| tissue type | #1001 |
| parenteral administration | #1002 |
| rivaroxaban apixaban | #1002 |
| eclamptic | #1003 |
| hyperprolactinaemia | #1005 |
| interleukin 6 | #1005 |
| extended | #1005 |
| pyridines | #1006 |
| orthosis | #1007 |
| 50 patients | #1007 |
| easier | #1007 |
| valsalva maneuver | #1009 |
| venous catheter | #1011 |
| individual participant data | #1012 |
| weighing | #1014 |
| ticlopidine | #1018 |
| pounds | #1018 |
| clotting time | #1019 |
| prostatic carcinoma | #1020 |
| 200 patients | #1022 |
| cha2ds2 vasc | #1023 |
| years risk | #1023 |
| humans randomized | #1024 |
| international prospective | #1024 |
| 076 | #1025 |
| diagnostic challenge | #1026 |
| prothrombin time | #1027 |
| decision analysis | #1030 |
| firstdegree relatives | #1030 |
| ixa | #1031 |
| prolactin | #1032 |
| cardiovascular event | #1033 |
| relatives | #1033 |
| risk hemorrhage | #1033 |
| 052 | #1035 |
| male netherlands | #1037 |
| graft occlusion | #1037 |
| 2 hours | #1039 |
| detect | #1040 |
| 025 | #1041 |
| 3 6 months | #1046 |
| patients severe asthma | #1047 |
| vwf levels | #1047 |
| examiner | #1050 |
| patients massive | #1050 |
| continuation | #1052 |
| patients analysis | #1053 |
| mean±sd | #1054 |
| 221 | #1054 |
| free triiodothyronine | #1056 |
| diseases liver | #1057 |
| coagulant | #1060 |
| 179 | #1060 |
| birth rate | #1060 |
| 610 | #1061 |
| pad | #1061 |
| published literature | #1062 |
| primary data | #1062 |
| false | #1064 |
| prekallikrein | #1065 |
| 150 | #1065 |
| live birth | #1066 |
| 00008 | #1066 |
| 101 | #1066 |
| cut | #1067 |
| lysosphingolipid | #1067 |
| pmol | #1068 |
| 95 increased risk | #1070 |
| register controlled | #1070 |
| observer variation | #1071 |
| specialties | #1072 |
| continued | #1073 |
| laboratory diagnosis | #1074 |
| thorax | #1074 |
| systematic search | #1078 |
| advocate | #1080 |
| 063 | #1080 |
| drawbacks | #1082 |
| f1 | #1087 |
| longterm therapy | #1087 |
| bandages | #1089 |
| stopping | #1095 |
| clarifications | #1095 |
| idarucizumab | #1096 |
| diagnostic utility | #1096 |
| mandated | #1096 |
| 1223 | #1099 |
| 083 | #1099 |
| 62 | #1102 |
| 96 | #1104 |
| fourfold | #1105 |
| blueprint | #1105 |
| clinical protocols | #1107 |
| peptide brain | #1107 |
| pending | #1111 |
| incidence pulmonary | #1112 |
| assigned | #1113 |
| diagnostic approach | #1115 |
| haemodialysis | #1116 |
| bypass grafts | #1116 |
| 252 | #1117 |
| qualified | #1118 |
| sensitivity specificity | #1119 |
| critical appraisal | #1120 |
| randomized controlled trials | #1122 |
| resistance factor | #1123 |
| probands | #1123 |
| new developments | #1124 |
| advised | #1125 |
| 445 | #1126 |
| new perspectives | #1126 |
| heparininduced thrombocytopenia | #1127 |
| cip | #1127 |
| patients pad | #1128 |
| discretion | #1132 |
| judged | #1132 |
| ≤10 | #1133 |
| statistic | #1133 |
| 95 confidence interval | #1134 |
| pulse rate | #1135 |
| gram negative | #1137 |
| 1043 | #1139 |
| disseminated | #1140 |
| superior efficacy | #1141 |
| 635 | #1141 |
| 86 | #1143 |
| 734 | #1145 |
| 844 | #1147 |
| roc curve | #1150 |
| refusal | #1150 |
| medline | #1151 |
| medical records | #1151 |
| embolectomy | #1153 |
| longterm complications | #1154 |
| risk recurrence | #1155 |
| patients influenza | #1156 |
| blood loss | #1156 |
| anticoagulation therapy | #1156 |
| prophylaxis treatment | #1157 |
| 3040 | #1158 |
| patients increased | #1159 |
| extension study | #1161 |
| cvc | #1162 |
| published guidelines | #1163 |
| bristol | #1163 |
| safety concerns | #1164 |
| stable angina | #1164 |
| intermittent | #1164 |
| viii | #1164 |
| hyperhomocysteinemia | #1164 |
| age 65 years | #1165 |
| thromboembolism risk | #1165 |
| angiogram | #1167 |
| glucocorticoid treatment | #1172 |
| crossover design | #1172 |
| atherosclerotic disease | #1172 |
| perioperative bleeding | #1172 |
| practice guideline | #1173 |
| occlusive diseases | #1173 |
| macroglobulin | #1176 |
| 5 years patients | #1176 |
| analysis studies | #1178 |
| findings patients | #1178 |
| 79 | #1179 |
| concealed | #1181 |
| conceive | #1181 |
| unaware | #1182 |
| hospitalized patients | #1182 |
| patients obesity | #1182 |
| combined therapy | #1186 |
| conclusive | #1186 |
| degree relatives | #1189 |
| occult | #1189 |
| adult analysis | #1191 |
| cus | #1194 |
| administration oral | #1195 |
| 21 patients | #1197 |
| cardiotonic agents | #1199 |
| international society | #1199 |
| mandate | #1199 |
| hypercortisolism | #1200 |
| 83 | #1203 |
| quantitative trait locus | #1204 |
| categorized | #1204 |
| 015 | #1204 |
| increase plasma | #1205 |
| 31 | #1207 |
| biomarkers blood | #1210 |
| 56 patients | #1212 |
| multicenter randomized | #1214 |
| pph | #1214 |
| 103 | #1218 |
| warranted | #1221 |
| patient treatment | #1221 |
| scores patients | #1221 |
| ultrasound screening | #1222 |
| 6months | #1223 |
| 64 patients | #1224 |
| peak levels | #1224 |
| vasc | #1225 |
| 16 patients | #1226 |
| sixfold | #1227 |
| blind | #1227 |
| consensus guidelines | #1228 |
| metabolic syndrome patients | #1228 |
| trial background | #1229 |
| radionuclide | #1229 |
| peptide hydrolases | #1229 |
| 65 patients | #1230 |
| rules | #1232 |
| doubles | #1232 |
| aspirin | #1234 |
| postoperative hemorrhage | #1238 |
| coronary angiography patients | #1238 |
| milliliter | #1238 |
| humans length | #1240 |
| clinical criteria | #1241 |
| patients fh | #1242 |
| vte prophylaxis | #1244 |
| neurohormone | #1245 |
| multinational | #1246 |
| thrombolytic | #1247 |
| knee arthroplasty | #1248 |
| intermediate risk | #1250 |
| subgroups | #1252 |
| ml1 | #1252 |
| matter lesions | #1252 |
| artery pulmonary | #1254 |
| oral vitamin | #1257 |
| search strategy | #1257 |
| extensive | #1257 |
| prospective cohort | #1258 |
| symptomatic patients | #1259 |
| major surgery | #1262 |
| entity | #1266 |
| troponins | #1266 |
| visiting | #1266 |
| macroglobulins | #1267 |
| 172 | #1270 |
| amputations | #1273 |
| equally | #1274 |
| intensive patients | #1274 |
| design study | #1276 |
| antiplatelet agents | #1278 |
| proportionally | #1279 |
| 75 years | #1281 |
| statin users | #1281 |
| routine screening | #1281 |
| factors ultrasonography | #1285 |
| thyroxine | #1287 |
| 050 | #1288 |
| blockers | #1290 |
| dermatan sulfate | #1292 |
| janssen | #1295 |
| scan | #1295 |
| perfusion defects | #1295 |
| predictive | #1297 |
| hemofiltration | #1297 |
| insufficiently | #1298 |
| cardiovascular complications | #1299 |
| low prevalence | #1299 |
| dutch | #1300 |
| prolong | #1302 |
| 61 | #1303 |
| pf4 | #1303 |
| pulmonary circulation | #1304 |
| scores | #1305 |
| 95 mortality | #1307 |
| cyproterone | #1312 |
| risk difference | #1312 |
| 1st | #1312 |
| apoa | #1312 |
| adamts13 activity | #1313 |
| 0·7 | #1314 |
| tests severity | #1314 |
| current strategies | #1314 |
| claudication | #1316 |
| atrial fibrillation | #1316 |
| carotid imt | #1317 |
| international guidelines | #1318 |
| replacement hip | #1320 |
| study time | #1321 |
| coagulation factor | #1322 |
| vienna | #1323 |
| increases risk | #1324 |
| glycoprotein gpiib | #1325 |
| lipoproteina | #1325 |
| patients coronavirus disease | #1326 |
| beneficial | #1329 |
| vascular diseases | #1329 |
| antibodies monoclonal antibodies | #1329 |
| low moderate | #1330 |
| thyroid disorders | #1330 |
| plasminogen activators | #1330 |
| 77 | #1331 |
| coagulation cascade | #1331 |
| 6 months patients | #1331 |
| 126 | #1332 |
| frequent complication | #1333 |
| adjusted age | #1335 |
| transurethral resection | #1336 |
| likelihood ratio | #1342 |
| 91 | #1342 |
| venous catheters | #1342 |
| blood sample | #1343 |
| daily patients | #1344 |
| surgical trauma | #1347 |
| antitrypsin | #1347 |
| patients relatives | #1351 |
| neurosurgery | #1355 |
| arthroplasty patients | #1356 |
| patients stable angina | #1357 |
| allcause mortality 95 | #1359 |
| experimental model | #1359 |
| 15 patients | #1359 |
| arsenal | #1363 |
| vwf | #1363 |
| limb salvage | #1363 |
| vtes | #1365 |
| 95 patients | #1366 |
| operatively | #1367 |
| 12 month | #1369 |
| heart valves | #1370 |
| starting | #1372 |
| ethinyl | #1373 |
| acetylsalicylic | #1375 |
| costeffectiveness analysis | #1376 |
| utmost | #1378 |
| consented | #1382 |
| management patients | #1383 |
| gps | #1384 |
| 224 | #1385 |
| dl1 | #1385 |
| noninferiority | #1385 |
| disorders blood | #1386 |
| ivt | #1389 |
| patients cvd | #1392 |
| substitute | #1394 |
| screening tests | #1399 |
| record linkage | #1400 |
| patients control subjects | #1400 |
| antisense oligonucleotide | #1402 |
| equipoise | #1402 |
| 82 | #1402 |
| mandatory | #1403 |
| clinical challenges | #1404 |
| 1886 | #1405 |
| patients advanced cancer | #1405 |
| obese patients | #1406 |
| pregnancy loss | #1406 |
| 515 | #1408 |
| categories | #1408 |
| 994 | #1409 |
| reflected | #1410 |
| inception | #1411 |
| tranexamic | #1413 |
| adamts13 | #1417 |
| 0·1 | #1418 |
| 7 weeks | #1419 |
| 6 weeks | #1419 |
| thrombotic complications | #1419 |
| 3 6 | #1419 |
| total knee | #1420 |
| 95 0 | #1421 |
| followup data | #1422 |
| university hospitals | #1422 |
| daily | #1424 |
| ≥55 | #1424 |
| 061 | #1424 |
| eightfold | #1425 |
| randomised controlled trials | #1427 |
| 080 | #1427 |
| rgs | #1430 |
| casecontrol study | #1430 |
| outcome pregnancy | #1438 |
| 096 | #1439 |
| imaging radiopharmaceuticals | #1439 |
| principal | #1443 |
| 78 | #1443 |
| 1123 | #1445 |
| drug levels | #1446 |
| outcome studies | #1446 |
| weight bmi | #1446 |
| underreporting | #1451 |
| support systems | #1452 |
| population patients | #1454 |
| confusion | #1454 |
| platelet factor | #1455 |
| aged blood | #1455 |
| dip | #1456 |
| mbe | #1457 |
| conclusions patients | #1459 |
| prospectively | #1460 |
| multicenter studies | #1461 |
| humans | #1463 |
| inaccuracy | #1464 |
| actual | #1466 |
| funded | #1466 |
| avoided | #1468 |
| 0·9 | #1468 |
| 26 patients | #1469 |
| heart failure hf | #1469 |
| groin | #1471 |
| risk factors mortality | #1472 |
| 1215 | #1473 |
| prevalences | #1473 |
| centrally | #1474 |
| systemic infection | #1477 |
| probability | #1477 |
| lowest tertile | #1478 |
| remained | #1480 |
| atherothrombotic | #1481 |
| undetermined | #1482 |
| dysfunction patients | #1483 |
| cushing syndrome | #1485 |
| analysis randomized | #1485 |
| phase iii trials | #1486 |
| methodologic | #1486 |
| general practice | #1491 |
| patients control | #1495 |
| procoagulant activity | #1495 |
| randomly | #1496 |
| 64 | #1498 |
| aged natriuretic | #1499 |
| exposing | #1501 |
| imt | #1507 |
| fracture surgery | #1510 |
| specificity 100 | #1512 |
| odds ratio 95 | #1513 |
| adverse outcome | #1514 |
| growing body | #1514 |
| proximal | #1516 |
| pregnancy postpartum | #1520 |
| patients 10 | #1520 |
| ganz | #1520 |
| subgroup | #1521 |
| factor deficiency | #1522 |
| gsk | #1524 |
| chills | #1526 |
| contraindicated | #1527 |
| thrombotic events | #1527 |
| score | #1529 |
| time study | #1529 |
| oral contraceptive | #1534 |
| mechanical compression | #1536 |
| immobilisation | #1539 |
| comparator | #1540 |
| patients life | #1541 |
| humans neoplasm | #1542 |
| hemostatics humans | #1545 |
| 089 | #1548 |
| tsh levels | #1551 |
| live births | #1552 |
| patients severe sepsis | #1552 |
| 23 | #1554 |
| vascular thrombosis | #1555 |
| fees | #1556 |
| neonatal period | #1558 |
| patients year | #1559 |
| discriminatory | #1562 |
| hypothyroidism | #1563 |
| enfermedad | #1564 |
| pfa | #1564 |
| iii topic | #1565 |
| treatment prevention | #1566 |
| topic | #1566 |
| cushings syndrome | #1568 |
| deficient | #1568 |
| 95ci | #1568 |
| hyperlipoproteinemia type | #1568 |
| aged biomarkers | #1571 |
| 36 | #1575 |
| plasminogen activator | #1575 |
| humans platelet | #1576 |
| 012 | #1577 |
| hyperlipoproteinemia | #1580 |
| risk myocardial infarction | #1584 |
| activation markers | #1586 |
| thyroid dysfunction | #1586 |
| cocs | #1586 |
| study entry | #1586 |
| studies association | #1587 |
| adjusted hazard ratio | #1589 |
| volunteers | #1591 |
| 1·1 | #1594 |
| total mortality | #1594 |
| translates | #1597 |
| noncancer | #1598 |
| placebo | #1598 |
| exclude | #1599 |
| lmw | #1601 |
| figures | #1604 |
| paroxetine | #1606 |
| abdominal surgery | #1607 |
| complement pathway | #1609 |
| curability | #1610 |
| general surgery | #1613 |
| 162 | #1613 |
| ethinylestradiol | #1614 |
| recommending | #1615 |
| factors tomography | #1616 |
| prospective cohort studies | #1616 |
| postpartum period | #1616 |
| positive effects | #1616 |
| tests reproducibility | #1616 |
| perinatal outcome | #1618 |
| 155 | #1618 |
| imaging tomography | #1619 |
| cvd patients | #1619 |
| female hemostasis | #1619 |
| proportion | #1620 |
| 12month followup | #1621 |
| uncertain | #1621 |
| 079 | #1623 |
| competing risk | #1628 |
| isis | #1630 |
| major | #1631 |
| incidentally | #1632 |
| pa patients | #1632 |
| venous disease | #1632 |
| fresh frozen plasma | #1633 |
| clinical patients | #1633 |
| double | #1639 |
| study outcomes | #1639 |
| 029 | #1642 |
| 181 | #1643 |
| ctni | #1644 |
| stroke prevention | #1644 |
| patients hospitalized | #1647 |
| mismatched | #1648 |
| 997 | #1651 |
| dorsiflexion | #1651 |
| ≤4 | #1652 |
| 35 years | #1652 |
| thrombin activity | #1653 |
| studies data | #1653 |
| clotting | #1656 |
| remaining | #1660 |
| plasma concentration | #1661 |
| outcome data | #1663 |
| spiral | #1669 |
| disease adult | #1670 |
| homocysteine levels | #1670 |
| thrombi | #1674 |
| daily dosing | #1676 |
| inpatient treatment | #1676 |
| deficiency | #1677 |
| plasma level | #1677 |
| warfarin dose | #1680 |
| arthroscopy | #1684 |
| unreliable | #1686 |
| steroidal anti | #1686 |
| patients acs | #1687 |
| thrombin | #1690 |
| severe renal | #1694 |
| patients brain metastases | #1695 |
| prospective | #1702 |
| necrosis factor | #1705 |
| highest risk | #1707 |
| cancer screening | #1708 |
| awaiting | #1710 |
| yielded | #1712 |
| 033 | #1712 |
| hemorheology | #1715 |
| intravenous | #1715 |
| bronchospasm | #1720 |
| hematologic malignancies | #1720 |
| female femoral | #1721 |
| mb | #1721 |
| diagnostic evaluation | #1721 |
| cardioembolic | #1722 |
| cumulative incidence | #1723 |
| laser doppler | #1724 |
| 107 | #1726 |
| conference | #1726 |
| derived microparticles | #1729 |
| 021 | #1730 |
| volunteer | #1730 |
| 161 | #1733 |
| percentage patients | #1734 |
| clinical scores | #1735 |
| east asian | #1735 |
| patients icu | #1736 |
| rico | #1737 |
| 500 | #1738 |
| minor | #1739 |
| revised | #1744 |
| table | #1745 |
| patients ventricular | #1745 |
| 691 | #1745 |
| profession | #1746 |
| risk cardiovascular events | #1747 |
| hyperinsulinaemia | #1747 |
| turp | #1749 |
| apc | #1749 |
| pselectin | #1750 |
| homozygosity | #1750 |
| replacement | #1750 |
| 128 | #1752 |
| 133 | #1753 |
| intracranial hemorrhages | #1753 |
| 3 studies | #1755 |
| spontaneous | #1756 |
| arterial occlusive | #1758 |
| patients randomized | #1759 |
| audiometry | #1760 |
| treatment recommendations | #1760 |
| assessor | #1760 |
| current treatment | #1761 |
| primary setting | #1762 |
| long‐term | #1763 |
| fx | #1764 |
| human insulin | #1764 |
| duplicate | #1769 |
| arteriosclerosis | #1770 |
| hemorrhage | #1770 |
| initial management | #1770 |
| 2 6 | #1774 |
| allcause death | #1774 |
| 28 weeks | #1781 |
| hemostasis humans | #1782 |
| trough levels | #1785 |
| infusions | #1787 |
| ethinyl estradiol | #1789 |
| selfmanagement | #1790 |
| clinical consequences | #1790 |
| microparticle | #1793 |
| reid | #1793 |
| vascular surgical | #1794 |
| cardiac troponin | #1794 |
| healthy male volunteers | #1799 |
| 042 | #1800 |
| aggregation inhibitors | #1802 |
| 020 | #1802 |
| retrospective analysis | #1805 |
| hemophilia humans | #1808 |
| unpublished | #1810 |
| slc6a4 | #1812 |
| tumor necrosis | #1812 |
| 95 specificity | #1812 |
| overlapped | #1814 |
| 51 | #1815 |
| 078 | #1818 |
| conjoint | #1819 |
| economic evaluation | #1819 |
| interobserver | #1823 |
| awareness | #1824 |
| screening middle | #1825 |
| preference | #1825 |
| 303 | #1828 |
| placebo 95 | #1832 |
| undergoing coronary | #1834 |
| definite | #1837 |
| compressibility | #1837 |
| cushing | #1838 |
| kaplanmeier estimate | #1838 |
| severe sepsis | #1839 |
| 1 week | #1842 |
| central venous | #1842 |
| workup | #1848 |
| orthopaedic | #1849 |
| explanations | #1852 |
| hydroxyethyl starch | #1852 |
| 160 | #1854 |
| fibrinopeptide | #1862 |
| cancer therapies | #1865 |
| alpha 2 | #1867 |
| gramnegative | #1869 |
| serially | #1870 |
| humans pregnancy | #1874 |
| separately | #1876 |
| oral anticoagulation | #1880 |
| shrs | #1892 |
| diagnostic techniques | #1892 |
| thromboses | #1892 |
| lower incidence | #1893 |
| stable patients | #1895 |
| 067 | #1897 |
| 5 10 | #1897 |
| contraindications | #1900 |
| tnf | #1901 |
| diagnostic testing | #1901 |
| extremity | #1901 |
| clt | #1905 |
| induced thrombocytopenia | #1906 |
| plaster | #1906 |
| hazard ratio | #1906 |
| differential effects | #1907 |
| 95 year | #1909 |
| efficacy treatment | #1910 |
| referral | #1910 |
| random | #1911 |
| plato | #1913 |
| experimental mice mice | #1916 |
| 238 | #1918 |
| randomized | #1919 |
| 13 patients | #1920 |
| 793 | #1920 |
| administration | #1921 |
| pregnancy treatment | #1922 |
| stroke 95 | #1923 |
| 868 | #1923 |
| biotin | #1924 |
| 55 years | #1924 |
| venous pressure | #1926 |
| trials patients | #1926 |
| μg | #1927 |
| intracranial hemorrhage | #1927 |
| coronary syndromes | #1928 |
| 272 | #1929 |
| cardiovascular events patients | #1930 |
| chimpanzee | #1931 |
| adjusted | #1932 |
| nonfatal | #1934 |
| glucocorticoid | #1934 |
| relative risks | #1935 |
| 3months | #1935 |
| 17 | #1936 |
| acute | #1936 |
| thrombolytic treatment | #1937 |
| 27 | #1938 |
| randomized placebo | #1947 |
| safety effectiveness | #1950 |
| femoral vein | #1950 |
| 0·5 | #1952 |
| medical illness | #1954 |
| overtreatment | #1955 |
| prolongation | #1958 |
| intravascular | #1959 |
| major risk | #1960 |
| advanced age | #1961 |
| observer | #1962 |
| investigators | #1962 |
| 1050 | #1965 |
| permanent | #1966 |
| 80 female | #1967 |
| hyperglycaemia | #1970 |
| coronary angioplasty | #1971 |
| 48 hours | #1973 |
| surgical blood | #1973 |
| fibrin clot | #1973 |
| potent inhibitor | #1976 |
| renewed | #1976 |
| topic clinical trials | #1978 |
| hyperaldosteronism | #1981 |
| 771 | #1981 |
| specificity ultrasonography | #1981 |
| computerised | #1982 |
| patients pancreatic | #1985 |
| treatment cancer | #1986 |
| 1·0 | #1986 |
| randomized controlled | #1988 |
| coumarins | #1990 |
| 177 | #1991 |
| 018 | #1992 |
| prospero | #1992 |
| cmax | #1994 |
| drug drug therapy | #1994 |
| computerized | #1995 |
| cvt | #1995 |
| hemorrhage patients | #1996 |
| ors | #1998 |
| 602 | #1999 |
| autopsy | #2000 |
| 3 months patients | #2000 |
| transient increase | #2000 |
| clinical severity | #2000 |
| 53 | #2003 |
| 7 patients | #2006 |
| pneumonia patients | #2006 |
| pih | #2011 |
| mantel | #2013 |
| catheterization central | #2014 |
| angina unstable | #2017 |
| mongrel | #2017 |
| poc | #2019 |
| 225 | #2020 |
| type plasminogen | #2023 |
| pathophysiologic | #2024 |
| 35 | #2025 |
| patients statins | #2026 |
| annual | #2028 |
| 15th | #2031 |
| atheroma | #2032 |
| 097 | #2033 |
| patients lung | #2033 |
| pertechnetate | #2036 |
| costs cost | #2041 |
| medical record | #2041 |
| undergoing major | #2042 |
| abstracts | #2042 |
| questioned | #2043 |
| prediction rule | #2045 |
| thrice | #2045 |
| dichotomous | #2046 |
| normal | #2048 |
| superior vena cava | #2051 |
| quartiles | #2051 |
| inadequately | #2052 |
| pregnancy trimester | #2053 |
| 277 | #2053 |
| controversial | #2055 |
| stent implantation | #2056 |
| adherence guidelines | #2056 |
| hospitalized | #2057 |
| randomized comparison | #2060 |
| outpatient | #2061 |
| interobserver variability | #2062 |
| requested | #2063 |
| varies | #2063 |
| biological neoplasms | #2064 |
| clinical indications | #2064 |
| hemostatics | #2070 |
| mcnemar | #2074 |
| 188 | #2074 |
| national institute | #2074 |
| familial hypercholesterolemia | #2077 |
| unavailable | #2079 |
| searched | #2082 |
| disseminate | #2083 |
| ristocetin | #2086 |
| media thickness | #2087 |
| bypasses | #2087 |
| 03 | #2089 |
| versions | #2091 |
| 114 | #2092 |
| square distribution | #2092 |
| tissue plasminogen | #2093 |
| reference range | #2099 |
| preformed | #2099 |
| 038 | #2100 |
| lifetime risk | #2101 |
| 59 | #2101 |
| desmopressin | #2101 |
| placebos | #2102 |
| concealment | #2104 |
| hospital treatment | #2106 |
| fibrin deposition | #2107 |
| argatroban | #2108 |
| 031 | #2109 |
| substantial | #2109 |
| 1966 | #2109 |
| aged 80 | #2111 |
| debated | #2116 |
| jugular vein | #2117 |
| unnecessary | #2118 |
| independently | #2118 |
| initial | #2119 |
| exists | #2119 |
| development validation | #2120 |
| 11 | #2122 |
| clinicaltrialsgov | #2122 |
| coronary stent | #2122 |
| acl reconstruction | #2125 |
| original | #2125 |
| topic surveys | #2127 |
| patients cardiovascular disease | #2127 |
| chose | #2129 |
| controlled | #2129 |
| current recommendations | #2131 |
| odds ratios | #2132 |
| protamines | #2134 |
| congress | #2134 |
| 190 | #2136 |
| 788 | #2137 |
| hip arthroplasty | #2139 |
| heterozygous | #2141 |
| antagonists | #2142 |
| clot | #2145 |
| live | #2145 |
| bodyweight | #2146 |
| professionals | #2146 |
| pancreatic cancer patients | #2157 |
| oestrogens | #2160 |
| committee | #2160 |
| lowdose aspirin | #2163 |
| academic medical | #2167 |
| drains | #2170 |
| embase | #2171 |
| fibrinogen | #2175 |
| 1998 | #2178 |
| trimesters | #2179 |
| reproductive age | #2182 |
| 674 | #2183 |
| advanced cancer | #2183 |
| giant cell arteritis | #2185 |
| fifty | #2185 |
| 2 × | #2185 |
| patients diagnosed | #2187 |
| 631 | #2188 |
| controlled study | #2192 |
| superficial | #2194 |
| difference incidence | #2198 |
| adjust | #2202 |
| diagnostic performance | #2204 |
| pravastatin | #2205 |
| increased patients | #2205 |
| antagonist | #2206 |
| clinical implications | #2208 |
| lower limbs | #2209 |
| neutrophil elastase | #2212 |
| diagnosis differential | #2212 |
| doubled | #2213 |
| pao2 | #2219 |
| 364 | #2219 |
| insufficient | #2221 |
| comparing | #2222 |
| differential female | #2225 |
| 94 | #2225 |
| lung perfusion | #2226 |
| italian society | #2227 |
| 76 | #2233 |
| takeda | #2236 |
| nationwide cohort study | #2245 |
| clot formation | #2247 |
| congenital heart disease | #2252 |
| hemorrhages | #2253 |
| hivinfected patients | #2257 |
| clots | #2257 |
| kilogram | #2259 |
| aprotinin | #2261 |
| 8000 | #2264 |
| hyperthyroidism | #2265 |
| stroke aged | #2265 |
| 12 | #2266 |
| 6 months | #2267 |
| metaanalysis | #2267 |
| patients developed | #2273 |
| reverses | #2273 |
| arterial | #2274 |
| intrinsic pathway | #2275 |
| famine | #2278 |
| 656 | #2279 |
| ultrasonographic | #2281 |
| setting | #2284 |
| based case | #2284 |
| 14 patients | #2286 |
| ft3 | #2288 |
| case control | #2291 |
| patients heart failure | #2293 |
| aged molecular | #2295 |
| daily dose | #2296 |
| sole | #2298 |
| strategy | #2303 |
| 88 | #2308 |
| 0047 | #2310 |
| normalised | #2312 |
| tests | #2314 |
| metaanalysis studies | #2314 |
| initial therapy | #2316 |
| nephelometry | #2316 |
| obstetrics | #2317 |
| adjustments | #2319 |
| humans myocardial | #2324 |
| method female | #2324 |
| methodological | #2325 |
| 60 | #2327 |
| normalized | #2329 |
| brachial | #2332 |
| gradually | #2335 |
| random sample | #2336 |
| positive predictive | #2337 |
| transfusion requirements | #2340 |
| ultrasonography doppler | #2341 |
| 543 | #2343 |
| inhibitor | #2344 |
| lacked | #2344 |
| prescribe | #2347 |
| illness severity | #2350 |
| 20 weeks | #2351 |
| thr | #2353 |
| prefer | #2354 |
| cancer progression | #2364 |
| 053 | #2371 |
| 118 | #2372 |
| receiving | #2374 |
| 099 | #2375 |
| risk bias | #2375 |
| patients active | #2376 |
| hemostasis | #2377 |
| predictable | #2377 |
| enrolling | #2379 |
| acute coronary syndromes | #2379 |
| 187 | #2381 |
| anticardiolipin | #2382 |
| dosing regimen | #2382 |
| 145 | #2387 |
| scintigraphy | #2389 |
| 140 | #2391 |
| 244 | #2393 |
| complication rate | #2400 |
| patients liver cirrhosis | #2401 |
| 757 | #2401 |
| 086 | #2402 |
| letters | #2405 |
| curable | #2406 |
| postinjection | #2413 |
| periodicals | #2413 |
| protein | #2413 |
| risk estimates | #2414 |
| 22 | #2415 |
| sphingosine1 | #2415 |
| study drug | #2424 |
| internal medicine | #2424 |
| 32 | #2425 |
| sensitivity 100 | #2426 |
| guidelines | #2426 |
| legs | #2430 |
| coagulants | #2430 |
| 002 | #2430 |
| 0048 | #2430 |
| patients adult | #2431 |
| ci95 | #2432 |
| normal range | #2433 |
| prolonging | #2434 |
| ptca | #2434 |
| aminoglycoside | #2435 |
| cindex | #2437 |
| 030 | #2438 |
| cumulative | #2439 |
| 166 | #2441 |
| endogenous | #2445 |
| microplate | #2446 |
| 719 | #2448 |
| turbidimetry | #2448 |
| administration schedule | #2449 |
| transmigration | #2453 |
| homocysteine | #2454 |
| anticoagulant activity | #2455 |
| ≥75 | #2459 |
| extensively | #2463 |
| prognostic patients | #2464 |
| watchful | #2464 |
| potential benefits | #2466 |
| nephrotoxic | #2468 |
| therapy acute | #2468 |
| 477 | #2469 |
| comprised | #2469 |
| pharmacologic | #2473 |
| consisted | #2474 |
| cancer population | #2476 |
| current review | #2476 |
| 05 | #2481 |
| 50 | #2482 |
| 648 | #2485 |
| pathway inhibitor | #2485 |
| treatment efficacy | #2489 |
| 1015 | #2490 |
| 829 | #2490 |
| chest | #2493 |
| duration | #2493 |
| 25 | #2495 |
| 616 | #2503 |
| illness tomography | #2503 |
| bnp | #2504 |
| subsequent pregnancies | #2505 |
| 522 | #2507 |
| movie | #2508 |
| recurrence retrospective | #2509 |
| unstable angina | #2510 |
| presentation | #2512 |
| superinfection | #2513 |
| comprising | #2515 |
| drug female humans | #2516 |
| 479 | #2516 |
| sulfates | #2519 |
| 750 | #2520 |
| neutrophil extracellular traps | #2521 |
| 463 | #2521 |
| accurate diagnosis | #2523 |
| 152 | #2523 |
| treatment arms | #2524 |
| scientific | #2529 |
| establish | #2534 |
| 874 | #2537 |
| 164 | #2537 |
| 0046 | #2537 |
| nematode | #2540 |
| 67 | #2542 |
| pyrazoles | #2547 |
| arrive | #2549 |
| decided | #2552 |
| effectiveness analysis | #2553 |
| hours | #2560 |
| haematology | #2560 |
| hydroxyethyl | #2560 |
| 928 | #2565 |
| radiologist | #2566 |
| roc | #2568 |
| biologic | #2569 |
| clinical settings | #2570 |
| infrequent | #2572 |
| kits | #2574 |
| humans logistic | #2574 |
| 73 | #2574 |
| prevalence | #2575 |
| pill | #2575 |
| translate | #2577 |
| patients total | #2577 |
| 973 | #2578 |
| specificity | #2580 |
| cancer chemotherapy | #2581 |
| 374 | #2582 |
| efficacious | #2585 |
| 591 | #2585 |
| pivotal | #2588 |
| analysed | #2589 |
| bolus | #2595 |
| 657 | #2596 |
| multiple organ failure | #2599 |
| hypercholesterolaemia | #2600 |
| doppler duplex | #2602 |
| laboratory investigation | #2603 |
| burden disease | #2605 |
| manifest | #2605 |
| parenteral | #2606 |
| metaregression | #2606 |
| fatal outcome | #2608 |
| patients 2 | #2608 |
| 098 | #2610 |
| p0001 patients | #2613 |
| died | #2615 |
| 886 | #2618 |
| percent | #2619 |
| cost analysis | #2620 |
| aviation | #2620 |
| concentrate | #2621 |
| occlusive | #2622 |
| presenting | #2625 |
| assess | #2626 |
| prescribed | #2631 |
| agents steroidal | #2633 |
| trials rcts | #2635 |
| coincided | #2635 |
| chondroitin | #2635 |
| 10 day | #2637 |
| attractive | #2641 |
| 345 | #2641 |
| mutation patients | #2642 |
| greatest risk | #2643 |
| 23 patients | #2645 |
| decision | #2649 |
| risk cardiovascular disease | #2656 |
| 134 | #2659 |
| recurrence | #2660 |
| hamilton | #2661 |
| c677 | #2662 |
| benzimidazoles | #2662 |
| 679 | #2663 |
| shr | #2667 |
| quartile | #2674 |
| receive | #2675 |
| 439 | #2677 |
| valsalva | #2680 |
| trials | #2682 |
| 516 | #2683 |
| outcome ultrasonography | #2683 |
| initial dose | #2685 |
| iii | #2685 |
| inconclusive | #2686 |
| tmax | #2687 |
| mortality 95 | #2688 |
| tissue plasminogen activator | #2690 |
| 594 | #2691 |
| aso | #2691 |
| bleed | #2692 |
| schedule female | #2694 |
| stillbirth | #2698 |
| patients risk factors | #2702 |
| early discharge | #2703 |
| 14 | #2706 |
| previous stroke | #2720 |
| prematurely | #2725 |
| 897 | #2727 |
| txb2 | #2729 |
| management strategies | #2732 |
| dose low | #2732 |
| cart | #2736 |
| 595 | #2737 |
| 427 | #2739 |
| classifications | #2739 |
| therapeutic options | #2744 |
| risk ratio | #2745 |
| 848 | #2746 |
| predetermined | #2746 |
| baseline characteristics | #2747 |
| patients asthma | #2747 |
| direct comparison | #2752 |
| pan | #2755 |
| nephrotoxicity | #2758 |
| randomised trial | #2764 |
| contusions | #2765 |
| management acute | #2768 |
| 143 | #2768 |
| confounded | #2769 |
| antithyroid | #2772 |
| expert consensus | #2772 |
| alpha animals | #2772 |
| active control | #2775 |
| inpatient | #2776 |
| thrombomodulin | #2776 |
| 563 | #2777 |
| compression | #2778 |
| dosages | #2779 |
| leukocyte count | #2781 |
| mass screening | #2782 |
| 466 | #2783 |
| hemostatic | #2784 |
| primary outcomes | #2785 |
| percentiles | #2788 |
| 90th | #2789 |
| nadph2 | #2791 |
| consecutive series | #2802 |
| 402 | #2802 |
| cirrhosis patients | #2805 |
| reaching | #2805 |
| international | #2809 |
| secondary | #2811 |
| standardized | #2811 |
| embolic | #2812 |
| follow studies | #2813 |
| 406 | #2813 |
| prevalence risk factors | #2814 |
| httlpr | #2816 |
| discriminant analysis | #2817 |
| selectins | #2819 |
| consisting | #2823 |
| equivalency | #2825 |
| bid | #2826 |
| antiplatelet drugs | #2826 |
| genetic variations | #2830 |
| 557 | #2833 |
| male mass | #2834 |
| recurrence rate | #2835 |
| contacting | #2835 |
| ketoprostaglandin | #2836 |
| helminth | #2836 |
| kruskal | #2839 |
| crossover | #2839 |
| 554 | #2843 |
| partum | #2847 |
| anterior cruciate ligament | #2850 |
| carboxypeptidase | #2851 |
| iii trials | #2852 |
| doppler ultrasonography | #2852 |
| ≤2 | #2853 |
| postoperative patients | #2854 |
| post discharge | #2857 |
| new treatment | #2857 |
| specialised | #2858 |
| methods prospective | #2862 |
| 497 | #2870 |
| discontinuation | #2871 |
| 264 | #2876 |
| 628 | #2877 |
| 52 | #2879 |
| trimester pregnancy | #2880 |
| excessive | #2880 |
| hit | #2884 |
| mdct | #2885 |
| balloon angioplasty | #2886 |
| anterior cruciate | #2887 |
| 670 | #2895 |
| eligibility | #2896 |
| systematic review metaanalysis | #2897 |
| 21 | #2897 |
| central venous catheters | #2900 |
| statin | #2902 |
| slight | #2903 |
| severe asthma | #2903 |
| feasible | #2903 |
| 12 patients | #2908 |
| concomitantly | #2910 |
| supposed | #2911 |
| insulin receptors | #2914 |
| lowrisk patients | #2917 |
| leading death | #2917 |
| 39 | #2919 |
| routine clinical practice | #2920 |
| referrals | #2921 |
| older children | #2922 |
| 993 | #2928 |
| proportions | #2928 |
| clear | #2932 |
| risk stratification patients | #2934 |
| 2400 | #2934 |
| aggregation platelet | #2941 |
| control subjects patients | #2945 |
| meier estimate | #2946 |
| addison | #2952 |
| portal | #2954 |
| 100 | #2956 |
| returned | #2957 |
| 010 | #2960 |
| 270 | #2960 |
| 20 | #2961 |
| exercise therapy | #2962 |
| followup | #2962 |
| transabdominal | #2963 |
| 132 | #2974 |
| echocardiography patients | #2975 |
| 123 | #2978 |
| risk myocardial | #2981 |
| lecture | #2984 |
| declare | #2984 |
| eclampsia pregnancy | #2986 |
| glucose levels | #2987 |
| preoperatively | #2988 |
| adult blood | #2990 |
| pneumatic | #2991 |
| point | #2991 |
| n4 | #2992 |
| undefined | #2993 |
| treatable | #2996 |
| cvr | #2997 |
| microvessels | #2998 |
| 499 | #3004 |
| prostacyclin | #3012 |
| dipyridamole | #3013 |
| factors surveys | #3015 |
| antigen levels | #3015 |
| 2 patients | #3016 |
| 081 | #3019 |
| double‐blind | #3022 |
| 35 patients | #3023 |
| nested case | #3025 |
| early recognition | #3025 |
| comorbidity | #3026 |
| contraindication | #3028 |
| intention | #3035 |
| extremities | #3038 |
| 419 | #3040 |
| 50 years | #3040 |
| patients hf | #3041 |
| lymphopenia | #3043 |
| relevant articles | #3044 |
| 095 | #3045 |
| prenatal exposure | #3047 |
| summarize | #3050 |
| respondents | #3052 |
| respects | #3060 |
| subcutaneous injection | #3062 |
| 80 | #3063 |
| nomogram | #3063 |
| fourteen | #3065 |
| 95 p0001 | #3066 |
| patients data | #3067 |
| study prevalence | #3071 |
| subsequently | #3076 |
| 2 4 | #3076 |
| disease aged | #3077 |
| 524 | #3082 |
| 342 | #3083 |
| chronic renal failure | #3088 |
| angioplasty | #3088 |
| independent risk factors | #3089 |
| healthy | #3090 |
| clinical risk factors | #3098 |
| lancet | #3102 |
| reviewer | #3104 |
| practice guidelines | #3109 |
| trimester | #3110 |
| benchmark | #3110 |
| npv | #3115 |
| pregnant woman | #3119 |
| neutrophil activation | #3120 |
| wallis | #3122 |
| oac | #3122 |
| lifelong | #3122 |
| inadequacy | #3123 |
| intravenously | #3129 |
| claimed | #3132 |
| 136 | #3134 |
| 12 months | #3134 |
| meta‐analysis | #3137 |
| levels risk | #3142 |
| 082 | #3142 |
| placentae | #3143 |
| randomized clinical trial | #3145 |
| time interval | #3147 |
| arthroscopic | #3149 |
| idiopathic | #3153 |
| 507 | #3153 |
| marathon | #3155 |
| mega | #3156 |
| avoiding | #3158 |
| radiologists | #3165 |
| initial presentation | #3172 |
| seventh | #3173 |
| cornerstone | #3182 |
| test | #3184 |
| 494 | #3188 |
| revascularisation | #3191 |
| 409 | #3193 |
| pregnancy women | #3194 |
| diethylstilbestrol | #3194 |
| pacientes | #3197 |
| 945 | #3198 |
| plasmin | #3198 |
| tenth | #3199 |
| therapy risk | #3199 |
| gold standard | #3200 |
| vivo model | #3205 |
| res | #3207 |
| patient preference | #3211 |
| catheter | #3212 |
| cancer types | #3219 |
| suggested | #3219 |
| 153 | #3223 |
| intravenous infusion | #3223 |
| 72 hours | #3225 |
| 605 | #3227 |
| methodological quality | #3238 |
| observers | #3239 |
| meetings | #3241 |
| recombinant | #3241 |
| intravenous administration | #3242 |
| risk stroke | #3246 |
| alternative | #3249 |
| 198 | #3251 |
| bivalirudin | #3251 |
| 29 | #3253 |
| hypothyroid | #3253 |
| judgement | #3255 |
| scoring | #3255 |
| normotensive | #3256 |
| 054 | #3257 |
| patient preferences | #3261 |
| glargine | #3265 |
| validated | #3266 |
| patients evidence | #3267 |
| 116 | #3268 |
| immunoassay | #3271 |
| 414 | #3275 |
| 6 | #3277 |
| tranexamic acid | #3279 |
| gbd | #3280 |
| contraceptive | #3281 |
| inclusion | #3284 |
| arthroplasty replacement | #3288 |
| coumarin | #3289 |
| tumor markers | #3289 |
| replace | #3290 |
| 65 years | #3291 |
| swan | #3292 |
| recurrence rates | #3294 |
| efficacy outcomes | #3299 |
| 812 | #3314 |
| rtpa | #3315 |
| reversibility | #3316 |
| anticardiolipin antibodies | #3319 |
| discriminant | #3321 |
| vascular risk | #3322 |
| 104 | #3325 |
| hemophilia | #3328 |
| 972 | #3329 |
| reduces | #3330 |
| 465 | #3330 |
| cruciate ligament | #3331 |
| patients symptoms | #3334 |
| 74 | #3337 |
| meta | #3338 |
| acute coronary syndrome | #3339 |
| cerebrovascular disease | #3344 |
| inpatients | #3344 |
| evaluating | #3349 |
| 362 | #3349 |
| spontaneous abortion | #3354 |
| diagnosing | #3354 |
| 273 | #3355 |
| diagnosis cancer | #3356 |
| common complication | #3356 |
| 15 | #3357 |
| lysate | #3358 |
| 581 | #3359 |
| 092 | #3361 |
| miscarriages | #3365 |
| prevalent | #3371 |
| thrombolysis | #3376 |
| treatment modalities | #3377 |
| 363 | #3378 |
| humans lower | #3379 |
| concluded | #3379 |
| 301 | #3379 |
| intima media | #3380 |
| computed tomography | #3382 |
| hematomas | #3387 |
| calf | #3389 |
| function patients | #3389 |
| contraception | #3390 |
| repeated | #3394 |
| 413 | #3395 |
| p0002 | #3397 |
| cava | #3399 |
| 311 | #3400 |
| tunica | #3403 |
| 553 | #3403 |
| acute treatment | #3403 |
| humans kaplan | #3408 |
| saved | #3415 |
| differs | #3418 |
| preventive | #3419 |
| randomisation | #3419 |
| hypothesised | #3420 |
| study risk | #3420 |
| surgical patients | #3420 |
| thrombocythemia | #3422 |
| odds | #3424 |
| confirm | #3425 |
| testimony | #3430 |
| competing | #3434 |
| natriuretic | #3437 |
| 70 | #3439 |
| ease | #3443 |
| asian patients | #3444 |
| 124 | #3445 |
| 519 | #3447 |
| 487 | #3451 |
| 168 | #3452 |
| prevalence incidence | #3452 |
| evening | #3458 |
| covid19 infection | #3464 |
| differ | #3470 |
| 34 | #3470 |
| intensive chemotherapy | #3471 |
| pregnancy complications | #3472 |
| patients receive | #3472 |
| worsened | #3476 |
| induced platelet | #3479 |
| undiagnosed | #3482 |
| cancer metastasis | #3485 |
| antiphospholipid | #3485 |
| increased morbidity | #3486 |
| asymptomatic | #3487 |
| lower leg | #3487 |
| paradox | #3490 |
| personyears | #3490 |
| pacemaker | #3493 |
| statistical methods | #3494 |
| convergent validity | #3496 |
| failure hf | #3497 |
| 201 | #3504 |
| treat | #3506 |
| hemorrhagic complications | #3506 |
| inhibitors | #3506 |
| 938 | #3513 |
| tomography angiography | #3521 |
| discusses | #3522 |
| confirmed | #3522 |
| 291 | #3527 |
| quintiles | #3529 |
| 95 confidence intervals | #3530 |
| human cytomegalovirus | #3533 |
| lupus | #3533 |
| areas covered | #3537 |
| guidance | #3541 |
| societies | #3541 |
| 113 | #3544 |
| gastro | #3551 |
| current practice | #3551 |
| 10 | #3552 |
| stroke risk | #3559 |
| baboons | #3560 |
| 344 | #3562 |
| benefits risks | #3564 |
| neutralize | #3565 |
| nsaids | #3566 |
| bibliographic | #3567 |
| depends | #3571 |
| patients recurrence | #3573 |
| inconsistent | #3575 |
| safety profiles | #3580 |
| 508 | #3584 |
| evaluates | #3592 |
| prognosis prospective | #3596 |
| necessity | #3596 |
| patient management | #3598 |
| prognostic significance | #3604 |
| vitamin | #3605 |
| risk stratification | #3606 |
| consensus document | #3617 |
| platelet function | #3619 |
| treated | #3619 |
| interval | #3622 |
| platelet activation | #3622 |
| mutation | #3624 |
| lipid profiles | #3626 |
| q3 | #3629 |
| kappa | #3629 |
| organ damage | #3635 |
| analysis performed | #3640 |
| 75 | #3641 |
| bypass surgery | #3642 |
| undergo | #3642 |
| homozygote | #3642 |
| externally | #3645 |
| p006 | #3645 |
| occlusions | #3646 |
| 30 | #3649 |
| 1960 | #3649 |
| fibrillation | #3651 |
| interindividual variability | #3651 |
| coronary events | #3656 |
| atherogenic | #3658 |
| newer | #3662 |
| patients 95 | #3667 |
| outcome administration | #3671 |
| optimal management | #3671 |
| endovascular treatment | #3678 |
| blinding | #3679 |
| treatment complications | #3680 |
| limited data | #3683 |
| 68 | #3684 |
| clopidogrel | #3685 |
| mammography | #3693 |
| myalgia | #3703 |
| 478 | #3706 |
| rationale | #3707 |
| 813 | #3708 |
| rebound | #3720 |
| diagnostic process | #3721 |
| drug monitoring | #3721 |
| inhibitors humans | #3725 |
| pharmacodynamics | #3725 |
| 130 | #3729 |
| unknown | #3731 |
| patient population | #3733 |
| serine proteases | #3736 |
| 349 | #3738 |
| effective | #3739 |
| humans intracranial | #3739 |
| factor 4 | #3741 |
| 585 | #3743 |
| 299 | #3744 |
| network meta | #3746 |
| homozygous | #3747 |
| 495 | #3750 |
| practitioner | #3752 |
| deterioration | #3754 |
| randomised | #3754 |
| objectives | #3759 |
| 8 patients | #3762 |
| subgroup analyses | #3762 |
| 00001 | #3765 |
| host defense | #3769 |
| statin therapy | #3772 |
| scarce | #3773 |
| computed ultrasonography | #3774 |
| clinicians patients | #3774 |
| inherited | #3775 |
| interpretable | #3778 |
| 517 | #3778 |
| 483 | #3782 |
| aminoglycosides | #3789 |
| total knee arthroplasty | #3789 |
| thyroid hormones | #3789 |
| 525 | #3791 |
| 412 | #3795 |
| 441 | #3797 |
| life illness | #3801 |
| 333 | #3802 |
| versus | #3803 |
| vessel wall | #3804 |
| compelling | #3804 |
| preexisting | #3808 |
| outcome measure | #3814 |
| 330 | #3815 |
| patients lung cancer | #3815 |
| valid | #3816 |
| iu | #3818 |
| 55 patients | #3821 |
| fv | #3823 |
| stasis | #3824 |
| lost | #3825 |
| compares | #3830 |
| itching | #3831 |
| proved | #3834 |
| osmolar | #3837 |
| elective | #3838 |
| hydrolases | #3839 |
| patient education | #3843 |
| 197 | #3849 |
| meeting | #3856 |
| irs | #3856 |
| anaesthesia | #3857 |
| 4 patients | #3858 |
| congresses | #3859 |
| acquired resistance | #3860 |
| review data | #3860 |
| male neoplasms | #3862 |
| preferred | #3864 |
| occurring | #3867 |
| death | #3880 |
| optimisation | #3884 |
| cancer survival | #3884 |
| sensitivity | #3885 |
| record | #3885 |
| avoids | #3887 |
| calculated | #3888 |
| difference | #3890 |
| 184 | #3890 |
| 351 | #3890 |
| 10000 | #3902 |
| methylamines | #3903 |
| halflives | #3903 |
| methimazole | #3904 |
| patients time | #3905 |
| incidence prevalence | #3908 |
| angiography | #3915 |
| specificity tomography | #3915 |
| coronary thrombosis | #3918 |
| decide | #3927 |
| 474 | #3931 |
| ankle | #3932 |
| 955 | #3935 |
| 458 | #3938 |
| jak2 | #3939 |
| extravasation | #3945 |
| 405 | #3946 |
| case fatality | #3946 |
| preeclampsia | #3952 |
| neurology | #3953 |
| 56 | #3956 |
| p004 | #3961 |
| dichotomy | #3961 |
| randomized clinical trials | #3963 |
| women | #3964 |
| carboxypeptidases | #3965 |
| postoperatively | #3966 |
| clinical effectiveness | #3968 |
| uncontrolled | #3970 |
| risk cancer | #3970 |
| austrian | #3971 |
| behalf | #3971 |
| cardiovascular events | #3972 |
| 2nd | #3975 |
| data studies | #3975 |
| quality assurance | #3980 |
| 986 | #3982 |
| pregnancy | #3982 |
| continuous infusion | #3983 |
| flying | #3986 |
| unstable | #3986 |
| month | #3987 |
| 488 | #3990 |
| systematic analysis | #3994 |
| sequentially | #4006 |
| calculate | #4010 |
| lower risk | #4011 |
| limited evidence | #4014 |
| patients evaluated | #4016 |
| scored | #4023 |
| secondary prevention | #4026 |
| 538 | #4028 |
| equivalence | #4029 |
| gln | #4031 |
| meyer | #4032 |
| cerebral venous | #4041 |
| introduction | #4045 |
| 296 | #4045 |
| 423 | #4047 |
| 262 | #4051 |
| ended | #4052 |
| validating | #4058 |
| received | #4062 |
| recurrent disease | #4066 |
| cruciate | #4073 |
| elevated | #4074 |
| compare | #4075 |
| pcc | #4077 |
| bariatric | #4077 |
| avoid | #4080 |
| 429 | #4081 |
| 326 | #4083 |
| hour | #4088 |
| oligosaccharides | #4089 |
| natriuretic peptide | #4089 |
| angioplasty balloon | #4091 |
| maneuver | #4092 |
| 3000 | #4093 |
| 16 | #4098 |
| cutoff | #4099 |
| activation | #4099 |
| indications | #4099 |
| contact | #4102 |
| pharmacological | #4106 |
| infusion rate | #4109 |
| 392 | #4113 |
| 335 | #4117 |
| 6 months treatment | #4119 |
| ptm | #4120 |
| completing | #4125 |
| patients low risk | #4133 |
| withdrawn | #4137 |
| 008 | #4137 |
| 41 | #4138 |
| bms | #4146 |
| patients died | #4149 |
| medical students | #4152 |
| haemorrhagic | #4154 |
| continue | #4158 |
| study control | #4161 |
| nulliparous | #4167 |
| patients prostate cancer | #4171 |
| 2030 | #4171 |
| antitumour | #4177 |
| steroidal | #4178 |
| multidisciplinary approach | #4189 |
| direct | #4192 |
| therapy combination | #4198 |
| casts | #4200 |
| 411 | #4212 |
| 485 | #4212 |
| medical center | #4214 |
| 408 | #4215 |
| weighted | #4221 |
| additional | #4222 |
| 452 | #4223 |
| 121 | #4226 |
| 289 | #4226 |
| trough | #4229 |
| crosssectional analysis | #4230 |
| p0005 | #4230 |
| hormonal | #4234 |
| veins | #4235 |
| patients mortality | #4242 |
| cox regression | #4242 |
| 178 | #4246 |
| nsaid | #4261 |
| 263 | #4263 |
| abbreviated | #4267 |
| encountered | #4268 |
| atrial fibrillation patients | #4274 |
| fab | #4279 |
| late pregnancy | #4285 |
| pai1 | #4286 |
| rise | #4287 |
| oral aged | #4294 |
| q4 | #4296 |
| 228 | #4303 |
| share | #4304 |
| 10 patients | #4306 |
| 105 | #4310 |
| rehospitalization | #4314 |
| patients increased risk | #4315 |
| 185 | #4316 |
| tat | #4319 |
| separate | #4322 |
| concentrates | #4328 |
| intima | #4329 |
| devised | #4331 |
| 294 | #4339 |
| 102 | #4340 |
| 455 | #4340 |
| pronounced | #4342 |
| incidental findings | #4345 |
| managed | #4350 |
| potential risk factors | #4350 |
| detrimental | #4356 |
| 253 | #4359 |
| agreed | #4360 |
| young age | #4363 |
| specialist | #4379 |
| minutes | #4383 |
| rapid | #4383 |
| retrospective studies | #4384 |
| 447 | #4385 |
| cd11b | #4387 |
| 288 | #4391 |
| 170 | #4392 |
| concurrently | #4394 |
| slice | #4394 |
| risk cardiovascular | #4396 |
| steadily | #4402 |
| 239 | #4406 |
| 71 | #4407 |
| negative | #4407 |
| bowel diseases | #4407 |
| general | #4407 |
| guideline recommendations | #4408 |
| postoperative day | #4409 |
| ventilation | #4413 |
| lacking | #4417 |
| splanchnic | #4417 |
| dose aspirin | #4419 |
| immunoassays | #4419 |
| recombinant proteins | #4423 |
| 3 patients | #4426 |
| author | #4427 |
| 148 | #4428 |
| 281 | #4429 |
| primary myelofibrosis | #4430 |
| appropriateness | #4433 |
| profoundly | #4436 |
| completed | #4438 |
| platelet | #4440 |
| cellulitis | #4441 |
| sixteen | #4442 |
| concomitant | #4445 |
| assays | #4453 |
| 334 | #4458 |
| vascular surgery | #4459 |
| 192 | #4459 |
| proband | #4461 |
| cytomegalovirus infection | #4461 |
| total costs | #4474 |
| 377 | #4479 |
| 443 | #4482 |
| cd18 | #4486 |
| clinical manifestations | #4486 |
| pancreatic cancer | #4487 |
| inadequate | #4487 |
| coronavirus disease covid19 | #4489 |
| smr | #4492 |
| risk prediction | #4493 |
| bus | #4497 |
| current management | #4498 |
| 476 | #4499 |
| doubling | #4500 |
| infected patients | #4502 |
| activation platelet | #4503 |
| comprises | #4503 |
| 54 | #4513 |
| primary diagnosis | #4515 |
| alpha2 | #4516 |
| therapeutic | #4532 |
| septic | #4534 |
| 3 groups | #4535 |
| male pulmonary | #4541 |
| 526 | #4542 |
| elastase | #4544 |
| hitherto | #4546 |
| fairly | #4552 |
| cardiovascular death | #4559 |
| 985 | #4564 |
| 1250 | #4567 |
| cerebrovascular disorders | #4571 |
| calculating | #4571 |
| multicenter trial | #4574 |
| 2c | #4585 |
| debate | #4586 |
| disadvantage | #4588 |
| plasma concentrations | #4591 |
| 283 | #4592 |
| preserves | #4594 |
| attenuating | #4594 |
| eventually | #4595 |
| gradual | #4595 |
| simplified | #4596 |
| 204 | #4596 |
| 4 | #4601 |
| 4000 | #4601 |
| encouraged | #4603 |
| icer | #4610 |
| frequently | #4611 |
| vii | #4613 |
| acetylsalicylic acid | #4613 |
| vaginal | #4614 |
| 917 | #4619 |
| assay | #4634 |
| subclinical atherosclerosis | #4636 |
| hospital costs | #4640 |
| risks benefits | #4640 |
| 242 | #4642 |
| genetic risk factors | #4644 |
| escalating | #4648 |
| priori | #4654 |
| 003 | #4658 |
| habitual | #4658 |
| survey | #4659 |
| transurethral | #4663 |
| 171 | #4670 |
| myelofibrosis | #4670 |
| thyroid hormone | #4673 |
| 40 | #4675 |
| 407 | #4679 |
| fh | #4680 |
| day | #4680 |
| recurrent stroke | #4681 |
| wheezing | #4693 |
| unchanged | #4698 |
| ranging | #4698 |
| 5 patients | #4701 |
| complicated | #4703 |
| truncated | #4709 |
| therapeutic intervention | #4715 |
| differential humans | #4719 |
| immobilization | #4725 |
| 129 | #4727 |
| orthopedic | #4735 |
| cardiovascular morbidity | #4738 |
| current guidelines | #4739 |
| therapeutic strategies | #4744 |
| ranged | #4769 |
| 027 | #4774 |
| chronic renal | #4775 |
| baseline patients | #4775 |
| acute coronary | #4784 |
| 44 | #4785 |
| scheduled | #4785 |
| molecular | #4792 |
| knee | #4800 |
| insulin glargine | #4801 |
| prophylactic | #4802 |
| arthroplasty | #4803 |
| alternatively | #4810 |
| extracranial | #4813 |
| courses | #4819 |
| diagnostic imaging | #4825 |
| therapy humans | #4836 |
| echocardiography | #4846 |
| 174 | #4848 |
| cholesterol levels | #4853 |
| acl | #4861 |
| definition | #4861 |
| efficiency | #4869 |
| nonvalvular atrial fibrillation | #4870 |
| gpiib | #4870 |
| increased plasma | #4875 |
| unexposed | #4876 |
| gynecological | #4880 |
| antiphospholipid syndrome | #4881 |
| screening tool | #4884 |
| 322 | #4886 |
| antiplatelet therapy | #4891 |
| total | #4891 |
| treating | #4896 |
| abstracted | #4897 |
| doses | #4902 |
| ischemic heart disease | #4905 |
| preparations | #4906 |
| tests prognosis | #4906 |
| served | #4910 |
| chlamydophila | #4913 |
| fmd | #4913 |
| 560 | #4914 |
| recommendation | #4918 |
| geriatrics | #4920 |
| acute ischemic | #4923 |
| renal dysfunction | #4929 |
| 556 | #4932 |
| 154 | #4933 |
| 870 | #4934 |
| cpb | #4939 |
| 325 | #4951 |
| 26 | #4952 |
| satisfied | #4957 |
| appeared | #4959 |
| fund | #4972 |
| dose | #4976 |
| manufacturers | #4976 |
| orthopedics | #4982 |
| albeit | #4982 |
| recommended | #4987 |
| cardiology | #5000 |
| 389 | #5006 |
| references | #5006 |
| reminder | #5009 |
| epoprostenol | #5009 |
| probnp | #5014 |
| point mutation | #5018 |
| risk women | #5023 |
| syndrome patients | #5033 |
| 156 | #5040 |
| screening test | #5040 |
| proposal | #5042 |
| global burden | #5044 |
| primary health | #5045 |
| analytic | #5047 |
| obstetrical | #5048 |
| lasted | #5049 |
| patients sepsis | #5051 |
| limitations | #5055 |
| diagnosis management | #5058 |
| patients myocardial infarction | #5062 |
| spinal surgery | #5065 |
| 255 | #5068 |
| conflicting | #5070 |
| saphenous | #5075 |
| inaccessible | #5078 |
| 1a | #5079 |
| switched | #5084 |
| evaluable | #5089 |
| regarded | #5089 |
| hip fractures | #5090 |
| relation | #5090 |
| transluminal | #5093 |
| menstrual | #5094 |
| fashion | #5098 |
| amputation | #5102 |
| external validation | #5103 |
| arteritis | #5107 |
| inflammatory responses | #5109 |
| oxadiazoles | #5110 |
| dalys | #5112 |
| tailor | #5115 |
| admission patients | #5118 |
| composite | #5120 |
| discriminative | #5123 |
| vivo studies | #5124 |
| bay | #5124 |
| 108 | #5125 |
| 282 | #5129 |
| 0018 | #5130 |
| ischaemic stroke | #5130 |
| 131 | #5131 |
| female | #5131 |
| transfused | #5134 |
| balancing | #5136 |
| contrast media | #5136 |
| fetal death | #5138 |
| activator | #5139 |
| scans | #5143 |
| 341 | #5146 |
| n6 | #5150 |
| kg1 | #5151 |
| disagreement | #5157 |
| shortly | #5157 |
| preclinical studies | #5160 |
| doppler | #5165 |
| 11 patients | #5170 |
| predispose | #5170 |
| hazard | #5171 |
| readers | #5173 |
| prescriptions | #5174 |
| graft failure | #5178 |
| weaknesses | #5185 |
| renal impairment | #5186 |
| 70 patients | #5190 |
| infarctions | #5191 |
| screening | #5193 |
| threefold | #5198 |
| highest | #5202 |
| extracellular vesicles | #5204 |
| acs | #5205 |
| 144 | #5206 |
| hospital patients | #5208 |
| remains | #5209 |
| excess mortality | #5210 |
| doppler color | #5221 |
| polysaccharides | #5223 |
| heparan | #5229 |
| emergencies | #5233 |
| articles | #5233 |
| indwelling | #5241 |
| flowmetry | #5242 |
| gram | #5244 |
| 3 | #5248 |
| platelet aggregation | #5252 |
| considerably | #5253 |
| comparison | #5262 |
| testing | #5264 |
| plasma levels | #5265 |
| estimate | #5288 |
| 365 | #5289 |
| pooling | #5289 |
| aware | #5300 |
| thrombus | #5301 |
| 36 patients | #5301 |
| urokinase | #5302 |
| atherogenesis | #5302 |
| triage | #5303 |
| case reports | #5305 |
| benefit | #5308 |
| reversal | #5310 |
| stroke treatment | #5314 |
| contrasted | #5316 |
| orthomyxoviridae | #5319 |
| openlabel | #5320 |
| 70 years | #5325 |
| aged postoperative | #5330 |
| animal drug evaluation | #5332 |
| dizziness | #5334 |
| absent | #5335 |
| factor humans | #5336 |
| stratify | #5340 |
| reagent | #5341 |
| acute ischemic stroke | #5341 |
| blood vessel | #5343 |
| ultrasound imaging | #5344 |
| fatality | #5347 |
| contrast agents | #5355 |
| arose | #5361 |
| schedule drug | #5363 |
| male | #5363 |
| based guidelines | #5370 |
| hyper | #5372 |
| obstetric | #5376 |
| accepted | #5383 |
| thyrotropin | #5401 |
| informed consent | #5402 |
| blood products | #5405 |
| selected patients | #5406 |
| adult | #5407 |
| heart valve | #5409 |
| intracranial | #5411 |
| questionnaire | #5414 |
| register | #5415 |
| summarized | #5416 |
| 19 | #5417 |
| noninvasive | #5421 |
| clinical risk | #5424 |
| nonsignificant | #5429 |
| protein levels | #5430 |
| concerns | #5439 |
| charts | #5440 |
| hyperprolactinemia | #5441 |
| familiarity | #5442 |
| 37 | #5445 |
| 630 | #5448 |
| retrieved | #5450 |
| cancer growth | #5455 |
| presently | #5456 |
| congenital heart | #5465 |
| registered | #5470 |
| recombinant human | #5474 |
| intermediate | #5475 |
| 340 | #5476 |
| 395 | #5484 |
| allocation | #5488 |
| 247 | #5490 |
| occurrences | #5490 |
| moyamoya disease | #5491 |
| ntprobnp | #5493 |
| kaplan meier | #5496 |
| 260 | #5497 |
| patient risk | #5497 |
| discomfort | #5499 |
| continuing | #5499 |
| 9 patients | #5500 |
| postal | #5503 |
| ssris | #5515 |
| correctly | #5517 |
| weight | #5524 |
| 309 | #5530 |
| period | #5533 |
| limitation | #5539 |
| erythema | #5539 |
| suggestions | #5541 |
| survival benefit | #5542 |
| imputed | #5545 |
| receptor1 | #5563 |
| established | #5563 |
| 175 | #5565 |
| 545 | #5566 |
| management | #5569 |
| reduce risk | #5573 |
| 46 | #5573 |
| 324 | #5595 |
| excludes | #5597 |
| circulating levels | #5598 |
| equivalent | #5598 |
| categorical | #5600 |
| stm | #5607 |
| grounds | #5617 |
| expert | #5620 |
| 02 | #5624 |
| microgram | #5626 |
| minus | #5627 |
| premenopausal women | #5629 |
| retrieve | #5633 |
| food preferences | #5637 |
| drug administration | #5641 |
| platelet count | #5643 |
| reclassification | #5644 |
| 80 years | #5644 |
| 65 | #5651 |
| trial | #5653 |
| 087 | #5667 |
| published data | #5671 |
| 48 | #5676 |
| seventy | #5684 |
| 214 | #5689 |
| latex | #5690 |
| platelet glycoprotein | #5692 |
| reproducible | #5696 |
| 1997 | #5698 |
| meier | #5714 |
| 370 | #5718 |
| return | #5721 |
| 40 years | #5729 |
| atherosclerotic | #5730 |
| 89 | #5732 |
| perform | #5734 |
| 995 | #5748 |
| 091 | #5755 |
| stand | #5756 |
| 0014 | #5761 |
| metabolic effects | #5764 |
| semiquantitative | #5771 |
| milder | #5771 |
| 241 | #5777 |
| recurrence patients | #5781 |
| varied | #5784 |
| creatinine clearance | #5788 |
| 3rd | #5791 |
| incidence rates | #5804 |
| mpo | #5804 |
| 95 women | #5809 |
| orthopedic procedures | #5810 |
| male middle aged | #5811 |
| url | #5812 |
| 1000 | #5819 |
| aircraft | #5819 |
| income countries | #5828 |
| diagnosed | #5840 |
| undergoing surgery | #5843 |
| true | #5852 |
| atrial | #5852 |
| 088 | #5854 |
| attending | #5856 |
| 290 | #5857 |
| women pregnancy | #5857 |
| hip | #5866 |
| advantageous | #5875 |
| complete resolution | #5878 |
| reliable | #5894 |
| occurrence | #5894 |
| excluded | #5899 |
| aged models | #5919 |
| adding | #5923 |
| safety patients | #5927 |
| 22 patients | #5928 |
| aged platelet | #5928 |
| graded | #5934 |
| premenopause | #5938 |
| revision | #5938 |
| 353 | #5945 |
| prodrugs | #5946 |
| rrs | #5949 |
| 141 | #5952 |
| gastrointestinal hemorrhage | #5954 |
| janus kinase | #5959 |
| rcts | #5962 |
| 43 | #5962 |
| families | #5967 |
| 328 | #5971 |
| deemed | #5977 |
| savings | #5980 |
| counseling | #5985 |
| blood platelets | #5987 |
| blood | #5990 |
| receiver operating | #5996 |
| guideline | #5998 |
| cancer incidence | #6006 |
| current standard | #6013 |
| therapeutic interventions | #6028 |
| nadir | #6034 |
| registries risk | #6039 |
| patients experience | #6042 |
| allocated | #6044 |
| ≥3 | #6052 |
| wash | #6059 |
| advance | #6062 |
| quarter | #6065 |
| spect | #6068 |
| glycosaminoglycans | #6069 |
| decompensated | #6074 |
| 24 | #6076 |
| bacteremia | #6090 |
| type iii | #6101 |
| topics | #6101 |
| suggestive | #6105 |
| emerging evidence | #6113 |
| prevent | #6117 |
| safety data | #6120 |
| directly | #6133 |
| 72 | #6135 |
| 267 | #6136 |
| lipid profile | #6140 |
| ≥2 | #6144 |
| normalization | #6151 |
| centuries | #6153 |
| 47 | #6157 |
| generation | #6160 |
| ffa | #6160 |
| lobar | #6161 |
| agents blood | #6164 |
| 292 | #6165 |
| informed | #6173 |
| pharmacodynamic | #6188 |
| lung male | #6190 |
| updating | #6192 |
| advantages disadvantages | #6194 |
| lower | #6195 |
| bilateral | #6198 |
| cyclosporine | #6208 |
| tumour growth | #6212 |
| pathogenetic | #6221 |
| femoral artery | #6224 |
| mortality morbidity | #6228 |
| terminated | #6228 |
| new drugs | #6229 |
| 312 | #6230 |
| evidence base | #6232 |
| vitro studies | #6234 |
| crp | #6235 |
| discontinued | #6236 |
| 111 | #6240 |
| abdomen | #6248 |
| denmark | #6254 |
| proportional | #6268 |
| practitioners | #6273 |
| colleagues | #6273 |
| administered | #6277 |
| 1978 | #6283 |
| screened | #6293 |
| infused | #6297 |
| 840 | #6318 |
| prostatectomy | #6330 |
| 017 | #6334 |
| saphenous vein | #6339 |
| 63 | #6340 |
| 135 | #6340 |
| percentile | #6344 |
| higher doses | #6345 |
| adequacy | #6347 |
| divided | #6348 |
| apache | #6351 |
| screen | #6357 |
| opinions | #6360 |
| opposed | #6362 |
| percentage | #6370 |
| longterm followup | #6372 |
| risk mortality | #6386 |
| dyslipidemias | #6390 |
| kaplan | #6391 |
| consensus | #6392 |
| 208 | #6397 |
| potential mechanisms | #6404 |
| factor gene | #6405 |
| roche | #6405 |
| initiated | #6408 |
| compensated | #6411 |
| investigating | #6427 |
| ultrasound | #6441 |
| restenosis | #6442 |
| bootstrap | #6452 |
| collection | #6457 |
| post operative | #6464 |
| enzyme linked | #6467 |
| bariatric surgery | #6468 |
| coronary syndrome | #6469 |
| decreased risk | #6471 |
| 218 | #6472 |
| perfusion | #6475 |
| imbalance | #6484 |
| angina pectoris | #6493 |
| calendar | #6498 |
| peripheral artery disease | #6501 |
| accuracy | #6501 |
| incidence risk | #6502 |
| cancer cell | #6502 |
| complement activation | #6505 |
| pregnancies | #6519 |
| surgical procedure | #6520 |
| supervised | #6521 |
| models male | #6522 |
| 138 | #6523 |
| washout | #6524 |
| 318 | #6524 |
| triiodothyronine | #6524 |
| peripheral | #6525 |
| vena | #6527 |
| increased incidence | #6532 |
| cochrane | #6532 |
| highrisk patients | #6532 |
| placebo patients | #6536 |
| replaced | #6537 |
| bowel | #6538 |
| exogenous | #6538 |
| aspirin patients | #6540 |
| thirteen | #6540 |
| year | #6546 |
| superior | #6549 |
| clinical assessment | #6550 |
| cohorts | #6555 |
| dilemma | #6560 |
| crt | #6561 |
| dosing | #6576 |
| tertile | #6581 |
| 231 | #6586 |
| limited | #6589 |
| md | #6592 |
| prediction | #6596 |
| treatment choice | #6600 |
| pooled | #6601 |
| occurs | #6610 |
| 510 | #6611 |
| belgium | #6620 |
| crude | #6621 |
| injections | #6638 |
| genetic testing | #6641 |
| pancreatic neoplasms | #6641 |
| individual | #6650 |
| complications | #6650 |
| complaints | #6652 |
| degranulation | #6663 |
| methylenetetrahydrofolate | #6665 |
| liver diseases | #6674 |
| patents | #6680 |
| smoking cessation | #6696 |
| 17 patients | #6704 |
| routinely | #6706 |
| tumour progression | #6708 |
| saline | #6709 |
| 194 | #6713 |
| approval | #6727 |
| recognised | #6729 |
| hazard ratios | #6729 |
| thromboxane | #6734 |
| allcause mortality | #6744 |
| multicenter | #6747 |
| appropriately | #6748 |
| increasing age | #6751 |
| body temperature | #6766 |
| 385 | #6766 |
| q1 | #6768 |
| clinical signs | #6771 |
| age patients | #6774 |
| 2 groups | #6780 |
| defined | #6780 |
| expense | #6781 |
| 42 patients | #6791 |
| train | #6796 |
| hyperglycemia | #6801 |
| reached | #6803 |
| premedication | #6803 |
| response relationship | #6807 |
| plasma proteins | #6807 |
| benefits | #6810 |
| cardiovascular risk | #6821 |
| 256 | #6831 |
| 280 | #6838 |
| iqr | #6839 |
| glucocorticoids | #6840 |
| summary | #6850 |
| 279 | #6854 |
| cancer diagnosis | #6856 |
| systematic | #6870 |
| points | #6877 |
| ambulatory | #6883 |
| weekly | #6884 |
| reviews | #6891 |
| physicians | #6893 |
| fibrillation patients | #6898 |
| disturbances | #6912 |
| adverse event | #6912 |
| sought | #6918 |
| 112 | #6923 |
| 251 | #6940 |
| complications patients | #6948 |
| vasopressin | #6957 |
| failure | #6965 |
| subsequent | #6971 |
| hematologic | #6974 |
| 246 | #6976 |
| intensity | #6976 |
| humans hydroxymethylglutaryl | #6982 |
| papers | #6983 |
| tpa | #6986 |
| intervals | #6987 |
| addressed | #6989 |
| 259 | #6992 |
| shock septic | #6995 |
| 222 | #6995 |
| adapted | #6998 |
| disclosed | #7001 |
| incidence risk factors | #7008 |
| hazards models | #7015 |
| cardiovascular disease | #7019 |
| myeloperoxidase | #7020 |
| lung cancer patients | #7023 |
| stenting | #7024 |
| responded | #7026 |
| cohort | #7037 |
| 1 patient | #7038 |
| unacceptable | #7039 |
| interleukin8 | #7042 |
| reductases | #7045 |
| preventing | #7056 |
| curve | #7058 |
| patients baseline | #7065 |
| animal doseresponse relationship | #7071 |
| reduced risk | #7075 |
| written | #7080 |
| applicability | #7084 |
| asymptomatic patients | #7086 |
| monoclonal antibody | #7098 |
| hospitalization humans | #7101 |
| computed | #7104 |
| betacoronavirus covid19 | #7104 |
| novartis | #7108 |
| complications pregnancy | #7111 |
| infarction stroke | #7114 |
| superiority | #7116 |
| interquartile range | #7120 |
| select | #7122 |
| carotid intima | #7141 |
| internationality | #7146 |
| surveys questionnaires | #7160 |
| 163 | #7166 |
| pharmacy | #7167 |
| patients renal | #7171 |
| physicians patients | #7177 |
| randomization | #7184 |
| liver cirrhosis | #7187 |
| 211 | #7188 |
| brain metastases | #7190 |
| oral animals | #7192 |
| walking | #7195 |
| drawn | #7196 |
| combination | #7197 |
| withdrawal | #7204 |
| 5year | #7204 |
| cardiovascular disease cvd | #7210 |
| acting | #7210 |
| disposition | #7212 |
| paucity | #7218 |
| humans lung | #7221 |
| 20 patients | #7225 |
| sulfate | #7240 |
| operating characteristic | #7244 |
| vldl | #7250 |
| treatment children | #7250 |
| hematocrit | #7255 |
| 199 | #7257 |
| retrospective cohort study | #7257 |
| alongside | #7258 |
| clinical benefit | #7265 |
| controls | #7267 |
| diagnostics | #7270 |
| option | #7273 |
| grouped | #7275 |
| young women | #7278 |
| products | #7282 |
| likelihood | #7284 |
| modest | #7290 |
| sensitivity analysis | #7290 |
| atrium | #7291 |
| 360 | #7303 |
| types | #7304 |
| factors stroke | #7305 |
| undergoing | #7327 |
| partial | #7330 |
| patients isolated | #7332 |
| pectoris | #7338 |
| ischemic stroke | #7338 |
| 1c | #7352 |
| interleukin6 | #7352 |
| standardised | #7356 |
| myocardial infarction | #7356 |
| p0001 | #7356 |
| betacoronavirus | #7357 |
| simple | #7360 |
| radiology | #7379 |
| pap | #7392 |
| patients aspirin | #7400 |
| angiopathies | #7401 |
| regimens | #7405 |
| 109 | #7409 |
| bias | #7411 |
| peptide fragments | #7413 |
| iiia | #7424 |
| intravenous injection | #7429 |
| 420 | #7431 |
| propranolol | #7438 |
| favourable | #7440 |
| hypercholesterolemia | #7441 |
| respective | #7444 |
| dose dependent | #7447 |
| infusion | #7448 |
| clinical setting | #7454 |
| ways | #7465 |
| risk adverse | #7497 |
| il6 | #7510 |
| mortality rates | #7515 |
| 209 | #7516 |
| considerations | #7517 |
| exclusions | #7518 |
| patient safety | #7520 |
| urgently | #7522 |
| angina | #7522 |
| cmv infection | #7541 |
| phase iii | #7555 |
| 257 | #7558 |
| € | #7559 |
| interim | #7561 |
| injection | #7564 |
| 191 | #7578 |
| cinahl | #7578 |
| comorbid | #7578 |
| pheochromocytoma | #7585 |
| ischaemic | #7598 |
| antibodies monoclonal | #7601 |
| reasons | #7602 |
| tended | #7608 |
| pooled analysis | #7609 |
| azathioprine | #7615 |
| 13 | #7616 |
| predictor | #7620 |
| femoral | #7640 |
| random allocation | #7646 |
| epidemiological studies | #7647 |
| 29 patients | #7647 |
| abrupt | #7655 |
| derivation | #7662 |
| interquartile | #7675 |
| manifestation | #7676 |
| temporary | #7679 |
| positive patients | #7687 |
| 18 | #7705 |
| medical conditions | #7705 |
| seventeen | #7710 |
| 304 | #7719 |
| ligament | #7732 |
| consent | #7733 |
| study association | #7735 |
| cytomegalovirus | #7736 |
| severe | #7742 |
| adverse outcomes | #7745 |
| costs | #7753 |
| cardiac surgical | #7760 |
| 189 | #7770 |
| cochrane library | #7771 |
| pregnancy outcome | #7787 |
| manufacturer | #7802 |
| 110 | #7802 |
| ≤ | #7803 |
| 9 | #7811 |
| oxygenases | #7813 |
| male gender | #7815 |
| interleukin | #7816 |
| pts | #7819 |
| 31 patients | #7828 |
| label | #7828 |
| hormone replacement | #7828 |
| cpr | #7829 |
| 5 | #7833 |
| abortion | #7838 |
| influenza | #7845 |
| radiation exposure | #7850 |
| regular | #7877 |
| academic | #7878 |
| tramadol | #7878 |
| septic patients | #7880 |
| 95 confidence | #7884 |
| replacing | #7886 |
| patients chemotherapy | #7888 |
| iib | #7908 |
| journals | #7922 |
| strict | #7927 |
| expertise | #7928 |
| bioavailability | #7930 |
| adoption | #7934 |
| urogenital | #7939 |
| highrisk | #7939 |
| diseased | #7944 |
| increasing evidence | #7947 |
| disadvantages | #7949 |
| 243 | #7965 |
| patients 1 | #7972 |
| human blood | #7973 |
| fragment | #7975 |
| new class | #7976 |
| 28 | #7989 |
| individualized | #7990 |
| aim | #7992 |
| premenopausal | #7995 |
| advice | #8016 |
| qol | #8022 |
| malignant disease | #8026 |
| pulmonary disease | #8031 |
| 99mtc | #8034 |
| oligonucleotides | #8040 |
| vascular disease | #8049 |
| medical | #8051 |
| 600 | #8051 |
| preventable | #8051 |
| list | #8059 |
| selective | #8062 |
| routine clinical | #8068 |
| fact | #8078 |
| lasting | #8080 |
| helpful | #8084 |
| 36 months | #8086 |
| outcome acute | #8092 |
| extracorporeal | #8095 |
| 248 | #8113 |
| 90 | #8114 |
| patients heart | #8120 |
| training | #8120 |
| 2004 | #8122 |
| initiating | #8123 |
| tsh | #8125 |
| cholesterol ldl | #8138 |
| sensorineural | #8140 |
| imaging studies | #8141 |
| investigational | #8141 |
| mild | #8156 |
| nosocomial | #8164 |
| multiple organ | #8175 |
| stroke | #8176 |
| 237 | #8183 |
| 158 | #8184 |
| arteries | #8190 |
| confidence | #8204 |
| parenteral nutrition | #8204 |
| renal dialysis | #8209 |
| 33 | #8223 |
| impairment | #8228 |
| renal function | #8228 |
| 81 | #8233 |
| therapy | #8235 |
| quantitative | #8240 |
| smoking | #8243 |
| lists | #8250 |
| lowest | #8250 |
| version | #8260 |
| 125i | #8264 |
| activated | #8264 |
| minimum | #8270 |
| mortality | #8280 |
| leukopenia | #8281 |
| 0008 | #8284 |
| agents | #8286 |
| 119 | #8290 |
| utilisation | #8298 |
| practice | #8310 |
| suffered | #8316 |
| schedule | #8320 |
| thrombectomy | #8322 |
| postulated | #8338 |
| endothelium vascular | #8338 |
| immunosorbent assay | #8339 |
| elimination | #8341 |
| linked immunosorbent | #8345 |
| hematology | #8351 |
| absence presence | #8382 |
| 2 years | #8382 |
| cell derived | #8384 |
| 229 | #8394 |
| draw | #8405 |
| occur | #8415 |
| 28 patients | #8415 |
| ≥50 | #8416 |
| reports | #8427 |
| 137 | #8433 |
| mentioned | #8436 |
| covid19 coronavirus | #8447 |
| 265 | #8452 |
| glucuronidase | #8458 |
| patient characteristics | #8459 |
| procedures operative | #8463 |
| transient ischemic | #8463 |
| 295 | #8466 |
| exceed | #8486 |
| knowledge | #8493 |
| 27 patients | #8496 |
| covariate | #8501 |
| evaluate | #8501 |
| criterion | #8504 |
| inborn | #8519 |
| validate | #8528 |
| rabbits | #8537 |
| atherosclerosis | #8557 |
| large cohort | #8558 |
| menstrual cycle | #8563 |
| 193 | #8565 |
| 250 | #8568 |
| adjusted life | #8574 |
| leukocytes | #8581 |
| adolescent | #8582 |
| 146 | #8582 |
| row | #8590 |
| thirty | #8596 |
| carotid arteries | #8596 |
| safety profile | #8602 |
| cox | #8604 |
| intensities | #8605 |
| risks | #8606 |
| fish oil | #8624 |
| 15 years | #8624 |
| attenuates | #8625 |
| entry | #8639 |
| thresholds | #8646 |
| presumed | #8652 |
| emissioncomputed | #8654 |
| 223 | #8655 |
| hydroxymethylglutaryl coa | #8656 |
| valves | #8658 |
| syndrome | #8664 |
| factors patients | #8666 |
| evaluations | #8679 |
| certainty | #8687 |
| markers | #8689 |
| renal failure | #8690 |
| biomarkers | #8693 |
| polytetrafluoroethylene | #8698 |
| publication aged aged | #8706 |
| portal vein | #8708 |
| 1 2 | #8723 |
| hold | #8723 |
| additional studies | #8726 |
| cardiotonic | #8729 |
| definitions | #8731 |
| address | #8733 |
| judgment | #8744 |
| platelet counts | #8754 |
| requiring | #8755 |
| endovascular | #8756 |
| practical | #8756 |
| cardiovascular | #8756 |
| vasoactive | #8762 |
| 236 | #8763 |
| interpret | #8766 |
| undetected | #8778 |
| subpopulation | #8789 |
| medical treatment | #8792 |
| illnesses | #8798 |
| cardiovascular mortality | #8802 |
| 249 | #8834 |
| internship | #8836 |
| convenient | #8837 |
| hydroxymethylglutaryl | #8837 |
| resolving | #8863 |
| representative | #8864 |
| 2 | #8872 |
| cesarean | #8876 |
| merits | #8887 |
| endarterectomy | #8896 |
| chronic liver disease | #8902 |
| mimics | #8903 |
| early treatment | #8910 |
| surgical intervention | #8911 |
| planned | #8914 |
| micrograms | #8914 |
| epoxide | #8916 |
| aged myocardial | #8919 |
| influenced | #8934 |
| normal subjects | #8936 |
| proportional hazards | #8945 |
| signs symptoms | #8945 |
| clinicians | #8956 |
| cessation | #8958 |
| experienced | #8960 |
| heparan sulfate | #8962 |
| leads | #8973 |
| 24 hours | #8977 |
| rct | #8980 |
| options | #9002 |
| patients placebo | #9002 |
| chemoprevention | #9005 |
| comprise | #9005 |
| societies medical | #9007 |
| clinical events | #9007 |
| reply | #9017 |
| receiver | #9026 |
| rank | #9043 |
| 7 | #9061 |
| databases factual | #9064 |
| early mortality | #9075 |
| diagnose | #9080 |
| mps | #9080 |
| frequency | #9083 |
| jan | #9088 |
| statins | #9090 |
| alpha1 | #9115 |
| blood proteins | #9116 |
| prone | #9142 |
| time points | #9147 |
| valve prosthesis | #9147 |
| patient patients | #9150 |
| pelvis | #9158 |
| square | #9165 |
| life threatening | #9170 |
| molecular mechanisms | #9179 |
| 75 patients | #9183 |
| advanced stage | #9184 |
| lysis | #9190 |
| editor | #9193 |
| consensus statement | #9209 |
| 361 | #9213 |
| considerable | #9225 |
| platelets | #9226 |
| 1 month | #9227 |
| pci | #9230 |
| dyspnea | #9230 |
| performs | #9233 |
| contrast | #9238 |
| 4 hours | #9259 |
| extrinsic | #9263 |
| hazards | #9264 |
| illness surveys | #9264 |
| experts | #9266 |
| uncomplicated | #9267 |
| mumol | #9278 |
| attenuation | #9283 |
| rabbit | #9286 |
| positive | #9286 |
| trial registration | #9297 |
| corresponded | #9298 |
| dialysis | #9319 |
| feasibility | #9320 |
| earlier | #9339 |
| suboptimal | #9342 |
| patients negative | #9355 |
| p0004 | #9355 |
| preceded | #9376 |
| loss | #9378 |
| 014 | #9380 |
| higher incidence | #9380 |
| purposes | #9383 |
| invited | #9384 |
| single center | #9385 |
| death patients | #9391 |
| radioactivity | #9394 |
| bacterial infections | #9401 |
| fourth | #9402 |
| 2b | #9412 |
| ascending | #9415 |
| haemorrhage | #9425 |
| 167 | #9436 |
| properly | #9442 |
| rheumatic | #9446 |
| hospitalised | #9448 |
| dysfunction | #9460 |
| belonged | #9480 |
| secondary analysis | #9483 |
| respiratory tract | #9486 |
| 169 | #9490 |
| 240 | #9493 |
| ipd | #9502 |
| factual | #9503 |
| valvular | #9505 |
| thyroid function | #9507 |
| selectin | #9509 |
| hrs | #9524 |
| inflammatory agents | #9529 |
| confirms | #9530 |
| designed | #9535 |
| cardiopulmonary bypass | #9540 |
| swelling | #9542 |
| 3 4 | #9544 |
| insight | #9557 |
| cooperation | #9561 |
| requirements | #9566 |
| hemoglobins | #9573 |
| rose | #9592 |
| il10 | #9597 |
| observational cohort | #9598 |
| lpa | #9600 |
| rates | #9617 |
| comparative effectiveness | #9630 |
| primary point | #9638 |
| kidney failure | #9638 |
| successful treatment | #9639 |
| laboratories | #9644 |
| cardiogenic | #9645 |
| optimal treatment | #9650 |
| 2008 | #9656 |
| hf | #9670 |
| published | #9674 |
| congestive | #9695 |
| pathophysiological | #9704 |
| patients hospital | #9713 |
| spontaneously | #9720 |
| modalities | #9721 |
| inappropriate | #9724 |
| reuptake | #9727 |
| acts | #9729 |
| identifier | #9730 |
| 2007 | #9732 |
| lactoferrin | #9734 |
| 42 | #9744 |
| substitutes | #9747 |
| hypothetical | #9754 |
| nested | #9764 |
| nonesterified | #9768 |
| 90 patients | #9777 |
| reproducibility | #9778 |
| sepsis | #9802 |
| 210 | #9803 |
| absence | #9813 |
| straightforward | #9814 |
| easily | #9817 |
| precise | #9817 |
| nmol | #9828 |
| coa reductase | #9828 |
| classification | #9836 |
| 212 | #9839 |
| craniotomy | #9839 |
| 0006 | #9849 |
| utility | #9855 |
| danish | #9857 |
| labile | #9865 |
| heterozygotes | #9871 |
| nonhuman primates | #9871 |
| discordant | #9908 |
| moderately | #9919 |
| cmv | #9930 |
| 60 years | #9933 |
| lower limb | #9936 |
| promise | #9937 |
| degradation | #9941 |
| 2003 | #9941 |
| tomography | #9944 |
| treatment strategy | #9951 |
| 216 | #9958 |
| low dose | #9971 |
| investigator | #9983 |
| detecting | #9992 |
| regimen | #9995 |
| pancreatic | #9997 |
| casecontrol studies | #9997 |
| 12 hours | #9997 |
| 213 | #10000 |
| neoplasm metastasis | #10001 |
| chance | #10008 |
| physician | #10015 |
| extending | #10027 |
| informative | #10028 |
| hereditary | #10041 |
| protective | #10045 |
| obstacles | #10045 |
| addressing | #10051 |
| medication adherence | #10052 |
| mthfr | #10079 |
| presentations | #10082 |
| familial | #10087 |
| higher prevalence | #10089 |
| chart | #10108 |
| recipients | #10113 |
| qualitative | #10117 |
| 1980 | #10134 |
| completely | #10145 |
| tested | #10150 |
| aged obesity | #10170 |
| 182 | #10176 |
| invasive | #10181 |
| abnormalities | #10186 |
| regularly | #10189 |
| cast | #10193 |
| multicentre | #10198 |
| investigations | #10199 |
| cell activation | #10199 |
| cardiovascular risk factors | #10209 |
| medical therapy | #10213 |
| clinical data | #10213 |
| tumor necrosis factoralpha | #10215 |
| replacement therapy | #10225 |
| routine | #10234 |
| syndrome humans | #10253 |
| heart failure | #10265 |
| 183 | #10280 |
| gaps | #10291 |
| hospitalization | #10293 |
| blood transfusion | #10293 |
| postpartum | #10305 |
| measuring | #10314 |
| aetiology | #10315 |
| 8 | #10318 |
| photon emission | #10329 |
| 032 | #10336 |
| dilution | #10336 |
| worldwide | #10337 |
| 667 | #10337 |
| greatly | #10352 |
| aorta | #10352 |
| indirectly | #10377 |
| restoration | #10378 |
| creatinine | #10381 |
| cardiopulmonary | #10385 |
| pneumonia viral | #10397 |
| medical management | #10404 |
| outcome measures | #10408 |
| p0003 | #10408 |
| tissue injury | #10411 |
| bidirectional | #10419 |
| reductase inhibitors | #10432 |
| circulation | #10432 |
| transfusion | #10435 |
| enrolment | #10446 |
| reflux | #10457 |
| priority | #10461 |
| patients age | #10461 |
| quality life | #10471 |
| phase 3 | #10481 |
| activity levels | #10489 |
| increased prevalence | #10489 |
| style | #10491 |
| 1991 | #10491 |
| 147 | #10501 |
| predictive factors | #10514 |
| sex age | #10526 |
| assessing | #10529 |
| necrosis | #10534 |
| matched | #10556 |
| lower rate | #10558 |
| portable | #10563 |
| ray | #10570 |
| patients moderate | #10570 |
| 125 | #10574 |
| p002 | #10576 |
| pulmonary artery | #10578 |
| inform | #10580 |
| recurrences | #10583 |
| antisense | #10583 |
| 293 | #10584 |
| 180 | #10598 |
| manifestations | #10601 |
| closer | #10602 |
| 159 | #10605 |
| microvascular | #10605 |
| vasoconstrictor | #10607 |
| hospitals | #10612 |
| medical oncology | #10615 |
| november | #10628 |
| percutaneous coronary | #10633 |
| persist | #10635 |
| fragments | #10637 |
| ascertained | #10641 |
| 1b | #10647 |
| publication administration | #10653 |
| postoperative | #10659 |
| held | #10674 |
| concerned | #10674 |
| pulmonary vascular | #10690 |
| discriminate | #10697 |
| term | #10697 |
| risk developing | #10704 |
| synergism | #10709 |
| multivariable analysis | #10713 |
| neutrophil | #10729 |
| consultation | #10735 |
| centres | #10751 |
| median duration | #10755 |
| decisions | #10759 |
| entire | #10774 |
| haemoglobin | #10797 |
| perioperative | #10798 |
| patients cirrhosis | #10804 |
| term mortality | #10829 |
| 300 | #10832 |
| 38 | #10849 |
| prospective observational | #10855 |
| sustained | #10865 |
| randomised controlled | #10867 |
| anatomical | #10873 |
| airways | #10903 |
| diagnoses | #10903 |
| neurosurgical | #10905 |
| monoclonal antibodies monoclonal | #10909 |
| coronavirus infections | #10921 |
| maximal | #10924 |
| threatening | #10963 |
| amniotic | #10987 |
| coronary intervention | #10989 |
| relative | #10990 |
| blocker | #10996 |
| needed | #11009 |
| obese | #11037 |
| neutropenia | #11057 |
| ischemic | #11057 |
| ethical | #11062 |
| attained | #11062 |
| summarizes | #11062 |
| treatment option | #11070 |
| balloon | #11071 |
| 12 weeks | #11074 |
| originally | #11083 |
| inability | #11108 |
| location | #11108 |
| catheters | #11143 |
| beta2 | #11159 |
| ischemic attack | #11165 |
| hematoma | #11189 |
| confirmation | #11199 |
| neoplasms risk | #11201 |
| metabolic syndrome | #11202 |
| iia | #11204 |
| strokes | #11217 |
| choice | #11228 |
| eligible patients | #11247 |
| risk groups | #11263 |
| 1992 | #11272 |
| cerebrovascular | #11281 |
| humans kidney | #11281 |
| waiting | #11282 |
| ≥1 | #11291 |
| endothelial function | #11297 |
| troponin | #11304 |
| determine | #11306 |
| 202 | #11308 |
| aged prevalence | #11331 |
| post | #11332 |
| adherent | #11338 |
| acute respiratory | #11345 |
| acute myocardial infarction | #11361 |
| event | #11363 |
| combination therapy | #11380 |
| glycoprotein | #11391 |
| factors smoking | #11395 |
| reconstructive | #11397 |
| apply | #11399 |
| developed | #11405 |
| 2005 | #11415 |
| competent | #11416 |
| medically | #11426 |
| treatment decisions | #11427 |
| prostaglandins | #11434 |
| diuretics | #11439 |
| hematological malignancies | #11443 |
| morbidity | #11445 |
| media | #11464 |
| protocol | #11487 |
| satisfying | #11502 |
| performances | #11525 |
| hospital admission | #11526 |
| occlusion | #11533 |
| placebo treatment | #11533 |
| multicenter study | #11542 |
| outflow | #11542 |
| enrolled | #11545 |
| humans intensive | #11570 |
| 55 | #11577 |
| chronic inflammation | #11600 |
| definitive | #11621 |
| baseline | #11624 |
| younger patients | #11624 |
| sct | #11638 |
| investigate | #11670 |
| normal controls | #11684 |
| contribution | #11687 |
| reference | #11694 |
| life qol | #11697 |
| lipopolysaccharides | #11699 |
| hypotension | #11715 |
| ascites | #11717 |
| myoglobin | #11741 |
| independent risk | #11745 |
| acute myocardial | #11753 |
| radiopharmaceuticals | #11783 |
| extent | #11786 |
| orally | #11790 |
| involving | #11792 |
| 2010 | #11802 |
| nonspecific | #11809 |
| vena cava | #11829 |
| distinction | #11841 |
| episodes | #11865 |
| eclampsia | #11872 |
| release | #11874 |
| woman | #11885 |
| 151 | #11891 |
| 006 | #11906 |
| elicited | #11912 |
| icu patients | #11915 |
| vasculitis | #11937 |
| activating | #11948 |
| age | #11953 |
| sulphate | #11955 |
| began | #11957 |
| lethality | #11967 |
| collectively | #11970 |
| inferior | #11978 |
| serum creatinine | #11979 |
| myocardial injury | #11980 |
| adp | #11981 |
| immunosorbent | #12006 |
| cardiovascular diseases | #12015 |
| mortality rate | #12041 |
| reduced | #12043 |
| dietary intake | #12057 |
| thirds | #12057 |
| minority | #12058 |
| monitored | #12061 |
| differently | #12066 |
| early pregnancy | #12076 |
| humanized | #12077 |
| wounds injuries | #12079 |
| fair | #12096 |
| thoracotomy | #12111 |
| evidenced | #12130 |
| 1995 | #12135 |
| elevated risk | #12140 |
| 085 | #12141 |
| profile | #12143 |
| prostate | #12153 |
| 149 | #12157 |
| 120 | #12170 |
| digoxin | #12177 |
| offset | #12179 |
| uncommon | #12187 |
| healthcare | #12202 |
| lung | #12208 |
| causality | #12208 |
| spent | #12219 |
| takes | #12233 |
| tendency | #12271 |
| pregnancy risk | #12276 |
| expectancy | #12281 |
| resolve | #12300 |
| flaps | #12302 |
| micromol | #12326 |
| mismatch | #12335 |
| favored | #12342 |
| births | #12351 |
| obstructive pulmonary | #12358 |
| epinephrine | #12365 |
| dependently | #12372 |
| prescription | #12394 |
| registration | #12398 |
| incremental | #12399 |
| switzerland | #12409 |
| inflammatory response | #12409 |
| consistent | #12418 |
| potential confounders | #12425 |
| echocardiographic | #12450 |
| fifty patients | #12451 |
| arginine | #12475 |
| patient discharge | #12480 |
| apparent | #12483 |
| prospective randomized | #12486 |
| sensitivity analyses | #12490 |
| 117 | #12494 |
| switch | #12513 |
| 10 years | #12521 |
| standards | #12524 |
| guide | #12540 |
| requires | #12540 |
| statistically | #12548 |
| prognostic | #12579 |
| chronic obstructive | #12584 |
| monoclonal | #12589 |
| rapidly | #12597 |
| tomography ray | #12611 |
| lipoprotein | #12619 |
| literature | #12637 |
| repeat | #12653 |
| single dose | #12673 |
| drug interactions | #12680 |
| hypertension pulmonary | #12684 |
| physiological | #12687 |
| pharmacogenetics | #12706 |
| 45 | #12708 |
| prostatic | #12708 |
| endocrine | #12709 |
| ifngamma | #12722 |
| minute | #12733 |
| dosage | #12736 |
| congestive heart failure | #12747 |
| cardiac surgery | #12756 |
| personal | #12770 |
| estrogens | #12778 |
| animal model | #12796 |
| thyroid | #12808 |
| settings | #12820 |
| malignancies | #12823 |
| infections | #12836 |
| burden | #12849 |
| intraoperative complications | #12862 |
| cancer patient | #12864 |
| reporting | #12866 |
| 196 | #12881 |
| 1999 | #12904 |
| cvd | #12906 |
| raised | #12910 |
| endpoints | #12912 |
| extracted | #12940 |
| confirming | #12947 |
| 18 years | #12976 |
| ray computed | #12983 |
| postoperative complications | #12990 |
| filters | #13009 |
| monotherapy | #13017 |
| transiently | #13024 |
| instance | #13041 |
| oral administration | #13041 |
| located | #13049 |
| tumor angiogenesis | #13067 |
| based cohort | #13094 |
| fold | #13100 |
| severity | #13106 |
| cancer risk | #13107 |
| escalation | #13107 |
| physical | #13112 |
| vomiting | #13112 |
| latin | #13125 |
| sexes | #13143 |
| drug therapy | #13144 |
| 0 | #13145 |
| ratio | #13159 |
| focused | #13189 |
| appearance | #13195 |
| compliance | #13199 |
| pregnant women | #13202 |
| optimal | #13213 |
| expensive | #13226 |
| support | #13231 |
| exist | #13235 |
| 142 | #13236 |
| lack | #13240 |
| narcotic | #13261 |
| formal | #13262 |
| commercially | #13265 |
| participant | #13273 |
| median follow | #13286 |
| indirect | #13288 |
| emission computed | #13352 |
| mediator | #13366 |
| maintain | #13391 |
| electronic databases | #13394 |
| hypothesized | #13395 |
| advantage | #13432 |
| admitted | #13437 |
| p00001 | #13442 |
| anti | #13455 |
| reliably | #13459 |
| surveys | #13463 |
| endothelial dysfunction | #13466 |
| transient | #13478 |
| patients experienced | #13481 |
| provided | #13489 |
| crosssectional study | #13491 |
| patients patient | #13494 |
| surrogate | #13537 |
| vivo | #13545 |
| retrospectively | #13548 |
| maintained | #13555 |
| 195 | #13556 |
| accurate | #13563 |
| pulmonary hypertension | #13563 |
| longterm outcomes | #13585 |
| monitoring | #13620 |
| laboratory | #13629 |
| elucidated | #13643 |
| abdominal | #13652 |
| whilst | #13665 |
| mitral | #13682 |
| north america | #13705 |
| marker | #13707 |
| competence | #13708 |
| vascular | #13708 |
| 45 years | #13716 |
| 2009 | #13734 |
| icu | #13748 |
| drug effects | #13753 |
| medicine | #13755 |
| healthy individuals | #13758 |
| inhibitory effects | #13763 |
| establishing | #13766 |
| pelvic | #13773 |
| explanation | #13773 |
| participating | #13774 |
| phospholipid | #13776 |
| heart diseases | #13789 |
| women risk | #13816 |
| conservative | #13820 |
| circulating | #13824 |
| condition | #13859 |
| kidney diseases | #13860 |
| systematically | #13868 |
| tissue | #13876 |
| coronary angiography | #13889 |
| internal | #13916 |
| techniques | #13923 |
| microparticles | #13927 |
| dissemination | #13928 |
| 1993 | #13939 |
| 176 | #13979 |
| require | #13986 |
| castration | #13998 |
| radioisotopes | #14011 |
| 48 patients | #14013 |
| insufficiency | #14022 |
| algorithms | #14029 |
| risk death | #14033 |
| members | #14033 |
| requirement | #14046 |
| independent predictors | #14058 |
| continuous | #14060 |
| organ failure | #14072 |
| focus | #14084 |
| situations | #14084 |
| vasoconstriction | #14119 |
| offer | #14137 |
| supporting | #14164 |
| activates | #14188 |
| cardiac output | #14194 |
| leukocyte | #14204 |
| mitral valve | #14205 |
| sensitivities | #14216 |
| document | #14242 |
| primary prevention | #14248 |
| newborns | #14256 |
| nausea | #14276 |
| making | #14285 |
| effectiveness | #14304 |
| independent | #14342 |
| inhibition | #14357 |
| 4 years | #14367 |
| meaningful | #14371 |
| pathologic | #14372 |
| female fetal | #14377 |
| acquired | #14378 |
| min1 | #14391 |
| 6 patients | #14391 |
| amniotic fluid | #14403 |
| substances | #14409 |
| pregnant | #14423 |
| disease chronic | #14460 |
| interleukin1 | #14489 |
| infarction | #14491 |
| influence | #14509 |
| interventions | #14510 |
| costeffectiveness | #14535 |
| locations | #14586 |
| participated | #14592 |
| similarities | #14608 |
| 205 | #14632 |
| renal insufficiency | #14637 |
| statistics | #14637 |
| reasonable | #14646 |
| comparative | #14648 |
| natural | #14667 |
| blood samples | #14672 |
| surgery patients | #14696 |
| entered | #14698 |
| pandemics | #14707 |
| classify | #14715 |
| institutes | #14736 |
| surveyed | #14741 |
| 39 patients | #14742 |
| sampled | #14749 |
| 2017 | #14783 |
| arms | #14785 |
| independent predictor | #14787 |
| validity | #14787 |
| databases | #14808 |
| heart association | #14814 |
| white matter | #14816 |
| complete | #14819 |
| stable | #14828 |
| cox proportional | #14835 |
| pge2 | #14844 |
| duplex | #14845 |
| population | #14872 |
| contribute | #14928 |
| retest | #14931 |
| criteria | #14938 |
| premature | #14952 |
| critical illness | #15004 |
| phospholipids | #15030 |
| european society | #15041 |
| cardiac catheterization | #15042 |
| prostheses | #15059 |
| questionnaires | #15082 |
| treatment failure | #15087 |
| sf36 | #15089 |
| elective surgical | #15107 |
| controlled clinical | #15109 |
| flight | #15110 |
| ldl | #15120 |
| relate | #15127 |
| health costs | #15128 |
| initiation | #15140 |
| obstruction | #15142 |
| obstructive | #15146 |
| stratification | #15164 |
| proper | #15177 |
| selection | #15187 |
| registries | #15197 |
| decrease | #15201 |
| copd | #15201 |
| randomized controlled trial | #15210 |
| unilateral | #15223 |
| ongoing | #15230 |
| induces | #15231 |
| individuals | #15239 |
| young patients | #15247 |
| previous | #15250 |
| methods retrospective | #15255 |
| drug | #15278 |
| disorders | #15278 |
| myocardial | #15279 |
| 4 weeks | #15296 |
| quantitation | #15298 |
| fewer | #15300 |
| hospital discharge | #15328 |
| quantify | #15340 |
| activators | #15356 |
| neonates | #15370 |
| consequence | #15405 |
| locally | #15441 |
| impaired | #15446 |
| pedigree | #15471 |
| randomised controlled trial | #15474 |
| women age | #15474 |
| grafts | #15484 |
| zealand | #15509 |
| asthma | #15511 |
| undetectable | #15512 |
| current literature | #15513 |
| records | #15520 |
| 1994 | #15522 |
| aggregation | #15535 |
| thrombocytopenia | #15537 |
| implementation | #15538 |
| pa | #15540 |
| intended | #15567 |
| reviewed | #15577 |
| surgery | #15590 |
| updated | #15592 |
| discharged | #15616 |
| immunoenzyme | #15617 |
| purpose | #15634 |
| heterozygosity | #15660 |
| centre | #15666 |
| standard | #15679 |
| patients admitted | #15702 |
| perinatal | #15711 |
| explain | #15726 |
| view | #15729 |
| unexpected | #15737 |
| detection | #15766 |
| start | #15808 |
| effectively | #15813 |
| examination | #15813 |
| prescribing | #15823 |
| vary | #15829 |
| febrile | #15847 |
| confer | #15849 |
| serologic | #15853 |
| reach | #15876 |
| interpretation | #15881 |
| janus | #15892 |
| numerous | #15899 |
| inter | #15907 |
| quality adjusted | #15919 |
| dyslipidemia | #15942 |
| prominent | #15961 |
| blocked | #15985 |
| severely | #15997 |
| discuss | #15997 |
| alanine | #15998 |
| external | #16007 |
| causal | #16021 |
| hepatectomy | #16025 |
| complication | #16054 |
| compared controls | #16057 |
| rarely | #16076 |
| systemic inflammation | #16077 |
| fever | #16082 |
| metabolic | #16112 |
| demonstrates | #16117 |
| insensitive | #16125 |
| affect | #16135 |
| conditional | #16136 |
| basis | #16144 |
| carotid | #16168 |
| bypass | #16221 |
| early | #16262 |
| antiretroviral | #16271 |
| neoplasms | #16294 |
| hospital | #16314 |
| special | #16336 |
| signs | #16384 |
| cost | #16418 |
| recommendations | #16420 |
| aimed | #16432 |
| area | #16442 |
| syndromes | #16485 |
| unable | #16508 |
| develop | #16513 |
| prevented | #16513 |
| cancer treatment | #16516 |
| 106 | #16543 |
| radiography | #16545 |
| calibrated | #16568 |
| multivariable | #16576 |
| 2021 | #16583 |
| descriptive | #16618 |
| alternatives | #16629 |
| integrins | #16641 |
| creactive protein | #16645 |
| gained | #16652 |
| consists | #16666 |
| weeks | #16674 |
| downregulation | #16681 |
| residual | #16708 |
| prior | #16725 |
| explained | #16763 |
| fat | #16775 |
| electrocardiography | #16807 |
| epidemiology | #16821 |
| potent | #16848 |
| thought | #16868 |
| genetic risk | #16876 |
| survival | #16892 |
| 093 | #16911 |
| humans liver | #16932 |
| constitute | #16939 |
| gestational age | #16946 |
| vasodilator | #16950 |
| driven | #16958 |
| critically patients | #16965 |
| enable | #16976 |
| verify | #16984 |
| smokers | #16998 |
| inherent | #17023 |
| carotid artery | #17040 |
| apolipoproteins | #17063 |
| individual patients | #17078 |
| markedly | #17097 |
| units | #17139 |
| estimates | #17144 |
| assayed | #17145 |
| elderly patients | #17150 |
| regard | #17197 |
| critically | #17220 |
| adjustment | #17237 |
| cooperative | #17262 |
| lung neoplasms | #17262 |
| estimated | #17274 |
| largest | #17288 |
| acute phase | #17288 |
| 400 | #17295 |
| clinician | #17339 |
| desirable | #17347 |
| 2019 | #17393 |
| limb | #17439 |
| dilated | #17443 |
| disease cvd | #17451 |
| synthetic | #17459 |
| increasingly | #17488 |
| kinds | #17510 |
| antibodies | #17538 |
| prompt | #17565 |
| demographics | #17584 |
| cirrhosis | #17586 |
| 0002 | #17604 |
| finding | #17620 |
| applicable | #17636 |
| obtaining | #17637 |
| coronary | #17653 |
| sex factors | #17688 |
| prosthesis | #17710 |
| independent risk factor | #17712 |
| distal | #17714 |
| multivariate analysis | #17792 |
| gastrointestinal | #17804 |
| selecting | #17815 |
| 3 years | #17833 |
| 2006 | #17840 |
| illustrated | #17852 |
| 1 | #17853 |
| hemorrhagic | #17855 |
| drugs | #17878 |
| current evidence | #17881 |
| undergone | #17883 |
| marked | #17903 |
| epidemiologic | #17920 |
| hospitalizations | #17922 |
| nationwide | #17924 |
| global | #17933 |
| percutaneous | #17942 |
| essential | #17964 |
| corticosteroids | #17975 |
| distant | #18007 |
| intensive | #18031 |
| reductase | #18047 |
| verified | #18052 |
| peptide | #18060 |
| defects | #18070 |
| 000 | #18092 |
| operated | #18111 |
| trend | #18115 |
| centers | #18134 |
| protein crp | #18152 |
| clinical significance | #18164 |
| consistently | #18169 |
| quality | #18175 |
| chemotherapy | #18203 |
| prenatal | #18250 |
| participate | #18252 |
| deaths | #18263 |
| year follow | #18286 |
| ventricular function | #18296 |
| metastases | #18296 |
| inflammatory bowel | #18314 |
| gestation | #18344 |
| tolerated | #18425 |
| attributable | #18434 |
| and or | #18480 |
| coa | #18497 |
| larger | #18513 |
| mutations | #18533 |
| humans hypertension | #18543 |
| stratified | #18569 |
| heart disease | #18579 |
| commercial | #18589 |
| bayes | #18675 |
| ≥ | #18700 |
| extra | #18726 |
| mechanisms | #18742 |
| questions | #18760 |
| plasma | #18797 |
| conventional | #18799 |
| monoclonal antibodies | #18844 |
| increases | #18850 |
| life | #18851 |
| vessel | #18855 |
| oligopeptides | #18887 |
| clearance | #18903 |
| validation | #18907 |
| classical | #18919 |
| hormone | #18938 |
| molecular basis | #19034 |
| single | #19069 |
| worse | #19094 |
| statistical | #19103 |
| soluble | #19124 |
| simultaneously | #19131 |
| tailored | #19134 |
| real | #19158 |
| 5 years | #19189 |
| variable | #19205 |
| moderate | #19239 |
| contributes | #19241 |
| decade | #19291 |
| infarct | #19308 |
| ages | #19312 |
| pubmed | #19345 |
| 0005 | #19412 |
| essentially | #19469 |
| ventricular | #19481 |
| investigates | #19493 |
| 2 3 | #19507 |
| therapies | #19511 |
| called | #19515 |
| partially | #19535 |
| explore | #19544 |
| endothelium | #19553 |
| systemic | #19561 |
| january | #19567 |
| uterine | #19582 |
| reversed | #19601 |
| procedures | #19611 |
| tka | #19675 |
| etiology | #19677 |
| operating | #19692 |
| guided | #19709 |
| histology | #19727 |
| characterised | #19753 |
| inflammation | #19779 |
| median followup | #19863 |
| exclusively | #19881 |
| autologous | #19886 |
| graft | #19904 |
| endothelial cell | #19986 |
| controlled trial | #20019 |
| comorbidities | #20045 |
| gestational | #20050 |
| 2002 | #20050 |
| additionally | #20057 |
| cytokines | #20058 |
| salvage | #20102 |
| inversely | #20149 |
| concentration | #20153 |
| predisposition disease | #20162 |
| diastolic | #20170 |
| small | #20201 |
| alterations | #20228 |
| body | #20230 |
| alpha | #20261 |
| polymorphism genetic | #20264 |
| variables | #20277 |
| subjects | #20283 |
| combine | #20369 |
| adjusting | #20377 |
| catheterization | #20391 |
| introduced | #20458 |
| 1 3 | #20492 |
| younger | #20499 |
| hormones | #20508 |
| length | #20512 |
| theoretically | #20515 |
| ability | #20536 |
| analyses | #20553 |
| clarify | #20561 |
| elisa | #20562 |
| persistent | #20562 |
| improves | #20570 |
| september | #20598 |
| persons | #20696 |
| humans models | #20753 |
| active | #20756 |
| observational | #20823 |
| incorporated | #20843 |
| prognosis | #20934 |
| fetal | #20955 |
| reduce | #21005 |
| measure | #21033 |
| auc | #21046 |
| report | #21048 |
| intrinsic | #21055 |
| responsible | #21081 |
| constructed | #21098 |
| innate | #21135 |
| operative | #21137 |
| attenuated | #21137 |
| 1 year | #21144 |
| designated | #21167 |
| october | #21177 |
| performing | #21185 |
| × | #21191 |
| upper | #21226 |
| reflecting | #21230 |
| selected | #21264 |
| depending | #21267 |
| preschool female | #21270 |
| 005 | #21324 |
| hemodynamics humans | #21403 |
| symptoms | #21425 |
| center | #21469 |
| differed | #21501 |
| 1990 | #21507 |
| 0004 | #21546 |
| logistic | #21639 |
| explored | #21757 |
| animals antibodies | #21767 |
| young | #21860 |
| 139 | #21894 |
| majority | #21894 |
| observe | #21969 |
| facilitate | #21994 |
| decreased | #22047 |
| progression | #22078 |
| genotype | #22116 |
| imaging | #22125 |
| coronary disease | #22178 |
| tract | #22180 |
| neoadjuvant | #22207 |
| generally | #22291 |
| regression | #22321 |
| surgical procedures | #22327 |
| authors | #22330 |
| demonstrated | #22352 |
| inhibiting | #22426 |
| newborn male | #22473 |
| varying | #22556 |
| significance | #22586 |
| represented | #22593 |
| slower | #22607 |
| allogeneic | #22614 |
| grade | #22615 |
| phase | #22698 |
| older | #22831 |
| differential | #22835 |
| july | #22843 |
| modified | #22851 |
| march | #22907 |
| application | #22920 |
| combining | #22961 |
| ratios | #22986 |
| 2012 | #23037 |
| anti inflammatory | #23123 |
| offered | #23214 |
| protocols | #23283 |
| 2016 | #23284 |
| challenging | #23285 |
| yielding | #23334 |
| prevents | #23432 |
| resting | #23488 |
| includes | #23496 |
| renal | #23566 |
| median | #23599 |
| inhibits | #23686 |
| inbred c57bl mice | #23705 |
| increasing | #23723 |
| endopeptidases | #23727 |
| advanced | #23745 |
| adverse | #23767 |
| naive | #23767 |
| reactive protein | #23807 |
| minimal | #23827 |
| interestingly | #23831 |
| showing | #23885 |
| longer | #23967 |
| surgical | #24020 |
| vascular endothelial | #24085 |
| prolonged | #24478 |
| generate | #24487 |
| count | #24514 |
| december | #24569 |
| unrelated | #24572 |
| determining | #24577 |
| activity | #24581 |
| changed | #24651 |
| implies | #24682 |
| underlying | #24749 |
| suggests | #24813 |
| august | #24821 |
| linearly | #24940 |
| february | #24945 |
| frequent | #25109 |
| june | #25175 |
| representing | #25214 |
| acceptable | #25300 |
| carried | #25310 |
| illness | #25373 |
| suitable | #25501 |
| enhance | #25503 |
| 0003 | #25598 |
| linked | #25616 |
| local | #25663 |
| mm | #25732 |
| fully | #25888 |
| reducing | #25912 |
| describes | #25923 |
| difficult | #26054 |
| supported | #26091 |
| scanning | #26181 |
| differentiate | #26212 |
| respect | #26378 |
| promising | #26384 |
| asked | #26410 |
| define | #26421 |
| defective | #26510 |
| female heart | #26685 |
| dependent | #26722 |
| leading | #26774 |
| improving | #27057 |
| contained | #27059 |
| national | #27215 |
| strongest | #27229 |
| quantitatively | #27333 |
| recognized | #27386 |
| commonly | #27411 |
| mass bmi | #27411 |
| implicated | #27484 |
| caused | #27495 |
| remain | #27689 |
| correlate | #27710 |
| artery | #27999 |
| cross | #28142 |
| recorded | #28182 |
| detected | #28405 |
| inflammatory | #28439 |
| multivariate | #28454 |
| examine | #28475 |
| beta | #28655 |
| allowed | #28793 |
| hypothesis | #28801 |
| improved | #28920 |
| required | #29047 |
| large | #29116 |
| chemically | #29137 |
| short | #29272 |
| patients chronic | #29316 |
| genetic predisposition | #29434 |
| bmi | #29470 |
| female health | #29531 |
| achieved | #29589 |
| 001 | #29634 |
| underwent | #29797 |
| 2011 | #30149 |
| indicating | #30233 |
| approved | #30511 |
| declined | #30756 |
| participants | #30828 |
| predisposition | #30981 |
| genotype humans | #31051 |
| aims | #31216 |
| measured | #31265 |
| antineoplastic agents | #31706 |
| expected | #31791 |
| specific | #31901 |
| endothelial | #32294 |
| modality | #32386 |
| inhibit | #32629 |
| conducted | #32675 |
| predicted | #32889 |
| inhibited | #33631 |
| agreement | #33673 |
| sensitive | #34362 |
| antineoplastic | #34560 |
| correlated | #34744 |
| greater | #34856 |
| poor | #35078 |
| neoplasms male | #35230 |
| humans magnetic | #35433 |
| 0001 | #35646 |
| free | #35793 |
| sectional | #35852 |
| include | #39773 |
| collected | #40746 |
| examined | #41010 |
| mediated | #41310 |
| neoplasm | #47468 |
Relatório de execução | |
Prominent publications by Harry Roger Büller
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
[ PUBLICATION ]
BACKGROUND: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.
OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.
METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.
RESULTS: For the ...
| Conhecido por Vte Patients | Venous Thromboembolism | Prophylaxis Lmwh | 3 Months | Practice Guidelines |
KOL-Index: 20177
OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...
| Conhecido por Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk |
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...
| Conhecido por Antithrombotic Therapy | Grade 1a | Venous Thromboembolic Disease | Vka Lmwh | Inr Range |
KOL-Index: 16684
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...
| Conhecido por Venous Thromboembolism | Bleeding Complications | Patients Malignancy | Retrospective Analysis | International Normalized |
KOL-Index: 16378
BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...
| Conhecido por Venous Thromboembolism | Patients Cancer | Hazard Ratio | Clinically Relevant Bleeding | Factor Inhibitors |
KOL-Index: 15975
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.
METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...
| Conhecido por Warfarin Patients | Hazard Ratio | Venous Thromboembolism | Pulmonary Embolism | Primary Efficacy Outcome |
ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer
[ PUBLICATION ]
ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.
BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...
| Conhecido por Willebrand Factor | Venous Thromboembolism | Vte Cancer | Vwf Adamts13 | Khorana Score |
KOL-Index: 15571
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...
| Conhecido por Oral Rivaroxaban | Venous Thromboembolism | Vitamin Antagonist | Continued Treatment | Hazard Ratio |
KOL-Index: 15512
BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...
| Conhecido por Hip Replacement | Dabigatran Enoxaparin | Venous Thromboembolism | Etexilate Versus | Primary Efficacy Outcome |
KOL-Index: 15505
CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.
DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...
| Conhecido por Pulmonary Embolism | Computed Tomography | Dimer Testing | Patients Suspected | 3 Months |
KOL-Index: 15415
BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.
METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...
| Conhecido por Total Hip | Dabigatran Etexilate | Thromboembolic Events | Knee Replacement | Vte Patients |
KOL-Index: 14849
BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.
METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...
| Conhecido por Subcutaneous Enoxaparin | Oral Dabigatran | Total Knee Replacement | Venous Thromboembolism | Prevention Vte |
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
[ PUBLICATION ]
BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.
METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...
| Conhecido por Unfractionated Heparin | Pulmonary Embolism | Initial Treatment | Subcutaneous Fondaparinux | Intravenous Injections |
KOL-Index: 14727
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort ...
| Conhecido por Anticoagulant Treatment | Recurrent Vte | Unprovoked Venous | 10 Years | 95 Confidence Interval |
Pessoas importantes para Pulmonary Embolism
Principais kols do mundo
Selecione uma frase de pesquisa pulmonary embolism , pulmonary embolism patients , pulmonary embolism 95 , pulmonary embolism diagnosis , pulmonary embolism treatment
Harry Roger Büller:Impacto especializado
Conceitos para os quaisHarry Roger Büllertem influência direta:Pulmonary embolism, Venous thromboembolism, Venous thrombosis, Major bleeding, Deep vein thrombosis, Atrial fibrillation, Vein thrombosis.
Harry Roger Büller:Kol Impact
Conceitos relacionados ao trabalho de outros autores para os quaisfor which Harry Roger Büller tem influência:Venous thromboembolism, Pulmonary embolism, Atrial fibrillation, Deep vein thrombosis, Oral anticoagulants, Major bleeding, Vte patients.
Tools
Este é o seu perfil? Reivindique seu perfil Copiar URL Incorporar link para o seu perfil |